Maxi Investments CY Ltd reduced its stake in shares of NVIDIA Corporation (NASDAQ:NVDA – Free Report) by 46.7% in the 2nd quarter, according to the company in its most recent filing with the Securities & Exchange Commission. The fund owned 73,990 shares of the computer hardware maker’s stock after selling 64,800 shares during the period. NVIDIA accounts for approximately 3.0% of Maxi Investments CY Ltd’s investment portfolio, making the stock its 8th biggest position. Maxi Investments CY Ltd’s holdings in NVIDIA were worth $14,805,000 as of its most recent SEC filing.
A number of other hedge funds and other institutional investors have also recently modified their holdings of NVDA. Bank of America Corp DE lifted its holdings in NVIDIA by 2.1% in the first quarter. Bank of America Corp DE now owns 191,200,989 shares of the computer hardware maker’s stock valued at $33,345,453,000 after buying an additional 4,019,505 shares during the period. Invesco Ltd. increased its stake in NVIDIA by 0.3% in the fourth quarter. Invesco Ltd. now owns 143,239,504 shares of the computer hardware maker’s stock valued at $26,714,167,000 after purchasing an additional 446,178 shares in the last quarter. Amundi increased its stake in NVIDIA by 10.4% in the first quarter. Amundi now owns 133,768,018 shares of the computer hardware maker’s stock valued at $23,329,141,000 after purchasing an additional 12,575,177 shares in the last quarter. J. Stern & Co. LLP raised its holdings in shares of NVIDIA by 13,709.1% during the fourth quarter. J. Stern & Co. LLP now owns 125,760,307 shares of the computer hardware maker’s stock valued at $23,454,297,000 after purchasing an additional 124,849,603 shares during the period. Finally, Dimensional Fund Advisors LP boosted its position in shares of NVIDIA by 0.6% during the 1st quarter. Dimensional Fund Advisors LP now owns 94,521,253 shares of the computer hardware maker’s stock worth $16,479,126,000 after purchasing an additional 555,221 shares in the last quarter. Institutional investors and hedge funds own 65.27% of the company’s stock.
Insiders Place Their Bets In related news, EVP Timothy S. Teter sold 30,460 shares of the stock in a transaction that occurred on Monday, September 21st. The stock was sold at an average price of $222.80, for a total transaction of $6,786,488.00. Following the completion of the sale, the executive vice president directly owned 2,687,660 shares of the company’s stock, valued at approximately $598,810,648. This trade represents a 1.12% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the SEC, which can be accessed through this link. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, Director Mark A. Stevens sold 622,239 shares of the stock in a transaction that occurred on Friday, September 4th. The shares were sold at an average price of $231.62, for a total value of $144,122,997.18. Following the sale, the director directly owned 2,336,531 shares of the company’s stock, valued at $541,187,310.22. The trade was a 21.03% decrease in their ownership of the stock. The SEC filing for this sale provides additional information. Insiders have sold a total of 1,766,118 shares of company stock valued at $399,450,353 in the last 90 days. 3.94% of the stock is currently owned by corporate insiders.
Wall Street Analyst Weigh In Several analysts have recently commented on NVDA shares. Daiwa Securities Group reduced their target price on NVIDIA from $255.00 to $245.00 and set an “outperform” rating for the company in a research note on Thursday, September 17th. Citigroup reiterated a “buy” rating and issued a $315.00 price target (up from $300.00) on shares of NVIDIA in a report on Thursday, August 27th. JPMorgan Chase & Co. raised their price objective on NVIDIA from $280.00 to $320.00 and gave the company an “overweight” rating in a research note on Thursday, August 27th. Raymond James Financial set a $515.00 price objective on NVIDIA and gave the company a “strong-buy” rating in a report on Thursday, August 27th. Finally, Jefferies Financial Group reissued a “buy” rating on shares of NVIDIA in a research report on Wednesday, August 26th. Five research analysts have rated the stock with a Strong Buy rating, forty-nine have given a Buy rating and one has issued a Hold rating to the company. Based on data from MarketBeat.com, NVIDIA presently has a consensus rating of “Buy” and a consensus target price of $321.89. View Our Latest Report on NVIDIA
NVIDIA News Summary Here are the key news stories impacting NVIDIA this week:
Positive Sentiment: SpaceX is reportedly seeking approximately $40 billion in debt financing to purchase NVIDIA GPUs, potentially creating a major future order and reinforcing demand for the company’s data-center products. Apollo, banks in talks to finance SpaceX’s $40 billion Nvidia GPU purchase Positive Sentiment: TSMC reported record quarterly revenue of roughly $46.7 billion, up 50% year over year, indicating that demand for advanced AI processors—including NVIDIA’s products—remains robust. Nvidia and AMD fuel a $46.7B TSMC quarter Positive Sentiment: NVIDIA committed $1 billion over five years to U.S. science initiatives spanning artificial intelligence, quantum computing, healthcare and energy security. The investment may strengthen government relationships and expand long-term technology adoption. NVIDIA Commits $1 Billion to Advance US Science Positive Sentiment: BNP Paribas Exane upgraded NVIDIA to “strong buy,” while Microsoft and PC manufacturers unveiled systems using NVIDIA’s RTX Spark chips, supporting expansion into local and personal AI computing. NVIDIA Stock Lifted to Strong-Buy Neutral Sentiment: A large options trade reportedly bets on additional upside, but the signal is speculative and does not change NVIDIA’s underlying earnings outlook. Nvidia Stock Slips. A Big Options Trade Signals Where It Might Go Next Negative Sentiment: OpenAI’s reported annualized revenue of about $50 billion was below a previously circulated $68 billion figure, prompting a selloff across AI stocks and raising questions about the pace of AI monetization. Nvidia, Oracle, CoreWeave and other AI stocks sink on OpenAI revenue report Negative Sentiment: Firmus, an NVIDIA-backed cloud-computing company, abandoned plans for a major Australian IPO, citing market conditions. The failed offering highlights tightening investor appetite for AI infrastructure financing. NVIDIA’s proposed $20 billion Groq transaction also faces a Delaware lawsuit alleging improper deal structuring, adding legal risk. Nvidia-Backed Firmus Scraps Australian IPO NVIDIA Trading Down 2.9% NASDAQ NVDA opened at $230.48 on Friday. The company has a current ratio of 4.59, a quick ratio of 3.85 and a debt-to-equity ratio of 0.14. The business has a fifty day simple moving average of $222.09 and a 200 day simple moving average of $209.29. NVIDIA Corporation has a 12 month low of $164.27 and a 12 month high of $243.37. The firm has a market capitalization of $5.55 trillion, a P/E ratio of 29.14, a PEG ratio of 1.83 and a beta of 2.22.
NVIDIA (NASDAQ:NVDA – Get Free Report) last announced its earnings results on Wednesday, August 26th. The computer hardware maker reported $2.22 EPS for the quarter, beating the consensus estimate of $2.09 by $0.13. NVIDIA had a net margin of 63.66% and a return on equity of 96.04%. The company had revenue of $96.22 billion during the quarter, compared to the consensus estimate of $92.27 billion. During the same quarter in the prior year, the company posted $1.05 earnings per share. The firm’s revenue for the quarter was up 105.9% on a year-over-year basis. On average, analysts predict that NVIDIA Corporation will post 9.25 EPS for the current fiscal year.
NVIDIA announced that its Board of Directors has initiated a stock repurchase plan on Monday, September 28th that allows the company to buyback $150.00 billion in shares. This buyback authorization allows the computer hardware maker to purchase up to 2.8% of its shares through open market purchases. Shares buyback plans are often an indication that the company’s board of directors believes its stock is undervalued.
NVIDIA Dividend Announcement The company also recently disclosed a quarterly dividend, which was paid on Thursday, October 1st. Shareholders of record on Thursday, September 10th were paid a $0.25 dividend. The ex-dividend date was Thursday, September 10th. This represents a $1.00 annualized dividend and a yield of 0.4%. NVIDIA’s dividend payout ratio (DPR) is 12.64%.
NVIDIA Profile (Free Report)
NVIDIA Corporation is a technology company that designs accelerated computing platforms, graphics processing units (GPUs), central processing units (CPUs), networking products and related software. Its technologies are used in artificial intelligence, data centers, scientific and technical computing, gaming, professional visualization, automotive systems and robotics.
The company’s products include GeForce GPUs and gaming software, data center computing platforms, networking solutions, and enterprise software for AI development and deployment.
Read More Five stocks we like better than NVIDIA Want Private-Market Access to Kalshi and Polymarket? Try This ETF Levi’s Stock Dip Reveals Value Opportunity Despite Q3 Headwinds PepsiCo Stock Looks Poised to Bottom With High Yield, Deep Value Alphabet’s $1.8 Billion Black Hills Deal Powers AI Data Center Push Want to see what other hedge funds are holding NVDA? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for NVIDIA Corporation (NASDAQ:NVDA – Free Report).
Receive News & Ratings for NVIDIA Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for NVIDIA and related companies with MarketBeat.com's FREE daily email newsletter.
Allstate Corp. ve druhém čtvrtletí snížila svůj podíl v NVIDIA o 17,7 % prodejem 237 507 akcií; nadále drží 1 104 410 akcií v hodnotě 220,981 milionu USD.
Allstate Corp lessened its stake in NVIDIA Corporation (NASDAQ:NVDA – Free Report) by 17.7% in the 2nd quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The institutional investor owned 1,104,410 shares of the computer hardware maker’s stock after selling 237,507 shares during the period. NVIDIA accounts for approximately 2.2% of Allstate Corp’s portfolio, making the stock its 7th largest position. Allstate Corp’s holdings in NVIDIA were worth $220,981,000 at the end of the most recent reporting period.
Other hedge funds also recently made changes to their positions in the company. Boyd Wealth Management LLC boosted its stake in NVIDIA by 273.4% during the 2nd quarter. Boyd Wealth Management LLC now owns 9,145 shares of the computer hardware maker’s stock worth $1,830,000 after purchasing an additional 6,696 shares during the period. Altshuler Shaham Ltd grew its holdings in shares of NVIDIA by 6,451.9% during the first quarter. Altshuler Shaham Ltd now owns 637,236 shares of the computer hardware maker’s stock worth $111,134,000 after buying an additional 627,510 shares during the last quarter. Storen Legacy Partners LLC purchased a new position in shares of NVIDIA during the fourth quarter worth about $1,350,000. Baker Tilly Wealth Management LLC increased its position in NVIDIA by 7.4% in the 2nd quarter. Baker Tilly Wealth Management LLC now owns 71,898 shares of the computer hardware maker’s stock valued at $14,386,000 after acquiring an additional 4,958 shares during the period. Finally, Arrowstreet Capital Limited Partnership increased its position in NVIDIA by 3.6% in the 4th quarter. Arrowstreet Capital Limited Partnership now owns 26,652,420 shares of the computer hardware maker’s stock valued at $4,970,704,000 after acquiring an additional 936,506 shares during the period. Hedge funds and other institutional investors own 65.27% of the company’s stock.
Insider Activity In other news, EVP Timothy Teter sold 30,460 shares of the firm’s stock in a transaction on Monday, September 21st. The shares were sold at an average price of $222.80, for a total value of $6,786,488.00. Following the transaction, the executive vice president owned 2,687,660 shares of the company’s stock, valued at approximately $598,810,648. This trade represents a 1.12% decrease in their position. The sale was disclosed in a legal filing with the SEC, which is available at this link. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, Director Mark Stevens sold 622,239 shares of the company’s stock in a transaction on Friday, September 4th. The stock was sold at an average price of $231.62, for a total transaction of $144,122,997.18. Following the sale, the director directly owned 2,336,531 shares of the company’s stock, valued at approximately $541,187,310.22. This trade represents a 21.03% decrease in their ownership of the stock. Additional details regarding this sale are available in the official SEC disclosure. In the last 90 days, insiders have sold 1,766,118 shares of company stock valued at $399,450,353. Company insiders own 3.94% of the company’s stock.
NVIDIA Stock Down 2.9% NVIDIA stock opened at $230.48 on Friday. The company has a debt-to-equity ratio of 0.14, a quick ratio of 3.85 and a current ratio of 4.59. The stock’s fifty day moving average is $222.09 and its two-hundred day moving average is $209.29. NVIDIA Corporation has a fifty-two week low of $164.27 and a fifty-two week high of $243.37. The firm has a market capitalization of $5.55 trillion, a price-to-earnings ratio of 29.14, a price-to-earnings-growth ratio of 1.83 and a beta of 2.22. NVIDIA (NASDAQ:NVDA – Get Free Report) last released its earnings results on Wednesday, August 26th. The computer hardware maker reported $2.22 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $2.09 by $0.13. The company had revenue of $96.22 billion for the quarter, compared to analyst estimates of $92.27 billion. NVIDIA had a net margin of 63.66% and a return on equity of 96.04%. The firm’s quarterly revenue was up 105.9% on a year-over-year basis. During the same period in the prior year, the firm earned $1.05 EPS. Analysts predict that NVIDIA Corporation will post 9.25 EPS for the current fiscal year.
NVIDIA announced that its board has initiated a stock buyback program on Monday, September 28th that permits the company to buyback $150.00 billion in outstanding shares. This buyback authorization permits the computer hardware maker to buy up to 2.8% of its shares through open market purchases. Shares buyback programs are often a sign that the company’s board of directors believes its stock is undervalued.
NVIDIA Dividend Announcement The firm also recently disclosed a quarterly dividend, which was paid on Thursday, October 1st. Stockholders of record on Thursday, September 10th were given a $0.25 dividend. The ex-dividend date of this dividend was Thursday, September 10th. This represents a $1.00 annualized dividend and a dividend yield of 0.4%. NVIDIA’s dividend payout ratio is presently 12.64%.
Wall Street Analysts Forecast Growth NVDA has been the subject of a number of recent research reports. UBS Group set a $300.00 price objective on NVIDIA and gave the stock a “buy” rating in a research report on Thursday, August 27th. The Goldman Sachs Group reiterated a “buy” rating on shares of NVIDIA in a research report on Thursday, September 10th. China Renaissance boosted their price objective on shares of NVIDIA from $319.00 to $330.00 and gave the company a “buy” rating in a research note on Monday, August 31st. Melius Research set a $420.00 price objective on shares of NVIDIA in a research report on Thursday, August 27th. Finally, Jefferies Financial Group reissued a “buy” rating on shares of NVIDIA in a report on Wednesday, August 26th. Five equities research analysts have rated the stock with a Strong Buy rating, forty-nine have assigned a Buy rating and one has issued a Hold rating to the company’s stock. Based on data from MarketBeat, NVIDIA currently has a consensus rating of “Buy” and an average target price of $321.89.
Read Our Latest Analysis on NVIDIA
NVIDIA News Summary Here are the key news stories impacting NVIDIA this week:
Positive Sentiment: SpaceX is reportedly seeking approximately $40 billion in debt financing to purchase NVIDIA GPUs, potentially creating a major future order and reinforcing demand for the company’s data-center products. Apollo, banks in talks to finance SpaceX’s $40 billion Nvidia GPU purchase Positive Sentiment: TSMC reported record quarterly revenue of roughly $46.7 billion, up 50% year over year, indicating that demand for advanced AI processors—including NVIDIA’s products—remains robust. Nvidia and AMD fuel a $46.7B TSMC quarter Positive Sentiment: NVIDIA committed $1 billion over five years to U.S. science initiatives spanning artificial intelligence, quantum computing, healthcare and energy security. The investment may strengthen government relationships and expand long-term technology adoption. NVIDIA Commits $1 Billion to Advance US Science Positive Sentiment: BNP Paribas Exane upgraded NVIDIA to “strong buy,” while Microsoft and PC manufacturers unveiled systems using NVIDIA’s RTX Spark chips, supporting expansion into local and personal AI computing. NVIDIA Stock Lifted to Strong-Buy Neutral Sentiment: A large options trade reportedly bets on additional upside, but the signal is speculative and does not change NVIDIA’s underlying earnings outlook. Nvidia Stock Slips. A Big Options Trade Signals Where It Might Go Next Negative Sentiment: OpenAI’s reported annualized revenue of about $50 billion was below a previously circulated $68 billion figure, prompting a selloff across AI stocks and raising questions about the pace of AI monetization. Nvidia, Oracle, CoreWeave and other AI stocks sink on OpenAI revenue report Negative Sentiment: Firmus, an NVIDIA-backed cloud-computing company, abandoned plans for a major Australian IPO, citing market conditions. The failed offering highlights tightening investor appetite for AI infrastructure financing. NVIDIA’s proposed $20 billion Groq transaction also faces a Delaware lawsuit alleging improper deal structuring, adding legal risk. Nvidia-Backed Firmus Scraps Australian IPO NVIDIA Company Profile (Free Report)
NVIDIA Corporation is a technology company that designs accelerated computing platforms, graphics processing units (GPUs), central processing units (CPUs), networking products and related software. Its technologies are used in artificial intelligence, data centers, scientific and technical computing, gaming, professional visualization, automotive systems and robotics.
The company’s products include GeForce GPUs and gaming software, data center computing platforms, networking solutions, and enterprise software for AI development and deployment.
See Also Five stocks we like better than NVIDIA Want Private-Market Access to Kalshi and Polymarket? Try This ETF Levi’s Stock Dip Reveals Value Opportunity Despite Q3 Headwinds PepsiCo Stock Looks Poised to Bottom With High Yield, Deep Value Alphabet’s $1.8 Billion Black Hills Deal Powers AI Data Center Push Want to see what other hedge funds are holding NVDA? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for NVIDIA Corporation (NASDAQ:NVDA – Free Report).
Receive News & Ratings for NVIDIA Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for NVIDIA and related companies with MarketBeat.com's FREE daily email newsletter.
OMERS ADMINISTRATION ve 2. čtvrtletí snížila svůj podíl ve společnosti NVIDIA o 17,1 % prodejem 815 634 akcií; nadále drží 3 964 779 akcií v hodnotě 793,3 milionu USD.
OMERS ADMINISTRATION Corp reduced its holdings in NVIDIA Corporation (NASDAQ:NVDA – Free Report) by 17.1% during the 2nd quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission. The firm owned 3,964,779 shares of the computer hardware maker’s stock after selling 815,634 shares during the period. NVIDIA comprises 4.7% of OMERS ADMINISTRATION Corp’s holdings, making the stock its largest position. OMERS ADMINISTRATION Corp’s holdings in NVIDIA were worth $793,313,000 as of its most recent SEC filing.
A number of other institutional investors and hedge funds have also made changes to their positions in NVDA. Lifetime Wealth Management P.C. acquired a new position in shares of NVIDIA during the 4th quarter worth about $26,000. Longview Financial Advisors Inc. acquired a new stake in NVIDIA in the 1st quarter worth about $27,000. Phillip James Consulting Co. purchased a new stake in NVIDIA during the 1st quarter worth approximately $40,000. Bard Associates Inc. raised its holdings in shares of NVIDIA by 8,866.7% during the second quarter. Bard Associates Inc. now owns 269 shares of the computer hardware maker’s stock valued at $54,000 after acquiring an additional 266 shares during the last quarter. Finally, Frankly Finances LLC acquired a new position in shares of NVIDIA during the second quarter valued at approximately $60,000. 65.27% of the stock is currently owned by hedge funds and other institutional investors.
Key Headlines Impacting NVIDIA Here are the key news stories impacting NVIDIA this week:
Positive Sentiment: SpaceX is reportedly seeking approximately $40 billion in debt financing to purchase NVIDIA GPUs, potentially creating a major future order and reinforcing demand for the company’s data-center products. Apollo, banks in talks to finance SpaceX’s $40 billion Nvidia GPU purchase Positive Sentiment: TSMC reported record quarterly revenue of roughly $46.7 billion, up 50% year over year, indicating that demand for advanced AI processors—including NVIDIA’s products—remains robust. Nvidia and AMD fuel a $46.7B TSMC quarter Positive Sentiment: NVIDIA committed $1 billion over five years to U.S. science initiatives spanning artificial intelligence, quantum computing, healthcare and energy security. The investment may strengthen government relationships and expand long-term technology adoption. NVIDIA Commits $1 Billion to Advance US Science Positive Sentiment: BNP Paribas Exane upgraded NVIDIA to “strong buy,” while Microsoft and PC manufacturers unveiled systems using NVIDIA’s RTX Spark chips, supporting expansion into local and personal AI computing. NVIDIA Stock Lifted to Strong-Buy Neutral Sentiment: A large options trade reportedly bets on additional upside, but the signal is speculative and does not change NVIDIA’s underlying earnings outlook. Nvidia Stock Slips. A Big Options Trade Signals Where It Might Go Next Negative Sentiment: OpenAI’s reported annualized revenue of about $50 billion was below a previously circulated $68 billion figure, prompting a selloff across AI stocks and raising questions about the pace of AI monetization. Nvidia, Oracle, CoreWeave and other AI stocks sink on OpenAI revenue report Negative Sentiment: Firmus, an NVIDIA-backed cloud-computing company, abandoned plans for a major Australian IPO, citing market conditions. The failed offering highlights tightening investor appetite for AI infrastructure financing. NVIDIA’s proposed $20 billion Groq transaction also faces a Delaware lawsuit alleging improper deal structuring, adding legal risk. Nvidia-Backed Firmus Scraps Australian IPO NVIDIA Price Performance NASDAQ:NVDA opened at $230.48 on Friday. NVIDIA Corporation has a 52 week low of $164.27 and a 52 week high of $243.37. The company has a quick ratio of 3.85, a current ratio of 4.59 and a debt-to-equity ratio of 0.14. The company has a market capitalization of $5.55 trillion, a P/E ratio of 29.14, a P/E/G ratio of 1.83 and a beta of 2.22. The stock’s fifty day moving average is $222.09 and its two-hundred day moving average is $209.29. NVIDIA (NASDAQ:NVDA – Get Free Report) last announced its quarterly earnings results on Wednesday, August 26th. The computer hardware maker reported $2.22 EPS for the quarter, beating the consensus estimate of $2.09 by $0.13. The business had revenue of $96.22 billion for the quarter, compared to analyst estimates of $92.27 billion. NVIDIA had a return on equity of 96.04% and a net margin of 63.66%.The company’s quarterly revenue was up 105.9% on a year-over-year basis. During the same quarter in the prior year, the company posted $1.05 EPS. Equities analysts expect that NVIDIA Corporation will post 9.25 EPS for the current year.
NVIDIA announced that its Board of Directors has authorized a stock buyback program on Monday, September 28th that authorizes the company to buyback $150.00 billion in outstanding shares. This buyback authorization authorizes the computer hardware maker to buy up to 2.8% of its stock through open market purchases. Stock buyback programs are often an indication that the company’s board of directors believes its shares are undervalued.
NVIDIA Dividend Announcement The business also recently announced a quarterly dividend, which was paid on Thursday, October 1st. Shareholders of record on Thursday, September 10th were given a $0.25 dividend. The ex-dividend date of this dividend was Thursday, September 10th. This represents a $1.00 dividend on an annualized basis and a yield of 0.4%. NVIDIA’s dividend payout ratio is presently 12.64%.
Insiders Place Their Bets In other NVIDIA news, CFO Colette Kress sold 34,918 shares of the stock in a transaction dated Thursday, September 17th. The shares were sold at an average price of $219.05, for a total transaction of $7,648,787.90. Following the completion of the transaction, the chief financial officer owned 765,103 shares of the company’s stock, valued at $167,595,812.15. This trade represents a 4.36% decrease in their ownership of the stock. The sale was disclosed in a filing with the SEC, which is available through the SEC website. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, EVP Timothy Teter sold 30,460 shares of the stock in a transaction that occurred on Monday, September 21st. The stock was sold at an average price of $222.80, for a total transaction of $6,786,488.00. Following the transaction, the executive vice president directly owned 2,687,660 shares of the company’s stock, valued at $598,810,648. The trade was a 1.12% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Insiders sold a total of 1,766,118 shares of company stock valued at $399,450,353 over the last 90 days. 3.94% of the stock is owned by company insiders.
Analysts Set New Price Targets Several brokerages recently commented on NVDA. Raymond James Financial set a $515.00 price target on NVIDIA and gave the stock a “strong-buy” rating in a research report on Thursday, August 27th. Zacks Research raised shares of NVIDIA from a “hold” rating to a “strong-buy” rating in a research note on Monday, September 21st. Piper Sandler started coverage on shares of NVIDIA in a report on Wednesday, September 9th. They set an “overweight” rating and a $300.00 target price for the company. TD Cowen reaffirmed a “buy” rating on shares of NVIDIA in a report on Tuesday, August 18th. Finally, KGI Securities increased their target price on shares of NVIDIA from $335.00 to $345.00 in a research report on Thursday, August 27th. Five analysts have rated the stock with a Strong Buy rating, forty-nine have issued a Buy rating and one has given a Hold rating to the company. Based on data from MarketBeat.com, the stock presently has a consensus rating of “Buy” and a consensus price target of $321.89.
View Our Latest Report on NVIDIA
NVIDIA Company Profile (Free Report)
NVIDIA Corporation is a technology company that designs accelerated computing platforms, graphics processing units (GPUs), central processing units (CPUs), networking products and related software. Its technologies are used in artificial intelligence, data centers, scientific and technical computing, gaming, professional visualization, automotive systems and robotics.
The company’s products include GeForce GPUs and gaming software, data center computing platforms, networking solutions, and enterprise software for AI development and deployment.
Featured Articles Five stocks we like better than NVIDIA Want Private-Market Access to Kalshi and Polymarket? Try This ETF Levi’s Stock Dip Reveals Value Opportunity Despite Q3 Headwinds PepsiCo Stock Looks Poised to Bottom With High Yield, Deep Value Alphabet’s $1.8 Billion Black Hills Deal Powers AI Data Center Push
Receive News & Ratings for NVIDIA Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for NVIDIA and related companies with MarketBeat.com's FREE daily email newsletter.
Panview Capital Ltd reduced its holdings in NVIDIA Corporation (NASDAQ:NVDA – Free Report) by 8.0% in the 2nd quarter, according to its most recent disclosure with the Securities and Exchange Commission. The fund owned 257,697 shares of the computer hardware maker’s stock after selling 22,303 shares during the quarter. NVIDIA makes up 9.1% of Panview Capital Ltd’s portfolio, making the stock its 5th biggest holding. Panview Capital Ltd’s holdings in NVIDIA were worth $51,563,000 as of its most recent SEC filing.
Several other hedge funds and other institutional investors also recently added to or reduced their stakes in NVDA. Bank of America Corp DE boosted its position in shares of NVIDIA by 2.1% in the first quarter. Bank of America Corp DE now owns 191,200,989 shares of the computer hardware maker’s stock worth $33,345,453,000 after acquiring an additional 4,019,505 shares during the last quarter. Invesco Ltd. boosted its holdings in shares of NVIDIA by 0.3% in the 4th quarter. Invesco Ltd. now owns 143,239,504 shares of the computer hardware maker’s stock valued at $26,714,167,000 after purchasing an additional 446,178 shares during the last quarter. Amundi boosted its holdings in shares of NVIDIA by 10.4% in the 1st quarter. Amundi now owns 133,768,018 shares of the computer hardware maker’s stock valued at $23,329,141,000 after purchasing an additional 12,575,177 shares during the last quarter. J. Stern & Co. LLP grew its stake in shares of NVIDIA by 13,709.1% during the 4th quarter. J. Stern & Co. LLP now owns 125,760,307 shares of the computer hardware maker’s stock valued at $23,454,297,000 after buying an additional 124,849,603 shares during the period. Finally, Dimensional Fund Advisors LP increased its holdings in shares of NVIDIA by 0.6% during the 1st quarter. Dimensional Fund Advisors LP now owns 94,521,253 shares of the computer hardware maker’s stock worth $16,479,126,000 after buying an additional 555,221 shares during the last quarter. Hedge funds and other institutional investors own 65.27% of the company’s stock.
Insider Buying and Selling In other NVIDIA news, EVP Timothy Teter sold 30,460 shares of the business’s stock in a transaction on Monday, September 21st. The shares were sold at an average price of $222.80, for a total value of $6,786,488.00. Following the transaction, the executive vice president owned 2,687,660 shares in the company, valued at $598,810,648. The trade was a 1.12% decrease in their position. The sale was disclosed in a filing with the SEC, which is available through the SEC website. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, CFO Colette Kress sold 34,918 shares of the company’s stock in a transaction dated Thursday, September 17th. The shares were sold at an average price of $219.05, for a total transaction of $7,648,787.90. Following the completion of the transaction, the chief financial officer directly owned 765,103 shares of the company’s stock, valued at approximately $167,595,812.15. The trade was a 4.36% decrease in their ownership of the stock. Additional details regarding this sale are available in the official SEC disclosure. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Insiders have sold 1,766,118 shares of company stock valued at $399,450,353 in the last quarter. Company insiders own 3.94% of the company’s stock.
NVIDIA News Summary Here are the key news stories impacting NVIDIA this week: Positive Sentiment: SpaceX is reportedly seeking approximately $40 billion in debt financing to purchase NVIDIA GPUs, potentially creating a major future order and reinforcing demand for the company’s data-center products. Apollo, banks in talks to finance SpaceX’s $40 billion Nvidia GPU purchase Positive Sentiment: TSMC reported record quarterly revenue of roughly $46.7 billion, up 50% year over year, indicating that demand for advanced AI processors—including NVIDIA’s products—remains robust. Nvidia and AMD fuel a $46.7B TSMC quarter Positive Sentiment: NVIDIA committed $1 billion over five years to U.S. science initiatives spanning artificial intelligence, quantum computing, healthcare and energy security. The investment may strengthen government relationships and expand long-term technology adoption. NVIDIA Commits $1 Billion to Advance US Science Positive Sentiment: BNP Paribas Exane upgraded NVIDIA to “strong buy,” while Microsoft and PC manufacturers unveiled systems using NVIDIA’s RTX Spark chips, supporting expansion into local and personal AI computing. NVIDIA Stock Lifted to Strong-Buy Neutral Sentiment: A large options trade reportedly bets on additional upside, but the signal is speculative and does not change NVIDIA’s underlying earnings outlook. Nvidia Stock Slips. A Big Options Trade Signals Where It Might Go Next Negative Sentiment: OpenAI’s reported annualized revenue of about $50 billion was below a previously circulated $68 billion figure, prompting a selloff across AI stocks and raising questions about the pace of AI monetization. Nvidia, Oracle, CoreWeave and other AI stocks sink on OpenAI revenue report Negative Sentiment: Firmus, an NVIDIA-backed cloud-computing company, abandoned plans for a major Australian IPO, citing market conditions. The failed offering highlights tightening investor appetite for AI infrastructure financing. NVIDIA’s proposed $20 billion Groq transaction also faces a Delaware lawsuit alleging improper deal structuring, adding legal risk. Nvidia-Backed Firmus Scraps Australian IPO NVIDIA Stock Down 2.9% NASDAQ NVDA opened at $230.48 on Friday. The stock has a market cap of $5.55 trillion, a PE ratio of 29.14, a P/E/G ratio of 1.83 and a beta of 2.22. NVIDIA Corporation has a fifty-two week low of $164.27 and a fifty-two week high of $243.37. The business has a 50 day moving average price of $222.09 and a two-hundred day moving average price of $209.29. The company has a quick ratio of 3.85, a current ratio of 4.59 and a debt-to-equity ratio of 0.14.
NVIDIA (NASDAQ:NVDA – Get Free Report) last posted its quarterly earnings data on Wednesday, August 26th. The computer hardware maker reported $2.22 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $2.09 by $0.13. The company had revenue of $96.22 billion for the quarter, compared to analyst estimates of $92.27 billion. NVIDIA had a net margin of 63.66% and a return on equity of 96.04%. The business’s quarterly revenue was up 105.9% on a year-over-year basis. During the same quarter last year, the firm posted $1.05 earnings per share. As a group, sell-side analysts predict that NVIDIA Corporation will post 9.25 EPS for the current fiscal year.
NVIDIA announced that its Board of Directors has authorized a share repurchase plan on Monday, September 28th that allows the company to buyback $150.00 billion in shares. This buyback authorization allows the computer hardware maker to reacquire up to 2.8% of its stock through open market purchases. Stock buyback plans are often an indication that the company’s leadership believes its shares are undervalued.
NVIDIA Announces Dividend The company also recently declared a quarterly dividend, which was paid on Thursday, October 1st. Investors of record on Thursday, September 10th were issued a dividend of $0.25 per share. This represents a $1.00 dividend on an annualized basis and a yield of 0.4%. The ex-dividend date of this dividend was Thursday, September 10th. NVIDIA’s dividend payout ratio (DPR) is presently 12.64%.
Wall Street Analyst Weigh In NVDA has been the topic of a number of research analyst reports. Zacks Research upgraded NVIDIA from a “hold” rating to a “strong-buy” rating in a report on Monday, September 21st. DZ Bank restated a “buy” rating on shares of NVIDIA in a report on Wednesday, August 26th. Phillip Securities lifted their price objective on NVIDIA from $285.00 to $300.00 and gave the company a “buy” rating in a research note on Monday, August 31st. KeyCorp restated an “overweight” rating and issued a $330.00 price target on shares of NVIDIA in a report on Monday, August 24th. Finally, China Renaissance lifted their price target on shares of NVIDIA from $319.00 to $330.00 and gave the company a “buy” rating in a research report on Monday, August 31st. Five equities research analysts have rated the stock with a Strong Buy rating, forty-nine have issued a Buy rating and one has given a Hold rating to the company. Based on data from MarketBeat.com, NVIDIA currently has an average rating of “Buy” and an average price target of $321.89.
Check Out Our Latest Report on NVIDIA
NVIDIA Profile (Free Report)
NVIDIA Corporation is a technology company that designs accelerated computing platforms, graphics processing units (GPUs), central processing units (CPUs), networking products and related software. Its technologies are used in artificial intelligence, data centers, scientific and technical computing, gaming, professional visualization, automotive systems and robotics.
The company’s products include GeForce GPUs and gaming software, data center computing platforms, networking solutions, and enterprise software for AI development and deployment.
Featured Articles Five stocks we like better than NVIDIA Want Private-Market Access to Kalshi and Polymarket? Try This ETF Levi’s Stock Dip Reveals Value Opportunity Despite Q3 Headwinds PepsiCo Stock Looks Poised to Bottom With High Yield, Deep Value Alphabet’s $1.8 Billion Black Hills Deal Powers AI Data Center Push
Receive News & Ratings for NVIDIA Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for NVIDIA and related companies with MarketBeat.com's FREE daily email newsletter.
Nvidia v první polovině fiskálního roku 2027 obdržela od zákazníků zálohy ve výši 15,6 miliardy USD, což podle článku potvrzuje silnou poptávku po GPU ze strany zákazníků.
SummaryNvidia receives massive customer advances—$15.6 billion in H1 FY2027—demonstrating significant real external demand beyond circular financing concerns.Customer prepayments, often from major players like Microsoft, are fueling Nvidia GPU purchases, indicating robust ecosystem-wide AI infrastructure investment.Despite some circular financing, billions in outside capital flow into NVDA, supporting confidence in the sustainability of current demand.I rate NVDA a Buy, as forward multiples and rapid revenue recognition suggest strong upside if external demand persists and supply constraints remain.Robert Way/iStock Editorial via Getty Images
Some investors are increasingly worried about Nvidia's (NVDA) circular financing: is the largest company in the world financing its own demand? Nvidia invests everywhere, including AI companies; it helps customers finance infrastructure, helps large buyers with longer payment
44 Followers
Analyst’s Disclosure: I/we have no stock, option or similar derivative position in any of the companies mentioned, and no plans to initiate any such positions within the next 72 hours. I wrote this article myself, and it expresses my own opinions. I am not receiving compensation for it (other than from Seeking Alpha). I have no business relationship with any company whose stock is mentioned in this article.
Seeking Alpha's Disclosure: Past performance is no guarantee of future results. No recommendation or advice is being given as to whether any investment is suitable for a particular investor. Any views or opinions expressed above may not reflect those of Seeking Alpha as a whole. Seeking Alpha is not a licensed securities dealer, broker or US investment adviser or investment bank. Our analysts are third party authors that include both professional investors and individual investors who may not be licensed or certified by any institute or regulatory body.
When one of the world's most aggressive builders reportedly moves to borrow billions just to secure a single supplier's hardware, it raises a question worth sitting with: what do they know that the rest of us are still catching up…
This post may contain links from our sponsors and affiliates, and Flywheel Publishing may receive compensation for actions taken through them.
My NVIDIA (NASDAQ:NVDA | NVDA Price Prediction) position grew again this week. My reason showed up Wednesday night, when reports said SpaceX wants to raise $40 billion in debt “to buy more Nvidia chips.” The report is still unconfirmed. Still, when one of the most aggressive builders on the planet talks about borrowing against its future to buy what Nvidia sells, I’m comfortable buying more.
My thesis is simple. Every serious AI builder needs Nvidia’s full stack, and now they are borrowing to get it. SpaceX AI already ranks among the lead partners receiving Vera CPU shipments, alongside OCI and AWS. A $40 billion loan aimed at Nvidia hardware tells me that customer wants far more.
Three Data Points Behind Every Purchase First, growth keeps speeding up. Revenue for Nvidia’s fiscal second quarter hit $96.22 billion, up 105.8% from a year earlier, and Data Center revenue rose 117% to $89.02 billion. Guidance for this quarter calls for $108.0 billion. Management expects growth of about 70% in fiscal 2028, and it says real demand runs “much higher” than what supply can cover.
Second, each new platform makes more. Nvidia puts its revenue opportunity per gigawatt at roughly $18 billion for Hopper, $25 billion for Blackwell and $40 billion for Vera Rubin. That gives me a second set of 40 billion reasons: every gigawatt SpaceX uses with Vera Rubin carries that much opportunity.
Third, the business throws off cash on a strong balance sheet. Nvidia posts a 55.60% net margin, a 92.21% return on invested capital, with 503x interest coverage. It returned about $26.0 billion to shareholders last quarter and still has about $99.0 billion left under its buyback authorization. The dividend yield is a negligible 0.0175%, so I own Nvidia for compounding, and I collect income elsewhere.
Why My Money Skips AMD Advanced Micro Devices (NASDAQ:AMD) is the obvious alternative, and I have looked hard at it. AMD trades at about 234 times trailing earnings, while Nvidia trades at about 46. AMD’s operating margin sits near 10.7%, against Nvidia’s 60.38%. AMD’s latest quarterly revenue grew a solid 50.1%, but Nvidia grew about twice as fast from a far bigger base. On these numbers, I pay a lower multiple for the faster grower with the higher margins.
Real Risk Hiding in the Financing Debt-funded demand cuts both ways. Nvidia’s supply obligations have increased to $279 billion, its guarantee obligations reach as high as $108.5 billion, and days sales outstanding rose to 60 days from 45. A report on OpenAI’s revenue pushed AI chip stocks lower Thursday, and Nvidia fell 2.94%. If borrowers like SpaceX pull back, those commitments will hurt.
I still own the position because demand exceeds supply. Management expects supply to stay the constraint “at least through the end of fiscal year 28,” and it puts the cloud industry backlog at “greater than 2 trillion.” All of that capacity still has to be powered, cooled, and connected by somebody, and we pulled together seven of those suppliers in a free report here.
What Keeps My Buy Button Active Nvidia expects Vera Rubin to make up about 20% of Data Center revenue this quarter and CPU revenue to more than double in fiscal 28. The next earnings report lands November 17, 2026. The world’s most ambitious builders keep borrowing billions to buy Nvidia, and I will keep putting my own savings to work right beside them.
Contact [email protected] for any questions or corrections.
AT&T zařazuje skládací iPhone Duo do nabídky a novým i stávajícím zákazníkům nabídne slevu až 1 200 USD při odevzdání způsobilého telefonu na protiúčet.
New and existing customers get our best deal on the new iPhone Duo, up to $1200 off, with eligible trade-in.1
Key Takeaways:
More confidence with America's Best Guarantee: a promise to always do our best by customers, and to make it right if we don't—when the connection matters, it has to be AT&T. More performance: Experience iPhone on America's largest wireless2 and fiber3 networks, with enhanced network intelligence and near real time insights to keep customers connected to the right network at the right time. More value and flexibility: New and existing customers can upgrade or switch to AT&T and get up to $1200 off with eligible iPhone trade-in.1 With AT&T Next Up Anytime® customers can get the latest iPhone model every year and save with Unlimited Your Way plans that let you mix and match by line to fit every need and budget. Plus, consumers who switch to AT&T get up to $800 to pay off their current device.4 , /PRNewswire/ --
What's New: AT&T is adding iPhone Duo to the latest iPhone lineup, including iPhone 18 Pro, and iPhone 18 Pro Max — available on our intelligent, reliable network, backed by the AT&T Guarantee®. iPhone Duo will be available for pre-order on Friday, Oct. 16, with general availability on Friday, Oct. 23. New and existing customers can both get up to $1200 off with eligible trade-in.1 Plus, customers who switch to AT&T get up to $800 to pay off their current device.4 With AT&T Next Up Anytime, customers can get the latest iPhone every year. With Unlimited Your Way, customers get value packed plans with the choice and flexibility to mix and match per line. Paired with AT&T's powerful combination of fiber and wireless, iPhone Duo helps make connectivity simple, seamless and reliable at home, at work and on the go.
Intelligent Network: AT&T is building America's strongest network, combining fiber and 5G into a resilient, seamless experience that makes advanced connectivity simple, with choices for everyone. Our network supports technologies that have only been imagined, delivers incredible speeds, and acts as its own backup—meaning customers stay connected no matter where they are.
At AT&T, fiber is our foundation, and we're deploying it faster than anyone—laying enough fiber each month to span the distance between New York and LA. As America's largest fiber internet provider,5 that fiber also connects the cell towers that deliver our powerful 5G wireless connectivity that keeps your iPhone Duo connected to every call, message and stream when on-the-go.
The AT&T Guarantee: Customers want the newest and the best devices. They also want a carrier confident enough to promise a connection they can count on, the deals they want, and the prompt, friendly service they deserve. We are committed to delivering on these promises, and if we fall short, we proactively make it right with America's Best Guarantee.
AT&T's Best Deals: New and existing customers get our best deal on the new iPhone Duo, up to $1200 off with eligible trade-in.1 Plus, customers who switch to AT&T get up to $800 to pay off their current device balance.4 They can also save $200 per line when ordering online.5
Plans for Everyone: AT&T is committed to delivering plans for everyone, unlike other providers. Our Unlimited Your Way customers have the ability to pick a plan that is right for each person in the family. Plans include:
Unlimited talk, text and data in and between the U.S., Canada and Mexico6 At least 5 GB of high-speed data per line Up to 250 GB of hotspot data per line7 AT&T 5G access8 AT&T Active Armor® mobile security9 Quotable: "We're committed to delivering the best customer experience, and we can't wait for customers to experience iPhone Duo and its breakthrough design on our intelligent, reliable network," said Jenifer Robertson, executive vice president and general manager, AT&T Consumer. "From our flexible plans and competitive offers to expert care, our goal is to make it simple for people to connect to what matters most on any device – including the new iPhone Duo. With AT&T, customers can get Apple's most advanced iPhone lineup yet, powered by the strength of our fiber and wireless network, all backed by America's Best Guarantee."
Business Customers: New and existing AT&T Business customers can also take advantage of the above deals on the latest iPhone models. Business customers can also complement a new device with business accessories and take advantage of our Trade-in Program to save even more as they upgrade.
FirstNet Ready: We are also giving America's first responders the best iPhone deals with FirstNet®, Built with AT&T—the only network built with and for public safety. And since the new iPhone models are FirstNet Ready®, first responders will have truly dedicated coverage and capacity when they need it and unique benefits like always-on priority and preemption across Band 14 spectrum and all AT&T commercial bands, helping them save lives and protect their communities no matter the emergency. Individual responders on FirstNet can learn more about FirstNet here and save up to 20% for their family members with AT&T.10
The latest iPhone models:
iPhone Duo is the first foldable iPhone, featuring a breakthrough design that's beautiful, versatile, and durable. iPhone Duo opens to a large 7.6-inch inner display for viewing content, gaming, and multitasking, and closes to a compact, pocketable 5.4-inch outer display. Built to last with an innovative hardware design and precision hinge, iPhone Duo is powered by A20 Pro to deliver pro performance and impressive all-day battery life, and offers an advanced camera system, with the folding design unlocking fun new ways to use the camera that aren't possible on any other iPhone. iOS 27 is also reimagined for the versatile ways users can interact with iPhone Duo.
iPhone 18 Pro and iPhone 18 Pro Max offer the new 48MP Fusion Main camera with variable aperture, the most advanced camera Apple has ever made, and new Pro controls let users customize their experience. Powered by A20 Pro, iPhone 18 Pro and iPhone 18 Pro Max deliver huge leaps in battery life and performance. iPhone Duo and iPhone 18 Pro models feature Apple Intelligence11 and Siri AI,12 an entirely new version of Siri, rolling out in beta in English with iOS 27, to bring AI capabilities together with a user's personal context to become an intelligent personal hub with privacy and security at the core. iPhone Duo is available in two refined colors: star white and night sky. iPhone 18 Pro and iPhone 18 Pro Max are available in four elegant finishes: black, silver, glacier, and an all-new burgundy.
iPhone Duo and iPhone 18 Pro models feature eSIM13, offering greater flexibility, better security, and seamless connectivity compared to traditional physical SIM cards, plus more battery life on eSIM-only models. iPhone Duo features an eSIM-only design that saves internal space to maximize battery capacity. eSIM-only models of iPhone 18 Pro and iPhone 18 Pro Max similarly take advantage of the space formerly occupied by the physical SIM with a larger battery that provides two additional hours of video playback.
New and existing customers can shop in store, online at ATT.com, or on the all-new AT&T app, available on the App Store.
For more details on Apple products, please visit www.apple.com.
Related articles on TechBuzz by AT&T:
What is fiber internet? Types of cell phones | AT&T Learn about foldable phones | AT&T Frequently Asked Questions
What is the AT&T Guarantee?
We value our customers, and we believe that connecting changes everything. We're committed to providing dependable connectivity with the deals you want, and the service you deserve, guaranteed, or we'll make it right.
With the AT&T Guarantee, customers can expect:
Connectivity you depend on. In the rare event of a network outage, we'll automatically credit your bill. And, when you have AT&T Fiber with Wireless we provide Internet Backup for no extra cost. Guaranteed.14 Deals you want. Our best deals on smartphones don't require the most expensive plan.15 And no hidden fees or equipment charges with fiber. Guaranteed. Prompt, friendly service you deserve. Speak to a friendly expert within five minutes or schedule a callback at a time that you choose.16 Plus, same or next day fiber technician availability. Guaranteed. What is AT&T Next Up Anytime?
Next Up Anytime is AT&T's smartphone upgrade option, created for early adopters who want the flexibility to upgrade their phone sooner.
For an extra $10/mo., you can upgrade your phone as soon as you've made your first installment payment.17 Then you can turn in your device and upgrade your phone to a new one when it's convenient for you:
What does Next Up Anytime get you?
First, incredible smartphone deals. Just upgrade to the latest phone once you've paid 33% of your existing installment plan.
Or, if you really can't wait, you can upgrade once you've made one installment payment and the first Next Up Anytime payment.
What's better than that? You can upgrade up to three times per year.
Also, Next Up Anytime is available for new smartphones with any of our AT&T Wireless plans.
What is AT&T Fiber?
Fiber optic internet uses thin glass cables and light to send data, allowing for hyper fast speeds.
There are several key benefits to choosing fiber internet:
Fast speeds: Fiber internet can reach speeds that make it ideal for streaming HD videos, online gaming, and using many devices at once. Equal upload and download speeds: As customers game, stream, share, and rely more on AI-enabled applications, symmetrical speeds are becoming increasingly important to the connectivity experience. With the nation's largest fiber network, AT&T Fiber delivers the equally fast upload and download speeds customers need at home for a more seamless experience. Reliable connectivity: Fiber internet offers consistent speeds even during busy times when many people are online. This means fewer interruptions and a smoother online experience. Fiber optic internet offers fast, reliable, and consistent service, making it one of the best choices for anyone who wants a top-quality home internet connection.
What are the benefits of choosing AT&T?
Whether you need reliable wireless service, great home internet, or both, AT&T delivers. AT&T Wireless helps you stay in touch with multiple plans to choose from. AT&T Fiber keeps your home connected with superfast speeds. We are the first and only provider to have a guarantee that includes both wireless and fiber networks.
At home, or on the go, AT&T delivers the fastest speeds across home internet and wireless. With America's largest wireless and fiber networks,18 AT&T already brings together two of the strongest connectivity assets in the industry: AT&T Fiber and wireless. Now, new analysis by Ookla of Speedtest Intelligence data shows customers who subscribe to both have the fastest converged experience in the nation.19
AT&T has the fastest upload speeds in America. Opensignal's first-ever Converged Report shows that AT&T wins the nation's fastest converged upload speeds by a wide margin. AT&T's converged upload speeds were more than twice as fast as the closest competitor. AT&T Fiber ranked #1 in both upload and download speeds, outperforming other fiber, cable and fixed wireless competitors by double digits. As AI becomes a bigger part of everyday life, upload speed is becoming increasingly important to a seamless connectivity experience. A recent broadband report showed that upstream usage grew faster than other broadband usage metrics in 2025.
Can I try AT&T Wireless for free?
Yes, you can download the AT&T app to test drive our network while keeping your current wireless service, cell phone, and phone number. No credit card required. It's a simple process—download the AT&T app, sign up in minutes, activate a new eSIM, and enjoy a risk-free trial for 30 days
What is AT&T ActiveArmor?
AT&T ActiveArmor® gives you 24/7 protection you can count on, whether at home or on the go. It combines comprehensive network protection with built-in, patented security technology that detects and prevents threats. Both of our security apps—one for mobile and one for AT&T internet—are designed to help stop fraudsters in their tracks, alert you about potential threats—so you can talk, text, and browse with greater confidence. We block or label more than 2 billion robocalls per month!
What are the best trade-in, upgrade, or preorder offers and eligibility rules?
AT&T makes it easy to get the latest smartphone with offers designed to deliver great value. Explore current trade-in deals, pricing, and upgrade eligibility to find the device that's right for you.
How do I transfer an eSIM, port my number, or add a second line?
AT&T makes it easy to bring your number, move your eSIM to a new device or add a line to your account. Whether you're adding service for a family member or setting up a new device, you'll find the tools and support you need online.
What are the best current smartphone deals and prices?
AT&T offers a range of deals on the latest smartphones, giving customers the choice and value they need. Explore current offers, pricing and financing options to find the right phone for your needs.
How do phone models, generations, specifications, and product tiers compare?
From camera features and battery life to display size and performance, every smartphone offers something different. AT&T's comparison tools can help you explore key features across devices so you can choose the iPhone that's right for you.
How can I switch and save with AT&T?
Switching to AT&T is simple. Customers get the choice, value, and experience only AT&T can deliver—from an intelligent network that performs to America's Best Guarantee. Customers who bring their number to AT&T may qualify for special offers and savings designed to make it easy to switch and stay connected.
FirstNet and the FirstNet logo are registered trademarks and service marks of the First Responder Network Authority. All other marks are the property of their respective owners.
1Up to $1,200 off after 36 monthly credits. Req's trade-in of an eligible smartphone with min. trade-in value $230 or more. Req. min. $1,999.99 on installment plan and activation on AT&T Premium 2.0 plan (min. $100/mo. + taxes & fees; before discounts). Other offers avail. based on device, plan, trade-in combo. Not all plans qualify. Well-qualified customers. Credits start w/in 3 bills. If svc cancelled, credits stop & device balance due. For new lines, if svc. on other lines cancelled w/in 90 days credits stop. No credit for optional $10/mo. Next Up Anytime upgrade feature. $35 Activation/Upgrade, additional fees, taxes & other charges, & restrictions apply. Subject to change. See att.com/iphone for more details.
2Compares cellular networks, excluding satellite.
3Based on the number of fiber to the home households using publicly available data.
4Requires port-in of new line(s) and eligible postpaid service. Up to $800 via reward card (redemption required). Reward Card amount based on remaining balance owed on your competing wireless provider smartphone (up to $800/line, up to 10 lines). Must submit most recent bill within 60 days of activation; card delivered w/in 8-10 weeks. $35 Activ./line, add'l fees, & other charges, & restr's apply. Subject to change.
5Limited Time Offer. Online Only. Requires activation of a new line of wireless service (voice & data). Discounts: Up to $200 off after 36 monthly bill credits ($5.56/mo. for 36 months). Purchase Requirements: Eligible smartphones must be purchased at full price ("No Commit"), or bring your own compatible, unlocked smartphone ("BYOD"), or purchased on a qualifying 0% APR 36-month installment plan ("New Smartphone"). For New Smartphone, $0 down is available for well-qualified customers; others may require a down payment. Tax on full retail price due at sale. Activation/upgrade fee of $35 applies. Credits: Credits start within 3 bills and are applied in equal amounts over 36 months. For BYOD, tax on wireless service, if any, is calculated after application of monthly bill credit. To get all credits, No-Commit/BYOD/New Smartphone must keep eligible service for 36 months after credits start and New Smartphone must remain on installment agreement. If wireless service is canceled, promo credits will stop, and the remaining balance on a New Smartphone must be paid. For new lines, must not cancel service on any other line within 90 days or credits may stop. If customer upgrades or pays up/off the installment agreement on New Smartphone early, the credits may stop. Eligible Plans: The offer requires a postpaid unlimited voice and data plan starting at $60/mo. plus taxes and fees before discounts. AT&T may temporarily slow data speeds if the network is busy. See att.com/unlimited for current unlimited plans. Value Plus, Value Plus VL, and Value Plus Unlimited plans are not eligible. LIMITS: Limit one (1) bill credit offer per eligible new line.
6AT&T may temporarily slow data speeds if the network is busy. Roaming may be at 2G speeds
7After allotted hotspot data (based on plan), speeds slowed to a max. of 128Kbps
8AT&T 5G requires compatible device. 5G coverage not available everywhere. Learn more at att.com/5Gforyou.
9Requires compatible device/service and download of ActiveArmor app. Other terms and restrictions apply. Visit att.com/legal/terms.activeArmorMobileSecurity for details
10Available only to verified FirstNet Subscriber Paid users. For more information, see firstnet.com/firstnetandfamily.
11Apple Intelligence is available with Siri settings and device language set to Chinese (simplified), Chinese (traditional), Danish, Dutch, English, French, German, Italian, Japanese, Korean, Norwegian, Portuguese, Spanish, Swedish, Turkish, or Vietnamese. Some features may not be available in all regions or languages. Some devices may not be available in all regions. Siri AI is rolling out in beta with iOS 27 and requires an Apple Intelligence-enabled device set to a supported language. Available in English to start. Siri AI will not be initially available in the EU on iOS. Certain Apple Intelligence features that rely on server-side models are subject to daily usage limits, including but not limited to Siri AI, intelligent photo editing tools, Image Playground, and AFM 3 Cloud models in Shortcuts. Daily limits may vary by feature, request complexity, system demand, system policies, and other factors. Expanded access to such features will be available for a fee in the future. Use of these features is subject to Apple Intelligence terms and conditions. Learn more at apple.com/apple-intelligence. Siri AI is not available for users under 13.
12 Siri AI will not be available initially in the EU on iOS, iPadOS, and watchOS. Features that rely on Siri AI will also not be available in the EU on iOS, iPadOS, and watchOS. Apple is working hard to find a path forward that preserves its users' privacy and security.
13Use of an eSIM requires a carrier that supports eSIM and a wireless service plan. See carrier for details. To learn more, visit apple.com/esim.
14Credit for fiber and Internet Air downtime lasting 20 minutes or more; or for wireless and downtime lasting 60 minutes or more caused by a single incident impacting 8 or more towers. Must be connected to impacted tower at onset of outage. Restrictions and exclusions apply. Internet Backup: Fiber internet only. Requires eligible wireless service, activation, and power source; speeds vary; AT&T may slow data speeds if the network is busy. Backup may not be available in all locations. See att.com/guarantee for full details.
15Offers vary by device. Restrictions may apply.
16Five minutes begins once customer is routed to support assistance. AT&T Fiber and postpaid wireless customers only. For small business customers, learn more about the AT&T Guarantee at att.com/businessguarantee.
17Req's elig. smartphone on the AT&T Installment Plan with extra $10/mo. Next Up Anytime feature, qual. credit and elig. svc. Upgrade eligible for smartphone deals with qual. turn-in and 33% of device balance paid. Must re-add Next Up Anytime on new smartphone installment. If Next Up Anytime is canceled, promotional credits on new smartphone will stop. Offers vary by device. Limits & restr's apply
18Largest Wireless: Compares cellular networks, excluding satellite. Largest Fiber: Based on the number of fiber to the home households using publicly available data.
19Based on Ookla® Speedtest Intelligence® data, United States, 1H 2026. See https://www.ookla.com/research/reports/united-states-converged-report-h1-2026 for details. All rights reserved.
About AT&T
We help more than 100 million U.S. families, friends and neighbors, plus nearly 2.5 million businesses, connect to greater possibility. From the first phone call 150 years ago to our 5G wireless and multi-gig internet offerings today, we @ATT innovate to improve lives. For more information about AT&T Inc. (NYSE:T), please visit us at about.att.com. Investors can learn more at investors.att.com.
Netflix bulls keep pointing to a cheap multiple and record buybacks, but the real question is whether those arguments can survive two more quarters of rising content costs and slipping viewer engagement.
This post may contain links from our sponsors and affiliates, and Flywheel Publishing may receive compensation for actions taken through them.
Netflix (NASDAQ:NFLX | NFLX Price Prediction) at $71.57 faces a bearish setup. The stock has fallen 41.06% over the past year, and its next earnings report will show whether that decline is finished.
Netflix runs the world’s largest subscription streaming service, with more than 325M paid memberships. Its ad business is expected to roughly double to about $3B in 2026. Still, the fallen through Warner Bros. deal, slower viewing growth and the close of the Paramount-Warner merger have pushed shares down from $121.43 a year ago.
Ads, Buybacks and a 19x Multiple Give Netflix Bulls a Real Case Netflix trades at a forward P/E of 19 and a PEG ratio of 1.219. Those are low multiples for a company guiding to FY2026 revenue of $51.0B to $51.4B, an operating margin of 31.5% and roughly $12.5B in free cash flow. Management says it reaches under 45% of roughly 800 million addressable households.
Capital returns support the floor. Netflix bought back $4.7B of stock last quarter, its largest quarterly buyback ever, and still has $27.1B of authorization left. Deutsche Bank upgraded the stock to Buy with a $95 target, saying that worries about U.S. viewing dominate strength abroad.
Netflix Is Spending More to Hold Viewers’ Attention Content expense should rise about 10% in 2026, while viewing hours grew only 2% in the first half. Q2 free cash flow fell to $1.53B from $2.27B. Revenue of $12.56B fell just short of the $12.58B estimate.
Growth is also slowing. Q3 guidance calls for 11% FX-neutral revenue growth. Goldman Sachs kept its Buy rating but cut its target to $90, citing softer engagement and competition from YouTube. With a beta of 1.613, the stock tends to swing more than the market when sentiment turns.
Profitability Gives Netflix a Cushion Against Deeper Losses Profitability remains strong for the company. Q2 operating margin reached 33.4%, and revenue grew 13.4%, with gains in all four regions. That profitability limits the downside case. Weak engagement limits the upside case.
The next report is the swing factor. Management forecast Q3 to $12.86B in revenue and diluted EPS of $0.82. A clean beat with faster engagement would favor buyers. Another miss would favor sellers.
Netflix Lags the S&P 500 Badly Despite a $92.55 Target At $71.57, Netflix sits well below the consensus target of $92.55, which means 29.3% upside. Targets are estimates, and they have been falling. Of 51 analysts:
Strong Buy: 7 Buy: 28 Hold: 15 Sell: 1 The stock trades at 22 times trailing earnings. It sits below both its 50-day average of $75.48 and its 200-day average of $83.80. Year to date, Netflix is down 23.67%, while the S&P 500 is up 13.49%. Over one year, the gap is -41.06% versus +14.98%.
Netflix Faces Pressure Until Engagement Turns At $71.57, the bearish case for Netflix centers on engagement.
Optimists highlight the low multiple. A stock’s multiple shrinks for a reason, and in this case the reason is that each content dollar buys less viewing growth. Two of the last four quarters brought EPS misses, including a 15.79% shortfall in Q3 FY25 and an 8.55% miss in Q1 FY26.
The most likely path lower comes over the next two quarters. Live sports and a consolidated Paramount-Warner will compete for viewers, while content costs keep rising faster than viewing hours. Buybacks can hold up per-share results, while engagement remains the core problem.
This view would need to change if engagement growth clearly speeds up and ad revenue reaches its target ahead of plan. Investors who track the stock should watch view hours, ad monetization and free cash flow conversion each quarter.
Netflix is cheaper than it was, but until engagement grows faster than content spending, the discount looks earned.
Contact [email protected] for any questions or corrections.
By You're currently following this author! Click to unsubscribe from email alerts.
A Walmart employee pulls an online order fulfillment cart at a store in Wisconsin. Dominick Reuter/Business Insider The push-and-pull continues for Walmart's online order picking teams.
The retail giant has reversed an earlier policy that reduced the number of bins workers haul on specialized carts, which was first reported by Business Insider in May and intended to improve visibility and safety. Under that guidance, workers were told to push carts unless they could not safely see ahead.
The online fulfillment carts are a key piece of equipment that Walmart store employees use to gather the items shoppers order for pickup or delivery.
Four Walmart employees in three states recently told Business Insider that their store leaders instructed their teams to return to hauling eight bins on their fulfillment carts and that they are now supposed to pull the carts rather than push them. Business Insider also observed the practice during a visit to a supercenter in Wisconsin on Tuesday.
A Walmart spokesperson confirmed the policy change, saying it followed a period of testing and evaluation. Reducing the bin load over the summer allowed the company to identify ways to improve the online order fulfillment process, the spokesperson said.
The spokesperson also said the company's safety policies, which require workers to maintain control of their carts and a line of sight ahead, have not changed.
"Safety of associates and customers is absolute," the spokesperson said.
The original policy change in May came about after a short-lived April attempt to require the pulling of eight-bin carts. The requirement was widely criticized by workers for contributing to injuries and strains, such as twisted shoulders and wrists, clipped heels and ankles, and bodily collisions when a heavily loaded cart proves difficult to stop.
"This update supports a safer environment for associates and customers while helping make Walmart the best and safest place to shop and work," a memo at the time said.
A store employee pulls an order fulfillment cart through a Walmart store. Dominick Reuter/Business Insider The issue reveals a tension for Walmart as it navigates the balance between accelerating e-commerce operations and maintaining a safe environment for workers and customers. The company relies on its US fleet of more than 4,600 stores to fulfill the bulk of its online orders, and individual locations may handle several hundred online orders per day.
As the holiday shopping season starts to pick up steam, Walmart on Wednesday introduced a new express pickup option for customers to order items in the Walmart app for curbside collection in as little as one hour, in addition to its increasingly fast delivery options.
A worker in Texas said that when her manager saw her pushing her cart as specified by prior guidance, she was escorted off the sales floor into an office, where she was told that "some people may have to get transferred out" if they are unable to pull carts. The worker also said she has been unable to use her dominant hand to pull the cart behind her due to a wrist strain.
"Something that is so minor, you're not gonna go and complain, for the most part," she said.
Workers shared photographs of warning labels that say the carts should only be pushed, not pulled. Marketing materials from the cart's manufacturer show a comparable model with six bins that have a combined weight capacity of 240 pounds. The top surface is about 3.5 feet high and intended as a work area, the brochure says. With bins on top, the total height is about 5 feet, as measured by Business Insider.
A Walmart online order fulfillment cart. Dominick Reuter/Business Insider Several workers told Business Insider that Walmart swapped out wheels on some carts to better position the cart's handle for pulling, but those changes have affected the carts' handling in some cases.
The spokesperson said Walmart did replace wheels to improve maneuverability when pulling the carts and to allow workers to adjust their position to maintain clear visibility.
Workers at a Michigan store said their colleagues have filed dozens of complaints to the state's occupational health and safety board over the issue. A response to one complaint said the agency was already investigating Walmart, according to a letter viewed and verified by Business Insider. Walmart declined to comment on the complaints or the investigation.
"I'm not willing to sacrifice my body and my health over this cart," a worker in Oklahoma told Business Insider.
Walmart has also faced multiple lawsuits in recent years involving customers who say they were injured by carts pushed by employees. Workers told Business Insider their managers attributed the changing cart policies to safety incidents at other Walmart US stores. Walmart declined to comment.
E-commerce sales are booming at Walmart. US digital sales were up 24% last quarter, including more than 40% growth of store-fulfilled deliveries and 20% growth in average weekly customers, CFO John David Rainey said in August. Last quarter was at least the ninth consecutive quarter of US e-commerce growth exceeding 20%.
A Walmart employee completes an online pickup order. Dominick Reuter/Business Insider Fulfillment speed is also getting faster, with roughly 40 US markets now offering delivery times of less than 30 minutes. Walmart US CEO David Guggina said at a September conference that this assumes about 15 minutes to pick an order and 15 minutes to drive it from the store to the customer.
"If you shrink that pick time — because it's a smaller order or we make it more efficient to pick in our stores with digital shelf labels — then you can deliver faster or you can deliver further at the same speed, and that's coming to life." he said.
But that acceleration is increasing pressure on stores' fulfillment teams, who are tasked with picking items from shelves quickly, accurately, and safely, workers previously told Business Insider.
The Walmart spokesperson said worker feedback to the company has been positive about the latest changes, especially the higher capacity to gather more items during each walk.
Read next
Dominick Reuter You're currently following this author! Click to unsubscribe from email alerts.
Dominick Reuter is a senior retail reporter for Business Insider, primarily covering Walmart, Target, Costco, and other big box retailers. His stories tend to focus on issues and trends that affect employees and customers, such as affordability challenges and the growing race to provide ultra-fast delivery services on e-commerce orders.Prior to joining BI in 2019, Dominick worked for more than a decade as an independent photojournalist covering a wide range of stories for global wire services and newspapers, including Reuters, the Wall Street Journal, and Agence France-Presse.Dominick studied photojournalism at Boston University and later earned a Masters in business and economics journalism from Columbia University.If you're an employee or customer with a story to share, please contact me via email or text/call/Signal at 646-768-4750.
Společnost Overbrook Management ve třetím čtvrtletí snížila svůj podíl v JPMorgan Chase o 17,2 % prodejem 3 039 akcií. Nadále drží 14 590 akcií v hodnotě 4,827 milionu USD.
Overbrook Management Corp cut its holdings in JPMorgan Chase & Co. (NYSE:JPM) by 17.2% during the third quarter, according to the company in its most recent Form 13F filing with the SEC. The fund owned 14,590 shares of the financial services provider’s stock after selling 3,039 shares during the quarter. JPMorgan Chase & Co. comprises 0.8% of Overbrook Management Corp’s portfolio, making the stock its 28th largest position. Overbrook Management Corp’s holdings in JPMorgan Chase & Co. were worth $4,827,000 as of its most recent SEC filing.
A number of other institutional investors have also recently bought and sold shares of the business. Concorde Asset Management LLC increased its holdings in JPMorgan Chase & Co. by 1.1% in the second quarter. Concorde Asset Management LLC now owns 2,660 shares of the financial services provider’s stock valued at $871,000 after purchasing an additional 29 shares during the last quarter. Elevation Wealth Management LLC grew its position in shares of JPMorgan Chase & Co. by 1.0% during the 2nd quarter. Elevation Wealth Management LLC now owns 3,074 shares of the financial services provider’s stock worth $1,006,000 after buying an additional 29 shares during the period. Henrickson Nauta Wealth Advisors Inc. grew its position in shares of JPMorgan Chase & Co. by 0.8% during the 2nd quarter. Henrickson Nauta Wealth Advisors Inc. now owns 3,531 shares of the financial services provider’s stock worth $1,156,000 after buying an additional 29 shares during the period. Arkansas Financial Group Inc. increased its stake in shares of JPMorgan Chase & Co. by 1.1% in the 2nd quarter. Arkansas Financial Group Inc. now owns 2,667 shares of the financial services provider’s stock valued at $873,000 after acquiring an additional 30 shares during the last quarter. Finally, Flynn Zito Capital Management LLC raised its position in shares of JPMorgan Chase & Co. by 1.1% in the 2nd quarter. Flynn Zito Capital Management LLC now owns 2,830 shares of the financial services provider’s stock valued at $926,000 after acquiring an additional 30 shares during the period. Institutional investors and hedge funds own 71.55% of the company’s stock.
Insider Activity at JPMorgan Chase & Co. In other news, insider Robin Leopold sold 2,500 shares of the business’s stock in a transaction dated Thursday, September 10th. The stock was sold at an average price of $352.81, for a total value of $882,025.00. Following the sale, the insider directly owned 71,047 shares in the company, valued at $25,066,092.07. The trade was a 3.40% decrease in their ownership of the stock. The sale was disclosed in a document filed with the SEC, which is available at the SEC website. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. 0.41% of the stock is currently owned by company insiders.
JPMorgan Chase & Co. Stock Performance Shares of JPM opened at $331.67 on Friday. The firm has a market cap of $881.63 billion, a P/E ratio of 14.21, a PEG ratio of 1.36 and a beta of 1.02. JPMorgan Chase & Co. has a twelve month low of $279.10 and a twelve month high of $366.50. The company has a debt-to-equity ratio of 1.30, a quick ratio of 0.85 and a current ratio of 0.85. The firm’s 50 day moving average price is $350.75 and its two-hundred day moving average price is $328.64. JPMorgan Chase & Co. (NYSE:JPM – Get Free Report) last issued its quarterly earnings data on Tuesday, July 14th. The financial services provider reported $6.14 earnings per share (EPS) for the quarter, topping the consensus estimate of $5.59 by $0.55. The company had revenue of $58.02 billion during the quarter, compared to the consensus estimate of $50.72 billion. JPMorgan Chase & Co. had a net margin of 21.86% and a return on equity of 18.23%. The firm’s revenue was up 27.7% compared to the same quarter last year. During the same quarter in the prior year, the firm earned $4.96 earnings per share. On average, analysts forecast that JPMorgan Chase & Co. will post 24.16 EPS for the current fiscal year.
JPMorgan Chase & Co. Increases Dividend The company also recently declared a quarterly dividend, which will be paid on Saturday, October 31st. Shareholders of record on Tuesday, October 6th will be paid a $1.65 dividend. The ex-dividend date of this dividend is Tuesday, October 6th. This represents a $6.60 annualized dividend and a dividend yield of 2.0%. This is a positive change from JPMorgan Chase & Co.’s previous quarterly dividend of $1.50. JPMorgan Chase & Co.’s dividend payout ratio (DPR) is 28.28%.
Key JPMorgan Chase & Co. News Here are the key news stories impacting JPMorgan Chase & Co. this week:
Positive Sentiment: JPMorgan’s 10% dividend increase highlights strong earnings power and capital-generation capacity. The increase appears comfortably supported by the bank’s payout ratio, which may reinforce income-focused investor interest. JPMorgan dividend article Positive Sentiment: TD Cowen initiated coverage with a Hold rating and a $370 price target, implying meaningful potential upside from the reference price. While not an outright bullish recommendation, the target provides a constructive valuation signal. Positive Sentiment: Chase is expanding its business-banking platform with payroll services, creating an additional source of client engagement, fee revenue and cross-selling opportunities. Chase payroll article Neutral Sentiment: Analysts expect solid third-quarter revenue and continued banking momentum, but investors will also be watching expenses, credit provisions, loan growth and net interest income. Strong results could support the shares, while any deterioration could pressure the premium valuation. JPMorgan Q3 earnings preview Neutral Sentiment: JPMorgan appointed Eleni Skoura to lead its Chase business in Germany. The leadership change may support European growth, but it is unlikely to materially affect near-term earnings. JPMorgan Germany leadership article Negative Sentiment: JPMorgan strategists warn that rapidly rising long-term Treasury yields, approaching 6% for the 30-year bond, can weigh on markets and increase pressure on bank valuations, credit conditions and trading activity. Negative Sentiment: Investors remain concerned about elevated operating costs, potential credit deterioration and JPM’s relatively premium valuation ahead of earnings. The bank’s warnings that housing affordability is near financial-crisis lows also point to a weak or “frozen” housing market, a risk for consumer and mortgage-related activity. Wall Street Analysts Forecast Growth Several research analysts recently weighed in on the stock. Bank of America lifted their price objective on shares of JPMorgan Chase & Co. from $408.00 to $420.00 and gave the stock a “buy” rating in a research note on Thursday, July 16th. Barclays reiterated an “overweight” rating on shares of JPMorgan Chase & Co. in a report on Tuesday. TD Cowen began coverage on shares of JPMorgan Chase & Co. in a research report on Thursday. They set a “hold” rating and a $370.00 price target on the stock. HSBC boosted their price target on shares of JPMorgan Chase & Co. from $369.00 to $377.00 and gave the company a “hold” rating in a report on Monday, September 28th. Finally, Evercore reaffirmed an “outperform” rating and set a $360.00 price objective on shares of JPMorgan Chase & Co. in a research note on Monday, July 6th. Fifteen analysts have rated the stock with a Buy rating and thirteen have issued a Hold rating to the company. Based on data from MarketBeat, JPMorgan Chase & Co. presently has a consensus rating of “Moderate Buy” and an average target price of $362.88.
Get Our Latest Stock Report on JPMorgan Chase & Co.
(Free Report)
JPMorgan Chase & Co is a global financial services company headquartered in New York City. Through its businesses, the company provides banking, investment banking, asset management, private banking, commercial banking, consumer lending and payment services to individuals, businesses, institutions and governments.
The company operates through major business areas that include Consumer & Community Banking, Commercial & Investment Banking, and Asset & Wealth Management. Its products and services include deposit accounts, credit cards, mortgages, auto loans, business financing, investment and advisory services, securities trading and custody, payment processing, and wealth-management solutions.
JPMorgan Chase serves customers in the United States and maintains operations and client relationships across international markets.
Featured Stories Five stocks we like better than JPMorgan Chase & Co. Want Private-Market Access to Kalshi and Polymarket? Try This ETF Levi’s Stock Dip Reveals Value Opportunity Despite Q3 Headwinds PepsiCo Stock Looks Poised to Bottom With High Yield, Deep Value Alphabet’s $1.8 Billion Black Hills Deal Powers AI Data Center Push Want to see what other hedge funds are holding JPM? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for JPMorgan Chase & Co. (NYSE:JPM – Free Report).
Receive News & Ratings for JPMorgan Chase & Co. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for JPMorgan Chase & Co. and related companies with MarketBeat.com's FREE daily email newsletter.
Johnson & Johnson uvedl, že ve studii fáze 3 dosáhlo po 112 týdnech odpovědi PASI 90 nejméně 72 % pacientů s lupénkou léčených přípravkem ICOTYDE, přičemž nebyly zaznamenány žádné nové bezpečnostní signály.
Phase 3 data presented at Fall Clinical Dermatology show high, sustained response rates in adults and adolescents, with nearly three-quarters achieving clear or almost clear skin at two years and a continued favorable safety profile , /PRNewswire/ -- Johnson & Johnson (NYSE: JNJ) today announced new two-year results from the Phase 3 ICONIC-LEADa study evaluating ICOTYDE® (icotrokinra), the first and only targeted oral peptide that precisely blocks the IL-23 receptor1, in adults and pediatric patients 12 years of age and older (adolescents) with moderate-to-severe plaque psoriasis.
These data, presented at Fall Clinical Dermatology (FCD) 2026, demonstrated consistently high levels of skin clearance and patient-reported symptom improvement at Week 112, with no new safety signals identified.2
"As plaque psoriasis is a chronic lifelong disease, durable results are essential in therapy selection. With two-year data that show long-term skin clearance and a consistent safety profile, ICOTYDE is transforming how we think about plaque psoriasis treatment," said Mark Lebwohl, M.D., Professor and Chair Emeritus, Department of Dermatology, Icahn School of Medicine at Mount Sinai and ICONIC-LEAD study investigator. b "I'm excited to have this practice-changing targeted oral peptide as a first-line systemic therapy for both my adult and adolescent patients."
ICOTYDE clinical data highlights2
High levels of skin clearance were observed at Week 112, with ≥72% of ICOTYDE-treated patients achieving a Psoriasis Area and Severity Index score (PASI)c of 90 and ≥70% achieving clear or almost clear skin (Investigator's Global Assessment [IGA]d 0/1) from Week 64 through Week 112. Complete skin clearance was sustained from Week 64 through Week 112, with ≥44% of ICOTYDE-treated patients achieving PASI 100 and ≥46% achieving IGA 0 (clear skin). Clinically meaningful improvement in itch was sustained in 78% of patients from Week 64 to Week 112. Among PASI 90 responders who were withdrawn from ICOTYDE at Week 24, 85% regained PASI 90 response within 24 weeks of retreatment. Safety findings through Week 112 remained consistent with the established safety profile of ICOTYDE, with no new safety signals identified. "These long-term results affirm that ICOTYDE, as the first and only targeted oral peptide, represents a groundbreaking shift in the treatment of plaque psoriasis," said David M. Lee, M.D., Ph.D., Global Immunology Therapeutic Area Head, Johnson & Johnson. "Due to the chronic nature of the disease, long-term management is key, and ICOTYDE is delivering on the promise of transformational innovation to meet the needs of patients."
Editor's notes:
a. ICONIC-LEAD is a Phase 3 RCT evaluating the efficacy and safety of ICOTYDE compared with placebo in 684 participants (ICOTYDE=456; placebo=228) 12 years of age or older with moderate-to-severe plaque PsO, with the higher efficacy bar of PASI 90 and IGA score of 0/1 with at least a 2-grade improvement as co-primary endpoints. ICONIC-LEAD enrolled 66 adolescent patients. Drug withdrawal and retreatment responses were also captured among PASI 75 or IGA 0/1 responders at Week 24.
b. Dr. Lebwohl is a paid consultant for Johnson & Johnson. He has not been compensated for any media work.
c. The Psoriasis Area and Severity Index (PASI) score grades the amount of surface area on each body region that is covered by psoriasis plaques and the severity of plaques for their redness, thickness and scaliness. PASI 100 corresponds to an improvement of 100% in PASI score from baseline.3
d. The Investigator's Global Assessment (IGA) is a five-point scale with a severity score ranging from 0 to 4, where 0 indicates clear, 1 is minimal, 2 is mild, 3 is moderate, and 4 indicates severe disease.4
About the ICONIC clinical development program
The pivotal Phase 3 ICONIC clinical development program includes four studies of ICOTYDE in patients with moderate-to-severe plaque PsO.
ICONIC-LEAD (NCT06095115) is a RCT to evaluate the efficacy and safety of ICOTYDE compared with placebo in participants with moderate-to-severe plaque PsO, with PASI 90 and IGA score of 0 or 1 with at least a 2-grade improvement as co-primary.5 ICONIC-TOTAL (NCT06095102) is a RCT to evaluate the efficacy and safety of ICOTYDE compared with placebo for the treatment of PsO in participants with at least moderate severity affecting special areas (e.g., scalp, genital, and/or hands and feet) with overall IGA score of 0 or 1 with at least a 2-grade improvement as the primary endpoint.6 ICONIC-ADVANCE 1 (NCT06143878) and ICONIC-ADVANCE 2 (NCT06220604) are RCTs to evaluate the efficacy and safety of ICOTYDE compared with both placebo and deucravacitinib in adults with moderate-to-severe plaque PsO. 7,8 Additional studies underway include: ICONIC-PsA 1 (NCT06878404) and ICONIC-PsA 2 (NCT06807424) in active psoriatic arthritis; ICONIC-ASCEND (NCT06934226) in moderate-to-severe plaque psoriasis; ICONIC-UC (NCT071196748) in moderately to severely active ulcerative colitis; and ICONIC-CD (NCT7196722) in moderately to severely active Crohn's disease.9,10,11,12,13
About plaque psoriasis
Plaque psoriasis (PsO) is a chronic immune-mediated disease resulting in overproduction of skin cells, which causes inflamed, scaly plaques that may be itchy or painful.14 It is estimated that 8 million Americans and more than 125 million people worldwide live with the disease.15 Nearly one-quarter of all people with plaque PsO have cases that are considered moderate-to-severe.15 Plaques typically appear as raised patches with a silvery white buildup of dead skin cells or scales. Plaques may appear red in lighter skin or more of a purple, gray or dark brown color in patients with darker skin tones. Plaques can appear anywhere on the body, although they most often appear on the scalp, knees, elbows, and torso.16 Living with plaque PsO can be a challenge and impact life beyond a person's physical health, including emotional health, relationships, and handling the stressors of life.17 Psoriasis on highly visible areas of the body or sensitive skin, such as the scalp, hands, feet, and genitals, can have an increased negative impact on quality of life.18
About ICOTYDE® (icotrokinra)
ICOTYDE® (icotrokinra) is the first and only targeted oral peptide designed to precisely block the IL-23 receptor, which underpins the inflammatory response in moderate-to-severe plaque PsO.1,19,20 ICOTYDE binds to the IL-23 receptor with single-digit picomolar affinity and demonstrated potent, precise inhibition of IL-23 signaling in human T cells.21 Clinical significance of these findings is unknown.
ICOTYDE is currently approved in the U.S. for the treatment of moderate-to-severe plaque PsO in adults and pediatric patients 12 years of age and older who weigh at least 40 kg who are candidates for systemic therapy or phototherapy. Patients on ICOTYDE take one pill, once daily upon waking with water on an empty stomach, at least 30 minutes prior to eating.22
ICOTYDE is also approved in Europe, Japan and China for the treatment of adults and adolescents with psoriasis.
ICOTYDE was jointly discovered and is being developed pursuant to the license and collaboration agreement between Protagonist and Johnson & Johnson. Johnson & Johnson retains exclusive worldwide rights to develop ICOTYDE in Phase 2 clinical trials and beyond, and to commercialize compounds derived from the research conducted pursuant to the agreement against a broad range of indications.23,24, 25
ICOTYDE is also being studied in active psoriatic arthritis, moderately to severely active ulcerative colitis and moderately to severely active Crohn's disease.9,10,11,12,13
ICOTYDE INDICATION AND IMPORTANT SAFETY INFORMATION
WHAT IS ICOTYDE (icotrokinra)?
ICOTYDETM 200 mg is a prescription medicine used to treat moderate to severe plaque psoriasis in adults and children 12 years of age and older who weigh at least 88 pounds (40 kg), who may benefit from taking injections or medicines by mouth (systemic therapy) or treatment using ultraviolet or UV light (phototherapy).
IMPORTANT SAFETY INFORMATION
What is the most important information I should know about ICOTYDE?
Infections. Medicines that interact with the immune system, such as ICOTYDE, may lower your ability to fight infections and may increase your risk of infections. Your healthcare provider may check you for infections and tuberculosis (TB) before starting treatment and may treat you for TB before you begin treatment with ICOTYDE if you have a history of TB or have active TB. Your healthcare provider should watch you closely for signs and symptoms of TB during and after treatment with ICOTYDE. Tell your healthcare provider right away if you have any infection or have symptoms of an infection, including:
fever, sweat, or chills cough shortness of breath blood in your mucus (phlegm) muscle aches warm, red, or painful skin or sores on your body different from your psoriasis weight loss diarrhea or stomach pain burning when you urinate or urinating more often than normal Before taking ICOTYDE, tell your healthcare provider about all of your medical conditions, including if you:
have an infection that does not go away or that keeps coming back. have tuberculosis (TB) or have been in close contact with someone with TB. have recently received or are scheduled to receive an immunization (vaccine). Avoid receiving live vaccines during treatment with ICOTYDE. have kidney problems. are pregnant or plan to become pregnant. It is not known if ICOTYDE can harm your unborn baby.
Pregnancy Safety Study. There is a pregnancy safety study for women who take ICOTYDE during pregnancy. The purpose of this study is to collect information about the health of you and your baby. If you are pregnant or become pregnant during treatment with ICOTYDE, you can report your pregnancy by calling 1-800-526-7736 or visiting www.ICOTYDE.com. are breastfeeding or plan to breastfeed. It is not known if ICOTYDE passes into your breast milk. Talk to your healthcare provider about the best way to feed your baby during treatment with ICOTYDE. Tell your healthcare provider about all the medicines you take, including prescription and over-the-counter medicines, vitamins, and herbal supplements.
What are the possible side effects of ICOTYDE?
ICOTYDE may cause serious side effects. See "What is the most important information I should know about ICOTYDE?"
The most common side effects of ICOTYDE include:
headache nausea cough fungal infection tiredness These are not all the possible side effects of ICOTYDE. Call your doctor for medical advice about side effects. You are encouraged to report negative side effects of prescription drugs to the FDA. Visit www.fda.gov/medwatch, or call 1-800-FDA-1088.
How should I take ICOTYDE?
Take ICOTYDE exactly as your healthcare provider tells you to take it. Take ICOTYDE 1 time a day when you wake up on an empty stomach with water. Wait at least 30 minutes after taking ICOTYDE before eating food. If you have difficulty swallowing tablets, ICOTYDE can be dispersed in water. For more information, please read the Medication Guide. If you miss a dose of ICOTYDE, take the dose as soon as you remember and go back to your regular schedule the next day. Please read the full Prescribing Information, including Medication Guide, for ICOTYDE and discuss any questions that you have with your doctor.
cp-564097v2
About Johnson & Johnson
At Johnson & Johnson, we believe health is everything. Our strength in healthcare innovation empowers us to build a world where complex diseases are prevented, treated, and cured, where treatments are smarter and less invasive, and solutions are personal. Through our expertise in Innovative Medicine and MedTech, we are uniquely positioned to innovate across the full spectrum of healthcare solutions today to deliver the breakthroughs of tomorrow and profoundly impact health for humanity.
Learn more at https://www.jnj.com/ or at www.innovativemedicine.jnj.com. Follow us at @JNJInnovMed.
Janssen Biotech, Inc. is a Johnson & Johnson company.
Cautions Concerning Forward-Looking Statements
This press release contains "forward-looking statements" as defined in the Private Securities Litigation Reform Act of 1995 regarding ICOTYDE™ (icotrokinra). The reader is cautioned not to rely on these forward-looking statements. These statements are based on current expectations of future events. If underlying assumptions prove inaccurate or known or unknown risks or uncertainties materialize, actual results could vary materially from the expectations and projections of Johnson & Johnson. Risks and uncertainties include, but are not limited to: challenges and uncertainties inherent in product research and development, including the uncertainty of clinical success and of obtaining regulatory approvals; uncertainty of commercial success; manufacturing difficulties and delays; competition, including technological advances, new products and patents attained by competitors; challenges to patents; product efficacy or safety concerns resulting in product recalls or regulatory action; changes in behavior and spending patterns of purchasers of health care products and services; changes to applicable laws and regulations, including global health care reforms; and trends toward health care cost containment. A further list and descriptions of these risks, uncertainties and other factors can be found in Johnson & Johnson's most recent Annual Report on Form 10-K, including in the sections captioned "Cautionary Note Regarding Forward-Looking Statements" and "Item 1A. Risk Factors," and in Johnson & Johnson's subsequent Quarterly Reports on Form 10-Q and other filings with the Securities and Exchange Commission. Copies of these filings are available online at www.sec.gov, www.jnj.com, investor.jnj.com or on request from Johnson & Johnson. Johnson & Johnson does not undertake to update any forward-looking statement as a result of new information or future events or developments.
1 Bissonnette R, et al. Data presentation. A phase 2, randomized, placebo-controlled, dose-ranging study of oral JNJ-77242113 for the treatment of moderate-to-severe plaque psoriasis: FRONTIER 1. Presented at WCD 2023, July 3-8.
2 Bissonnette R, et al. Data presentation. Durability of Clinical Response, Participant-Reported Outcomes, and Safety Through 2 Years With Icotrokinra in Adults and Adolescents With Moderate-to-Severe Plaque Psoriasis: Results From the Phase 3, ICONIC-LEAD Study. Presented at the Fall Clinical Dermatology Conference 2026. Poster presentation. October 2026.
3 Thompson Jr, D. How the Psoriasis Area and Severity Index works. Everyday Health. Available at: https://www.everydayhealth.com/psoriasis/living-with/how-the-pasi-index-works. Accessed October 2026.
4 Langley RG, Feldman SR, Nyirady J, van de Kerkhof P, Papavassilis C. The 5-point Investigator's Global Assessment (IGA) Scale: A modified tool for evaluating plaque psoriasis severity in clinical trials. J Dermatolog Treat. 2015 Feb;26(1):23-31. doi: 10.3109/09546634.2013.865009. Epub 2013 Dec 20. PMID: 24354461. Accessed October 2026.
5 Clinicaltrials.gov. A study of JNJ-2113 in adolescent and adult participants with moderate-to-severe plaque psoriasis (ICONIC-LEAD). Identifier NCT06095115. https://classic.clinicaltrials.gov/ct2/show/NCT06095115. Accessed October 2026.
6 Clinicaltrials.gov. A study of JNJ-2113 for the treatment of participants with plaque psoriasis involving special areas (scalp, genital, and/or palms of the hands and the soles of the feet) (ICONIC-TOTAL). Identifier NCT06095102. https://classic.clinicaltrials.gov/ct2/show/NCT06095102. Accessed October 2026.
7 Clinicaltrials.gov. A Study of JNJ-77242113 for the Treatment of Participants With Moderate-to-severe Plaque Psoriasis. Identifier NCT06143878. https://clinicaltrials.gov/study/NCT06143878?term=jnj-77242113&rank=10. Accessed October 2026.
8 Clinicaltrials.gov. A Study of JNJ-77242113 for the Treatment of Participants With Moderate-to-severe Plaque Psoriasis (ICONIC-ADVANCE 2). Identifier NCT06220604. https://clinicaltrials.gov/study/NCT06220604. Accessed October 2026.
9 Clinicaltrials.gov. A Study to Evaluate the Efficacy and Safety of JNJ-77242113 (Icotrokinra) in Biologic-naïve Participants With Active Psoriatic Arthritis (ICONIC-PsA 1). Identifier NCT06878404. https://clinicaltrials.gov/study/NCT06878404. Accessed October 2026.
10 A Study to Evaluate the Efficacy and Safety of Icotrokinra (JNJ-77242113) in Biologic-experienced Participants With Active Psoriatic Arthritis (ICONIC-PsA 2). Identifier NCT06807424. https://clinicaltrials.gov/study/NCT06807424. Accessed October 2026.
11 Clinicaltrials.gov. A Study to Assess Efficacy and Safety of JNJ-77242113 Compared to Placebo and Ustekinumab in Participants With Moderate-to-severe Plaque Psoriasis (ICONIC-ASCEND). Identifier NCT06934226. https://clinicaltrials.gov/study/NCT06934226. Accessed October 2026.
12 Clinicaltrials.gov. A Protocol of Icotrokinra Therapy in Adult and Adolescent Participants With Moderately to Severely Active Ulcerative Colitis (ICONIC-UC). Identifier NCT07196748. https://clinicaltrials.gov/study/NCT07196748. Accessed October 2026.
13 Clinicaltrials.gov. A Study of Icotrokinra in Participants With Moderately to Severely Active Crohn's Disease (ICONIC-CD). Identifier NCT07196722. https://clinicaltrials.gov/study/NCT07196722. Accessed October 2026.
14 National Psoriasis Foundation. About Psoriasis. Available at: https://www.psoriasis.org/about-psoriasis. Accessed October 2026.
15 National Psoriasis Foundation. Psoriasis Statistics. Available at: https://www.psoriasis.org/content/statistics. Accessed October 2026..
16 National Psoriasis Foundation. Plaque Psoriasis. Available at: https://www.psoriasis.org/plaque/. Accessed October 2026.
17 National Psoriasis Foundation. Life with Psoriasis. Available at: https://www.psoriasis.org/life-with-psoriasis/. Accessed October 2026.
18 National Psoriasis Foundation. High Impact Sites. Available at: https://www.psoriasis.org/high-impact-sites/. Accessed October 2026.
19Razawy W, et al. The role of IL‐23 receptor signaling in inflammation‐mediated erosive autoimmune arthritis and bone remodeling. Eur J Immunol. 2018 Feb; 48(2): 220–229.
20 Tang C, et al. Interleukin-23: as a drug target for autoimmune inflammatory diseases. Immunology. 2012 Feb; 135(2): 112–124.
21 Pinter A, et al. Data Presentation. JNJ-77242113 Treatment Induces a Strong Systemic Pharmacodynamic Response Versus Placebo in Serum Samples of Patients with Plaque Psoriasis: Results from the Phase 2, FRONTIER 1 Study. Presented at EADV 2023, October 11-14.
22 ICOTYDE® prescribing information.
23 Protagonist Therapeutics. Press release. Protagonist Therapeutics announces amendment of agreement with Janssen Biotech for the continued development and commercialization of IL-23 antagonists. Available at: https://www.prnewswire.com/news-releases/protagonist-therapeutics-announces-amendment-of-agreement-with-janssen-biotech-for-the-continued-development-and-commercialization-of-il-23-antagonists-301343621.html. Accessed October 2026.
24 Protagonist Therapeutics. Press release. Protagonist Reports positive results from Phase 1 and pre-clinical studies of oral Interleukin-23 receptor antagonist JNJ-2113. Available at: https://www.prnewswire.com/news-releases/protagonist-reports-positive-results-from-phase-1-and-pre-clinical-studies-of-oral-interleukin-23-receptor-antagonist-jnj-2113-301823039.html. Accessed October 2026.
25 Protagonist Therapeutics. Press release. Protagonist Therapeutics announces positive topline results for Phase 2b FRONTIER 1 clinical trial of oral IL-23 receptor antagonist JNJ-2113 (PN-235) in psoriasis. Available at: https://www.prnewswire.com/news-releases/protagonist-therapeutics-announces-positive-topline-results-for-phase-2b-frontier-1-clinical-trial-of-oral-il-23-receptor-antagonist-jnj-2113-pn-235-in-psoriasis-301764181.html. Accessed October 2026.
Strength of results and outlook demonstrate Delta's structural durability in high fuel cost environment
Record September quarter revenue on broad demand strength and healthy yield growth
Expect continued momentum in December quarter with revenue expected to grow approximately 20 percent
Outlook for full-year EPS of $5.10 to $5.60 and free cash flow of approximately $2.5 billion with a double-digit return on invested capital
Strengthening investment-grade balance sheet with plan to pay down more than $2 billion of debt in 2026
, /PRNewswire/ -- Delta Air Lines (NYSE: DAL) today reported financial results for the September quarter and provided its outlook for the December quarter and full year 2026. Highlights of the September quarter, including both GAAP and adjusted metrics, are on page five and incorporated here.
"Demand remains strong, supported by consumers' growing preference for experiences and travel, with air travel continuing to be one of the best values in the consumer economy. Against this backdrop, we delivered September quarter pre-tax profit of $1.5 billion, matching last year's performance, and generated $1.9 billion of free cash flow year-to-date. Our resilience reflects the structural durability we've built over many years, enabling us to effectively navigate one of the most elevated fuel environments in recent times. The foundation of that resilience is our people, whose commitment to delivering for our customers continues to set Delta apart," said Ed Bastian, Delta's chief executive officer.
"For the full year, we expect to generate a pre-tax profit of roughly $4.5 billion, absorbing a $6 billion increase in fuel costs. Looking ahead, our focus remains on profitable growth and delivering against our long-term financial framework, including mid-teens margins and returns, durable free cash flow and gross leverage of approximately one times."
September Quarter 2026 GAAP Financial Results
Operating revenue of $20.2 billion Operating income of $1.5 billion with an operating margin of 7.2 percent Pre-tax income of $1.1 billion with a pre-tax margin of 5.3 percent Earnings per share of $1.15 Operating cash flow of $1.7 billion September Quarter 2026 Non-GAAP Financial Results
Operating revenue of $17.6 billion Operating income of $1.7 billion with an operating margin of 9.4 percent Pre-tax income of $1.5 billion with a pre-tax margin of 8.5 percent Earnings per share of $1.72 Operating cash flow of $1.7 billion Financial Guidance1
4Q26
FY 2026
Total Revenue YoY (%)
Approx. 20%
Earnings Per Share
$5.10 - $5.60
Operating Margin
7% - 9%
Free Cash Flow ($B)
Approx. $2.5
Earnings Per Share
$1.15 - $1.65
Gross Leverage2
Approx. 2.2x
Guidance for the December quarter assumes fuel at the forward curve as of October 2, 2026, and includes a refinery benefit of approximately $0.40 per gallon. This results in a projected all-in fuel price for the quarter of approximately $4.25 per gallon.
Revenue Environment and Outlook
"September quarter revenue grew approximately 16 percent over prior year, on flat capacity, driven by broad demand strength and healthy yield growth as we cover higher costs and manage the business for margins," said Joe Esposito, Delta's chief commercial officer.
"Revenue momentum is continuing in the December quarter, with strength across all products and geographies, supporting our outlook for total revenue growth of approximately 20 percent over last year. With seats growing less than 2 percent, including a reduction in Main Cabin seats, our capacity positioning supports another quarter of sequential improvement in unit revenue with progression in both Domestic and International."
Broad demand strength continued in the September quarter: Delta delivered record September quarter total revenue of $17.6 billion, increasing 16 percent over the same period last year. Adjusted total unit revenue (TRASM) grew 15 percent over prior year, accelerating 3 points from the prior quarter. Main cabin unit revenue grew 17 percent over prior year on seats down low-single digits, marking another quarter of sequential progress. Strong revenue performance across all geographies: Domestic unit revenue grew 16 percent year-over-year on strong yields and a load factor that was 1 point higher than last year, reflecting the strength of Delta's brand and a measured approach to capacity. International unit revenue increased 12 percent, with performance led by Latin where unit revenue improved 22 percent over last year. Transatlantic unit revenue growth improved 4 points sequentially to 11 percent year-over-year. Transpacific revenue grew 13 percent over prior year on 8 percent higher capacity, supporting profitable growth through new routes to Asia. Continued momentum in diversified, high-margin revenue streams: Diverse revenue streams accounted for 61 percent of total revenue in the September quarter. Premium revenue grew 18 percent year-over-year with double-digit unit revenue growth driven by yield and load factor on a 6 percent increase in seats. Cargo revenue increased 29 percent year-over-year, with roughly equal growth between volume and yield. MRO revenue grew 28 percent year-over-year, bringing year-to-date revenue to $990 million. Growing member engagement across loyalty ecosystem: Total loyalty revenue grew 18 percent, with SkyMiles member engagement continuing to deepen in the air and beyond the flight. Co-brand card acquisitions and spend both grew double-digits, the eighth consecutive quarter of double-digit growth in cardholder spend. This momentum supported 15 percent growth in American Express remuneration in the quarter, positioning the full year to exceed $9 billion. Travel products and non-air partnership revenue increased 25 percent year-over-year. Corporate sales3 grew double-digits in all sectors: Corporate sales growth was led by the Banking, Technology, and Energy sectors, with particularly strong performance in Boston and Los Angeles. Recent corporate survey results indicate over 90 percent of respondents expect their corporate travel will increase or stay the same in 2027. _______________________________________
1 Non-GAAP measures; Refer to Non-GAAP reconciliations for historical comparison figures
2 Adjusted debt to EBITDAR
3 Corporate travel sales represent the revenue from tickets sold to corporate contracted customers, including tickets for travel during and beyond the referenced time
period
Cost Performance and Outlook
"Delta delivered earnings of $1.72 per share in the September quarter, in line with last year while absorbing more than $500 million of higher fuel costs compared to our guidance in early July. In the December quarter, we expect earnings of $1.15 to $1.65 per share, based on a fuel price of approximately $4.25 per gallon. This positions earnings consistent with last year at the upper end of the range," said Erik Snell, Delta's chief financial officer.
"The Delta team continues to deliver for our customers, widening our industry lead in on-time performance and achieving record baggage results. September quarter non-fuel unit costs increased 7.3 percent over the prior year on flat capacity, driven primarily by higher crew and revenue-related costs on capacity growth that was several points below our original plan, including nearly one point of impact from summer storms. With slightly higher capacity and continued operational efficiencies, we expect December quarter non-fuel unit cost growth to improve 1 to 2 points sequentially. Looking to next year, we remain on track for low-single-digit unit cost growth as capacity normalizes, operational improvements continue and we lap higher costs in our baseline."
September Quarter 2026 Cost Performance
Operating expense of $18.7 billion and adjusted operating expense of $15.9 billion Adjusted non-fuel costs of $11.1 billion Non-fuel CASM was 14.03¢, an increase of 7.3 percent year-over-year Adjusted fuel expense of $4.1 billion was up 62 percent year-over-year Adjusted fuel price of $3.61 per gallon increased 60 percent year-over-year with a refinery benefit of 13¢ per gallon Fuel efficiency, defined as gallons per 1,000 ASMs, was 14.5 Balance Sheet, Cash and Liquidity
"We generated $463 million of free cash flow in the September quarter. The strength of our cash flow generation allows us to consistently reinvest to compound our advantages while reinforcing our investment grade balance sheet. For the full year, we expect to deliver free cash flow of approximately $2.5 billion and pay down more than $2 billion of debt, positioning us to end the year with gross leverage of approximately 2.2x," Snell said.
Adjusted net debt of $13.4 billion at September quarter end, a reduction of $950 million from the end of 2025 Payments on debt and finance lease obligations for the September quarter of $1.2 billion Adjusted operating cash flow in the September quarter of $1.7 billion, and with gross capital expenditures of $1.4 billion, free cash flow was $463 million Air Traffic Liability ended the quarter at $9.6 billion Liquidity4 of $6.9 billion at quarter-end, including $3.1 billion in undrawn revolver capacity _________________________________
4 Includes cash and cash equivalents, short-term investments and undrawn revolving credit facilities
September Quarter 2026 Highlights
Operations, Network, and Fleet
Led all carriers5 in on-time arrival and departure performance for the quarter. Set a Delta September quarter record6 for Domestic mishandled baggage rate (MBR). Took delivery of 13 aircraft in the quarter, including A350-900, A321neo, and A220-300 aircraft. Announced new international service from Seattle to Tokyo-Narita, Los Angeles to Manila, Austin to Paris-Charles de Gaulle, Detroit to Athens, and Boston to Venice, with flights beginning in 2027, while extending seasonal service on select Transatlantic routes. Expanded position in Los Angeles with announcement of largest-ever schedule, with new and increased service to multiple U.S. destinations. Culture and People
Recognized by customers for the fifth consecutive year with the award for Best Airline Staff Service in North America at the Skytrax World Airline Awards. Accrued nearly $900 million in profit sharing year-to-date toward next February's payout. Named to TIME's America's Best Companies list, the only airline in the top 100. Ranked No. 1 on PEOPLE's Companies That Care list, the only airline recognized. Contributed $100,000 to American Red Cross earthquake relief efforts in Colombia. Established the Chief Data Officer position, welcoming Ramnik Bajaj to advance Delta's data and AI capabilities, accelerate innovation, and enhance decision-making, unlocking new opportunities for Delta. Customer Experience and Loyalty
Announced a strategic relationship with Hyatt, expanding the SkyMiles loyalty ecosystem with another category-leading premium brand. JD Power ranked the Delta SkyMiles Reserve, Platinum, and Gold American Express Cards in the top three, respectively, for airline co-brand card customer satisfaction in 2026. Accelerated co-brand card acquisitions, driven by innovative card offers, such as two round-trip Delta Comfort tickets and Delta's highest-ever introductory mileage offer for new Reserve Card sign-ups. Active SkyMiles member base continued to grow, led by Gen Z and millennials, with outsized growth in focus cities and coastal hubs. Enhanced long-standing partnership with Starbucks with more ways for SkyMiles members to earn rewards. Continued rollout of fast, free Wi-Fi for SkyMiles members across nearly all of Delta's fleet with recent satellite upgrades expected to provide meaningful enhancements to connectivity. Completed rollout of Delta Concierge, our AI-powered digital assistant, to all SkyMiles members. Expanded Delta Sync experiences and offers through new partnerships with DraftKings and Sport 24. Announced a reimagined Delta One wine program featuring a curated selection of wines from Napa Valley and destinations across Delta's global network, supported by Delta's Sky Sommelier program. Environmental Sustainability
Expanded SAF access through a multi-airport agreement with Shell Aviation. Completed a new SAF blending facility at Flint Hills Resources' Pine Bend Refinery, expanding SAF availability at Delta's second-largest hub in Minneapolis-St. Paul. Joined the launch of the Georgia Sustainable Aviation Fuel (SAF) Coalition as a founding member. Launched a partnership with the National Park Foundation to support conservation across America's national parks. ______________________________________
5 FlightStats preliminary data for Delta flights system wide. All carriers is defined as competitive set (AA, AS, B6, DL, UA, and WN) from July 1 - Sep 30, 2026. On-time performance includes A0, and A14. Departure performance defined as D0
6 Excludes 2020
September Quarter 2026 Results
September quarter results have been adjusted primarily for third-party refinery sales, gains/losses on investments and Monroe hedge results as described in the reconciliations in Note A.
GAAP
$
Change
%
Change
($ in millions except per share and unit costs)
3Q26
3Q25
Operating income
1,454
1,684
(230)
(14) %
Operating margin
7.2 %
10.1 %
(2.9) pts
(29) %
Pre-tax income
1,074
1,777
(703)
(40) %
Pre-tax margin
5.3 %
10.7 %
(5.4) pts
(50) %
Net income
756
1,417
(661)
(47) %
Diluted earnings per share
1.15
2.17
(1.02)
(47) %
Operating revenue
20,186
16,673
3,513
21 %
Total revenue per available seat mile (TRASM) (cents)
25.46
21.09
4.37
21 %
Operating expense
18,732
14,989
3,743
25 %
Cost per available seat mile (CASM) (cents)
23.63
18.96
4.67
25 %
Fuel expense
4,351
2,570
1,781
69 %
Average fuel price per gallon
3.80
2.26
1.54
68 %
Operating cash flow
1,713
1,847
(134)
(7) %
Capital expenditures
1,413
1,160
253
22 %
Total debt and finance lease obligations
12,851
14,879
(2,028)
(14) %
Adjusted
$
Change
%
Change
($ in millions except per share and unit costs)
3Q26
3Q25
Operating income
1,662
1,688
(26)
(2) %
Operating margin
9.4 %
11.1 %
(1.7) pts
(15) %
Pre-tax income
1,497
1,477
20
1 %
Pre-tax margin
8.5 %
9.7 %
(1.2) pts
(12) %
Net income
1,134
1,114
20
2 %
Diluted earnings per share
1.72
1.70
0.02
1 %
Operating revenue
17,585
15,197
2,388
16 %
TRASM (cents)
22.18
19.22
2.96
15 %
Operating expense
15,924
13,508
2,416
18 %
Non-fuel cost7
11,125
10,339
786
8 %
Non-fuel unit cost (CASM-Ex) (cents)
14.03
13.08
0.95
7.3 %
Fuel expense
4,143
2,565
1,578
62 %
Average fuel price per gallon
3.61
2.25
1.36
60 %
Operating cash flow
1,716
1,816
(100)
(6) %
Free cash flow
463
833
(370)
(44) %
Gross capital expenditures
1,408
1,113
295
27 %
Adjusted net debt
13,350
15,586
(2,236)
(14) %
______________________________________
7 Updated definition excludes aircraft fuel and related taxes, Third-party refinery sales, MRO expense, and profit sharing
About Delta Air Lines Through exceptional service and the power of innovation, Delta Air Lines (NYSE: DAL) never stops looking for ways to make every trip feel tailored to every customer.
There are 100,000 Delta people leading the way to deliver a world-class customer experience on up to 5,500 daily Delta and Delta Connection flights to more than 300 destinations on six continents, connecting people to places and to each other.
Delta served more than 200 million customers in 2025 – safely, reliably and with industry-leading customer service innovation – and was recognized by Cirium for being the top on-time airline in North America for the fifth consecutive year.
We remain committed to ensuring that the future of travel is connected, personalized and enjoyable. Our people's genuine, enduring motivation is to make every customer feel welcomed and cared for across every point of their journey with us.
Headquartered in Atlanta, Delta operates significant hubs and key markets in Amsterdam, Atlanta, Bogota, Boston, Detroit, Lima, London-Heathrow, Los Angeles, Mexico City, Minneapolis-St. Paul, New York-JFK and LaGuardia, Paris-Charles de Gaulle, Salt Lake City, Santiago (Chile), Sao Paulo, Seattle, Seoul-Incheon and Tokyo.
As the leading global airline, Delta's mission to connect the world creates opportunities, fosters understanding and expands horizons by connecting people and communities to each other and to their own potential.
A founding member of the SkyTeam alliance and powered by innovative and strategic partnerships throughout the world with Aeromexico, Air France-KLM, China Eastern, Korean Air, LATAM, Virgin Atlantic and WestJet, Delta brings more choice and competition to customers worldwide. Delta's premium product line is elevated by its unique partnership with Wheels Up Experience.
Delta is America's most-awarded airline thanks to the dedication, passion and professionalism of its people. In addition to the award from Cirium, Delta has been recognized as the World's Most Admired Airline and one of the Best 100 Companies to Work For according to Fortune; the top carrier for business travelers by Business Travel News; and best U.S. airline by Forbes Travel Guide's Verified Air Travel Awards. In addition, Delta has been named to the Civic 50 by Points of Light as one of the most community minded companies in the U.S.
Forward Looking Statements
Statements made in this press release that are not historical facts, including statements regarding our estimates, expectations, beliefs, intentions, projections, goals, aspirations, commitments or strategies for the future, should be considered "forward-looking statements" under the Securities Act of 1933, as amended, the Securities Exchange Act of 1934, as amended, and the Private Securities Litigation Reform Act of 1995. Such statements are not guarantees or promised outcomes and should not be construed as such. All forward-looking statements involve a number of risks and uncertainties that could cause actual results to differ materially from the estimates, expectations, beliefs, intentions, projections, goals, aspirations, commitments and strategies reflected in or suggested by the forward-looking statements. These risks and uncertainties include, but are not limited to, the possible effects of serious accidents involving our aircraft or aircraft of our airline partners; breaches or lapses in the security of technology systems we use and rely on, which could compromise the data stored within them, as well as failure to comply with evolving global privacy and security regulatory obligations or adequately address increasing customer focus on privacy issues and data security; disruptions in our information technology infrastructure; failure of the technology we use or depend on to perform effectively, including new and emerging technologies; increases in the price of aircraft fuel; extended disruptions in the supply of aircraft fuel, including from Monroe Energy, LLC ("Monroe"), our wholly-owned subsidiary that operates the Trainer refinery; failure to achieve expected results or returns from our commercial relationships with airlines in other parts of the world and the investments we have in certain of those airlines; the effects of a significant disruption in the operations or performance of third parties on which we rely; failure to comply with the financial or other covenants in our financing agreements; labor-related disruptions; the effects on our business of seasonality and other factors beyond our control, such as changes in value in our equity investments, severe weather conditions, natural disasters or other environmental events, including from the impact of climate change; failure or inability of insurance to cover a significant liability at Monroe's refinery; failure to comply with existing and future environmental regulations to which Monroe's refinery operations are subject, including those relating to the discharge of materials into the environment, waste management, pollution prevention measures and greenhouse gas emissions; significant damage to our reputation and brand, including from exposure to significant adverse publicity or inability to achieve certain sustainability goals; our ability to retain senior management and other key employees, and to maintain our company culture; disease outbreaks or other public health threats, and measures implemented to combat them; the effects of terrorist attacks, geopolitical conflict or security events; competitive conditions in the airline industry; extended interruptions or disruptions in service at major airports where we operate; significant problems associated with types of aircraft or engines we operate; the effects of extensive regulatory and legal compliance requirements we are subject to; the impact of laws and regulations governing environmental protection, including but not limited to regulation of hazardous substances, increased regulation to reduce emissions and other risks associated with climate change, and the cost of compliance with more stringent environmental regulations; and unfavorable economic or political conditions in the markets in which we operate or volatility in currency exchange rates.
Additional information concerning risks and uncertainties that could cause differences between actual results and forward-looking statements is contained in our Securities and Exchange Commission (SEC) filings, including our Annual Report on Form 10-K for the fiscal year ended December 31, 2025 and other filings filed with the SEC from time to time. Caution should be taken not to place undue reliance on our forward-looking statements, which represent our views only as of the date of this press release, and which we undertake no obligation to update except to the extent required by law.
DELTA AIR LINES, INC.
Consolidated Statements of Operations
(Unaudited)
Three Months Ended
Nine Months Ended
September 30,
September 30,
(in millions, except per share data)
2026
2025
$ Change
% Change
2026
2025
$ Change
% Change
Operating Revenue:
Passenger
$ 15,534
$ 13,506
$ 2,028
15 %
$ 43,443
$ 38,852
$ 4,591
12 %
Cargo
301
233
68
29 %
821
654
167
26 %
Other
4,351
2,934
1,417
48 %
11,533
7,855
3,678
47 %
Total operating revenue
20,186
16,673
3,513
21 %
55,797
47,361
8,436
18 %
Operating Expense:
Salaries and related costs
4,822
4,443
379
9 %
14,124
12,928
1,196
9 %
Aircraft fuel and related taxes
4,351
2,570
1,781
69 %
11,202
7,439
3,763
51 %
Refinery expense
2,601
1,476
1,125
76 %
6,346
3,679
2,667
72 %
Contracted services
1,277
1,166
111
10 %
3,729
3,442
287
8 %
Landing fees and other rents
1,021
921
100
11 %
2,912
2,650
262
10 %
Aircraft maintenance materials and outside repairs
662
667
(5)
(1) %
2,059
1,904
155
8 %
Passenger commissions and other selling expenses
703
645
58
9 %
2,019
1,869
150
8 %
Regional carrier expense
680
649
31
5 %
2,001
1,913
88
5 %
Depreciation and amortization
673
614
59
10 %
1,964
1,823
141
8 %
Passenger service
494
485
9
2 %
1,411
1,397
14
1 %
Profit sharing
389
392
(3)
(1) %
882
986
(104)
(11) %
MRO expense
267
212
55
26 %
868
581
287
49 %
Aircraft rent
159
135
24
18 %
469
408
61
15 %
Other
633
614
19
3 %
1,992
1,987
5
— %
Total operating expense
18,732
14,989
3,743
25 %
51,978
43,006
8,972
21 %
Operating Income
1,454
1,684
(230)
(14) %
3,819
4,355
(536)
(12) %
Non-Operating Income/(Expense):
Interest expense, net
(146)
(171)
25
(15) %
(442)
(521)
79
(15) %
Gain/(loss) on investments, net
(218)
311
(529)
NM
(419)
1,007
(1,426)
NM
Gain/(loss) on extinguishment of debt
2
(6)
8
NM
(3)
(26)
23
(88) %
Miscellaneous, net
(18)
(41)
23
(56) %
(87)
(143)
56
(39) %
Total non-operating income/(expense), net
(380)
93
(473)
NM
(951)
317
(1,268)
NM
Income Before Income Taxes
1,074
1,777
(703)
(40) %
2,868
4,672
(1,804)
(39) %
Income Tax Provision
(318)
(360)
42
(12) %
(798)
(886)
88
(10) %
Net Income
$ 756
$ 1,417
$ (661)
(47) %
$ 2,070
$ 3,786
$ (1,716)
(45) %
Basic Earnings Per Share
$ 1.15
$ 2.18
$ 3.17
$ 5.85
Diluted Earnings Per Share
$ 1.15
$ 2.17
$ 3.15
$ 5.80
Basic Weighted Average Shares Outstanding
655
649
654
648
Diluted Weighted Average Shares Outstanding
659
654
657
653
DELTA AIR LINES, INC.
Passenger Revenue
(Unaudited)
Three Months Ended
Nine Months Ended
September 30,
September 30,
(in millions)
2026
2025
$ Change
% Change
2026
2025
$ Change
% Change
Ticket - Premium products
$ 6,818
$ 5,796
$ 1,022
18 %
$ 19,100
$ 16,402
$ 2,698
16 %
Ticket - Main cabin
6,802
6,063
739
12 %
19,058
17,771
1,287
7 %
Loyalty travel awards
1,302
1,108
194
18 %
3,578
3,140
438
14 %
Travel-related services
612
539
73
14 %
1,707
1,539
168
11 %
Passenger revenue
$ 15,534
$ 13,506
$ 2,028
15 %
$ 43,443
$ 38,852
$ 4,591
12 %
DELTA AIR LINES, INC.
Other Revenue
(Unaudited)
Three Months Ended
Nine Months Ended
September 30,
September 30,
(in millions)
2026
2025
$ Change
% Change
2026
2025
$ Change
% Change
Refinery
$ 2,601
$ 1,476
$ 1,125
76 %
$ 6,346
$ 3,680
$ 2,666
72 %
Loyalty and related
1,346
1,129
217
19 %
3,911
3,338
573
17 %
MRO
296
231
65
28 %
990
621
369
59 %
Miscellaneous
108
98
10
10 %
286
216
70
32 %
Other revenue
$ 4,351
$ 2,934
$ 1,417
48 %
$ 11,533
$ 7,855
$ 3,678
47 %
DELTA AIR LINES, INC.
Total Revenue
(Unaudited)
Increase (Decrease)
3Q26 vs 3Q25
Revenue
3Q26 ($M)
Change
Unit Revenue
Yield
Capacity
Domestic
$ 10,594
16 %
16 %
15 %
— %
Atlantic
3,317
11 %
11 %
12 %
— %
Latin America
867
14 %
22 %
20 %
(6) %
Pacific
756
13 %
5 %
7 %
8 %
Passenger Revenue
$ 15,534
15 %
15 %
14 %
— %
Cargo Revenue
301
29 %
Other Revenue
4,351
48 %
Total Revenue
$ 20,186
21 %
21 %
Third Party Refinery Sales
(2,601)
Total Revenue, adjusted (See Note A)
$ 17,585
16 %
15 %
DELTA AIR LINES, INC.
Statistical Summary
(Unaudited)
Three Months Ended
Nine Months Ended
September 30,
September 30,
2026
2025
Change
2026
2025
Change
Revenue passenger miles (millions)
68,133
67,621
1
%
191,369
189,717
1
%
Available seat miles (millions)
79,288
79,054
—
%
227,145
225,099
1
%
Passenger mile yield (cents)
22.80
19.97
14
%
22.70
20.48
11
%
Passenger revenue per available seat mile (cents)
19.59
17.08
15
%
19.13
17.26
11
%
Total revenue per available seat mile (cents)
25.46
21.09
21
%
24.56
21.04
17
%
TRASM, adjusted - see Note A (cents)
22.18
19.22
15
%
21.77
19.41
12
%
Cost per available seat mile (cents)
23.63
18.96
25
%
22.88
19.11
20
%
CASM-Ex - see Note A (cents)
14.03
13.08
7.3
%
14.39
13.47
7
%
Passenger load factor
86 %
86 %
—
pts
84 %
84 %
—
pts
Fuel gallons consumed (millions)
1,146
1,138
1
%
3,256
3,226
1
%
Average price per fuel gallon
$ 3.80
$ 2.26
68
%
$ 3.44
$ 2.31
49
%
Average price per fuel gallon, adjusted - see Note A
$ 3.61
$ 2.25
60
%
$ 3.42
$ 2.31
48
%
DELTA AIR LINES, INC.
Consolidated Statements of Cash Flows
(Unaudited)
Three Months Ended
September 30,
(in millions)
2026
2025
Cash Flows From Operating Activities:
Net income
$ 756
$ 1,417
Depreciation and amortization
673
614
(Gain) loss on fair value investments
226
(307)
Changes in air traffic liability
(460)
(728)
Changes in profit sharing
386
392
Changes in balance sheet and other, net
132
459
Net cash provided by operating activities
1,713
1,847
Cash Flows From Investing Activities:
Property and equipment additions:
Flight equipment, including advance payments
(1,200)
(930)
Ground property and equipment, including technology
(213)
(230)
Acquisition of strategic investments and related
(45)
—
Other, net
155
125
Net cash used in investing activities
(1,303)
(1,035)
Cash Flows From Financing Activities:
Proceeds from short-term obligations
75
—
Proceeds from long-term obligations
—
217
Payments on debt and finance lease obligations
(1,234)
(459)
Cash dividends
(141)
(122)
Other, net
(1)
(6)
Net cash used in financing activities
(1,301)
(370)
Net (Decrease)/Increase in Cash, Cash Equivalents and Restricted Cash Equivalents
(891)
442
Cash, cash equivalents and restricted cash equivalents at beginning of period
4,773
3,529
Cash, cash equivalents and restricted cash equivalents at end of period
$ 3,882
$ 3,971
The following table provides a reconciliation of cash, cash equivalents and restricted cash reported within the Consolidated Balance Sheets to the total of the same
such amounts shown above:
Current assets:
Cash and cash equivalents
$ 3,787
$ 3,791
Restricted cash included in prepaid expenses and other
77
97
Other assets:
Restricted cash included in other noncurrent assets
18
83
Total cash, cash equivalents and restricted cash equivalents
$ 3,882
$ 3,971
DELTA AIR LINES, INC.
Consolidated Balance Sheets
(Unaudited)
September 30,
December 31,
(in millions)
2026
2025
ASSETS
Current Assets:
Cash and cash equivalents
$ 3,787
$ 4,310
Accounts receivable, net
4,325
2,850
Fuel, expendable parts and supplies inventories, net
2,637
1,601
Prepaid expenses and other
2,741
2,207
Total current assets
13,490
10,968
Noncurrent Assets:
Property and equipment, net
42,206
39,743
Operating lease right-of-use assets
6,120
6,244
Goodwill
9,753
9,753
Identifiable intangibles, net
5,960
5,966
Equity investments
3,824
4,222
Other noncurrent assets
4,695
4,421
Total noncurrent assets
72,558
70,349
Total assets
$ 86,048
$ 81,317
LIABILITIES AND STOCKHOLDERS' EQUITY
Current Liabilities:
Current maturities of debt and finance leases
$ 3,324
$ 1,605
Current maturities of operating leases
912
809
Air traffic liability
9,560
7,157
Accounts payable
6,595
5,226
Accrued salaries and related benefits
4,550
4,906
Loyalty program deferred revenue
5,451
4,876
Fuel card obligation
1,100
1,100
Other accrued liabilities
2,083
1,945
Total current liabilities
33,575
27,624
Noncurrent Liabilities:
Debt and finance leases
9,527
12,507
Noncurrent operating leases
5,072
5,353
Pension, postretirement and related benefits
3,031
3,156
Loyalty program deferred revenue
4,181
4,386
Deferred income taxes, net
4,232
3,444
Other noncurrent liabilities
3,917
3,994
Total noncurrent liabilities
29,960
32,840
Commitments and Contingencies
Stockholders' Equity:
22,513
20,853
Total liabilities and stockholders' equity
$ 86,048
$ 81,317
Note A: The following tables show reconciliations of non-GAAP financial measures. The reasons Delta uses these measures are described below. Reconciliations may not calculate exactly due to rounding.
Delta sometimes uses information ("non-GAAP financial measures") that is derived from the Consolidated Financial Statements, but that is not presented in accordance with accounting principles generally accepted in the U.S. ("GAAP"). Under the Securities and Exchange Commission rules, non-GAAP financial measures may be considered in addition to results prepared in accordance with GAAP, but should not be considered a substitute for or superior to GAAP results. The tables below show reconciliations of non-GAAP financial measures used in this release to the most directly comparable GAAP financial measures.
Forward Looking Projections. Delta is not able to reconcile forward looking non-GAAP financial measures without unreasonable effort because the adjusting items such as those used in the reconciliations below will not be known until the end of the period and could be significant.
Adjustments. These reconciliations include certain adjustments to GAAP measures that are made to provide comparability between the reported periods, if applicable, and for the reasons indicated below:
Third-party refinery sales. Refinery sales to third parties, and related expenses, are not related to our airline segment. Excluding these sales therefore provides a more meaningful comparison of our airline operations to the rest of the airline industry.
MTM adjustments and settlements on hedges. Mark-to-market ("MTM") adjustments are defined as fair value changes recorded in periods other than the settlement period. MTM fair value changes are not necessarily indicative of the actual settlement value of the underlying hedge in the contract settlement period, and therefore we remove this impact to allow investors to better understand and analyze our core performance. Settlements represent cash received or paid on hedge contracts closed (i.e., settled) during the applicable period. With respect to hedges related to Monroe's inventory, settlements often occur before the related refinery inventory is sold. Beginning in 2026, settlement gains and losses related to Monroe's inventory that remains on-hand at period end are excluded from our adjusted results. These settlement gains and losses will be reflected in adjusted results during the period the inventory is sold. This change was made to match the timing of expense and revenue recognition and we have similarly adjusted the presentation of reconciliations for prior periods included here.
MTM adjustments on investments. Unrealized MTM gains/losses result from our equity investments that are accounted for at fair value in non-operating expense. The gains/losses are driven by changes in stock prices, foreign currency fluctuations and other valuation techniques for investments in certain companies, particularly those without publicly-traded shares. Adjusting for these gains/losses allows investors to better understand and analyze our core operational performance in the periods shown.
Gain/loss on extinguishment of debt. This adjustment relates to early termination of a portion of our debt. Adjusting for these gains/losses allows investors to better understand and analyze our core operational performance in the periods shown.
Operating Revenue, adjusted and Total Revenue Per Available Seat Mile ("TRASM"), adjusted
Three Months Ended
3Q26 vs 3Q25
% Change
(in millions)
September 30, 2026
December 31, 2025
September 30, 2025
Operating revenue
$ 20,186
$ 16,003
$ 16,673
Adjusted for:
Third-party refinery sales
(2,601)
(1,397)
(1,476)
Operating revenue, adjusted
$ 17,585
$ 14,606
$ 15,197
16 %
Three Months Ended
3Q26 vs
3Q25 %
Change
2Q26 vs
2Q25 %
Change
September 30,
2026
June 30, 2026
December 31,
2025
September 30,
2025
June 30, 2025
TRASM (cents)
25.46
25.11
21.94
21.09
21.44
Adjusted for:
Third-party refinery sales
(3.28)
(2.66)
(1.92)
(1.87)
(1.47)
TRASM, adjusted
22.18
22.45
20.02
19.22
19.97
15 %
12 %
Nine Months Ended
September 30, 2026
September 30, 2025
TRASM (cents)
24.56
21.04
Adjusted for:
Third-party refinery sales
(2.79)
(1.63)
TRASM, adjusted
21.77
19.41
Pre-Tax Income, Net Income, and Diluted Earnings per Share, adjusted
Three Months Ended
Three Months Ended
September 30, 2026
September 30, 2026
Pre-Tax
Income
Net
Earnings
(in millions, except per share data)
Income
Tax
Income
Per Diluted Share
GAAP
$ 1,074
$ (318)
$ 756
$ 1.15
Adjusted for:
MTM adjustments on investments
218
MTM adjustments and settlements on hedges
208
Gain on extinguishment of debt
(2)
Non-GAAP
$ 1,497
$ (363)
$ 1,134
$ 1.72
Three Months Ended
Three Months Ended
December 31, 2025
December 31, 2025
Pre-Tax
Income
Net
Earnings
(in millions, except per share data)
Income
Tax
Income
Per Diluted Share
GAAP
$ 1,513
$ (294)
$ 1,219
$ 1.86
Adjusted for:
MTM adjustments on investments
(205)
MTM adjustments and settlements on hedges
3
Non-GAAP
$ 1,311
$ (297)
$ 1,015
$ 1.55
Three Months Ended
Three Months Ended
September 30, 2025
September 30, 2025
Pre-Tax
Income
Net
Earnings
(in millions, except per share data)
Income
Tax
Income
Per Diluted Share
GAAP
$ 1,777
$ (360)
$ 1,417
$ 2.17
Adjusted for:
MTM adjustments on investments
(311)
MTM adjustments and settlements on hedges
5
Loss on extinguishment of debt
6
Non-GAAP
$ 1,477
$ (363)
$ 1,114
$ 1.70
Pre-Tax Margin, adjusted
Three Months Ended
September 30, 2026
September 30, 2025
Pre-tax margin
5.3 %
10.7 %
Adjusted for:
Third-party refinery sales
1.1
0.9
MTM adjustments on investments
1.1
(1.9)
MTM adjustments and settlements on hedges
1.0
—
Pre-tax margin, adjusted
8.5 %
9.7 %
Operating Income, adjusted
Three Months Ended
(in millions)
September 30, 2026
September 30, 2025
Operating income
$ 1,454
$ 1,684
Adjusted for:
MTM adjustments and settlements on hedges
208
5
Operating income, adjusted
$ 1,662
$ 1,688
Operating Margin, adjusted
Three Months Ended
September 30, 2026
September 30, 2025
Operating margin
7.2 %
10.1 %
Adjusted for:
Third-party refinery sales
1.2
1.0
MTM adjustments and settlements on hedges
1.0
—
Operating margin, adjusted
9.4 %
11.1 %
Free Cash Flow. We present free cash flow because management believes this metric is helpful to investors to evaluate the company's ability to generate cash that is available for use for debt service or general corporate initiatives. Free cash flow is also used internally as a component of our incentive compensation programs. Free cash flow is defined as net cash from operating activities and net cash from investing activities, adjusted for (i) pension plan contributions, (ii) net cash flows related to certain airport construction projects and other, and (iii) strategic investments and related. These adjustments are made for the following reasons:
Pension plan contributions. Cash flows related to pension funding are included in our GAAP operating activities. We adjust to exclude these contributions to allow investors to understand the cash flows related to our core operations.
Net cash flows related to certain airport construction projects and other. Cash flows related to certain airport construction projects are included in our GAAP operating activities and capital expenditures. We have adjusted for these items, which were primarily funded by cash restricted for airport construction, to provide investors a better understanding of the company's free cash flow and capital expenditures that are core to our operations in the periods shown.
Strategic investments and related. Certain cash flows related to our investments in and related transactions with other airlines and associated companies are included in our GAAP investing activities. We adjust for this activity because it provides a more meaningful comparison to our airline industry peers.
Three Months Ended
(in millions)
September 30, 2026
September 30, 2025
Net cash provided by operating activities
$ 1,713
$ 1,847
Net cash used in investing activities
(1,303)
(1,035)
Adjusted for:
Pension plan contributions
—
6
Net cash flows related to certain airport construction projects and other
9
15
Strategic investments and related
45
—
Free cash flow
$ 463
$ 833
Nine Months Ended
(in millions)
September 30, 2026
Net cash provided by operating activities
$ 5,740
Net cash used in investing activities
(4,078)
Adjusted for:
Pension plan contributions
4
Net cash flows related to certain airport construction projects and other
83
Strategic investments and related
150
Free cash flow
$ 1,900
Operating Cash Flow, adjusted. We present operating cash flow, adjusted because management believes adjusting for the following item provides a more meaningful measure for investors:
Net cash flows related to certain airport construction projects and other. Cash flows related to certain airport construction projects are included in our GAAP operating activities. We adjust for these items, which were primarily funded by cash restricted for airport construction, to provide investors a better understanding of the company's operating cash flow that is core to our operations in the periods shown.
Three Months Ended
(in millions)
September 30, 2026
September 30, 2025
Net cash provided by operating activities
$ 1,713
$ 1,847
Adjusted for:
Net cash flows related to certain airport construction projects and other
3
(31)
Operating cash flow, adjusted
$ 1,716
$ 1,816
Operating revenue, adjusted related to premium products and diverse revenue streams
Three Months Ended
(in millions)
September 30, 2026
Operating revenue
$ 20,186
Adjusted for:
Third-party refinery sales
(2,601)
Operating revenue, adjusted
$ 17,585
Less: main cabin revenue
(6,802)
Operating revenue, adjusted related to premium products and diverse revenue streams
$ 10,783
Percent of operating revenue, adjusted related to premium products and diverse revenue streams
61 %
Adjusted Non-Fuel Cost and Non-Fuel Unit Cost or Cost per Available Seat Mile, ("CASM-Ex")
We adjust operating expense and CASM for certain items described above, as well as the following items and reasons described below:
Aircraft fuel and related taxes. The volatility in fuel prices impacts the comparability of year-over-year financial performance. The adjustment for aircraft fuel and related taxes allows investors to better understand and analyze our non-fuel costs and year-over-year financial performance.
MRO expense. We adjust for MRO expenses because this adjustment allows investors to better understand and analyze the airline's recurring cost performance and provides a more meaningful comparison of our core operating costs to the airline industry.
Profit sharing. We adjust for profit sharing because this adjustment allows investors to better understand and analyze our recurring cost performance and provides a more meaningful comparison of our core operating costs to the airline industry.
Three Months Ended
(in millions)
September 30, 2026
September 30, 2025
Operating expense
$ 18,732
$ 14,989
Adjusted for:
Aircraft fuel and related taxes
(4,351)
(2,570)
Third-party refinery sales
(2,601)
(1,476)
MRO expense
(267)
(212)
Profit sharing
(389)
(392)
Non-Fuel Cost
$ 11,125
$ 10,339
Three Months Ended
3Q26 vs 3Q25
% Change
September 30, 2026
December 31, 2025
September 30, 2025
CASM (cents)
23.63
19.93
18.96
Adjusted for:
Aircraft fuel and related taxes
(5.49)
(3.26)
(3.25)
Third-party refinery sales
(3.28)
(1.92)
(1.87)
MRO expense
(0.34)
(0.23)
(0.27)
Profit sharing
(0.49)
(0.48)
(0.50)
CASM-Ex
14.03
14.03
13.08
7.3 %
Nine Months Ended
September 30, 2026
September 30, 2025
CASM (cents)
22.88
19.11
Adjusted for:
Aircraft fuel and related taxes
(4.93)
(3.30)
Third-party refinery sales
(2.79)
(1.63)
MRO expense
(0.38)
(0.26)
Profit sharing
(0.39)
(0.44)
CASM-Ex
14.39
13.47
Operating Expense, adjusted
Three Months Ended
(in millions)
September 30, 2026
September 30, 2025
Operating expense
$ 18,732
$ 14,989
Adjusted for:
Third-party refinery sales
(2,601)
(1,476)
MTM adjustments and settlements on hedges
(208)
(5)
Operating expense, adjusted
$ 15,924
$ 13,508
Total fuel expense, adjusted and Average fuel price per gallon, adjusted
Average Price Per Gallon
Three Months Ended
Three Months Ended
September 30,
September 30,
% Change
September 30,
September 30,
% Change
(in millions, except per gallon data)
2026
2025
2026
2025
Total fuel expense
$ 4,351
$ 2,570
$ 3.80
$ 2.26
Adjusted for:
MTM adjustments and settlements on hedges
(208)
(5)
(0.18)
(0.01)
Total fuel expense, adjusted
$ 4,143
$ 2,565
62 %
$ 3.61
$ 2.25
60 %
Average Price Per Gallon
Nine Months Ended
Nine Months Ended
September 30,
September 30,
% Change
September 30,
September 30,
% Change
(in millions, except per gallon data)
2026
2025
2026
2025
Total fuel expense
$ 11,202
$ 7,439
$ 3.44
$ 2.31
Adjusted for:
MTM adjustments and settlements on hedges
(57)
19
(0.02)
0.01
Total fuel expense, adjusted
$ 11,144
$ 7,457
49 %
$ 3.42
$ 2.31
48 %
Adjusted Net Debt. We use adjusted gross debt, including fleet operating lease liabilities (comprised of aircraft and engine leases and regional aircraft leases embedded within our capacity purchase agreements) and unfunded pension liabilities (if applicable), in addition to adjusted debt and finance leases, to present estimated financial obligations. We reduce adjusted total debt by cash, cash equivalents, and LGA restricted cash, resulting in adjusted net debt, to present the amount of assets needed to satisfy the debt. Management believes this metric is helpful to investors in assessing the company's overall debt profile.
(in millions)
September 30, 2026
December 31, 2025
September 30, 2025
3Q26 vs 4Q25
$ Change
Debt and finance lease obligations
$ 12,851
$ 14,113
$ 14,879
Plus: sale-leaseback financing liabilities
1,733
1,779
1,793
Plus: unamortized discount/(premium) and debt issue cost, net and other
(9)
(6)
(1)
Adjusted debt and finance lease obligations
$ 14,575
$ 15,885
$ 16,670
Plus: fleet operating lease liabilities
2,580
2,780
2,790
Adjusted gross debt
$ 17,155
$ 18,665
$ 19,460
Less: cash and cash equivalents
(3,787)
(4,310)
(3,791)
Less: LGA restricted cash
(18)
(56)
(83)
Adjusted net debt
$ 13,350
$ 14,300
$ 15,586
$ (950)
Gross Capital Expenditures. We adjust capital expenditures for the following item to determine gross capital expenditures for the reason described below:
Net cash flows related to certain airport construction projects. Cash flows related to certain airport construction projects are included in capital expenditures. We adjust for these items because management believes investors should be informed that a portion of these capital expenditures from airport construction projects are either funded with restricted cash specific to these projects or reimbursed by a third party.
Three Months Ended
(in millions)
September 30, 2026
September 30, 2025
Flight equipment, including advance payments
$ 1,200
$ 930
Ground property and equipment, including technology
213
230
Adjusted for:
Net cash flows related to certain airport construction projects
SummaryCompaniesDelta cuts annual profit forecast as fuel bill rises by $6 billionSteep fare increases test how much more travelers will payRefinery expected to generate $700 million profit, cushioning fuel hitCHICAGO, Oct 9 (Reuters) - Delta Air Lines (DAL.N), opens new tab cut its annual profit forecast by nearly a quarter on Friday, as surging fuel costs, expected to add $6 billion to its bill in 2026, overwhelmed resilient travel demand and higher ticket prices.
Its shares fell 3.5% in premarket trading after the carrier cut its 2026 profit forecast for the first time this year and lifted its projected fuel-cost increase by $2 billion as the Iran war has driven jet fuel prices sharply higher worldwide. With no end to the war in sight, carriers are confronting their worst crisis since the pandemic.
Sign up here.
The downgrade underscores a growing challenge for the industry: whether passengers will absorb further fare increases if fuel prices remain elevated. Airlines have already raised fares substantially this year, and analysts warn further increases could test travelers' willingness to keep spending.
Delta, the first major global carrier to report third-quarter results, said fuel expenses for the period rose 62% from a year earlier to $4.1 billion, exceeding its July forecast by more than $500 million.
"All of it's fuel," Delta Chief Financial Officer Erik Snell told reporters when asked what drove the forecast cut, citing increases in both
crude oil and refined jet fuel prices since the summer.
Delta now expects adjusted annual earnings of $5.10 to $5.60 a share, down from the $6.50 to $7.50 it forecast in July. The new midpoint of $5.35 is below analysts' average estimate of $5.46, according to LSEG. It forecast $4.5 billion in adjusted pre-tax profit for 2026.
Third-quarter adjusted earnings of $1.72 a share narrowly missed analysts' average estimate of $1.76, according to LSEG. Its adjusted operating margin fell to 9.4% from 11.1%.
Rivals United Airlines (UAL.O), opens new tab, American Airlines (AAL.O), opens new tab and Southwest Airlines (LUV.N), opens new tab are due to report later this month. Ryanair Group (RYA.I), opens new tab CEO Michael O'Leary warned on Thursday that European airlines could face more than another year of elevated fuel costs due to the war.
HIGHER FARESUS airlines spent $42.9 billion on fuel for scheduled flights in the first eight months of 2026, nearly $13.2 billion more than a year earlier, despite using slightly less fuel, according to the Bureau of Transportation Statistics.
Strong demand and limited growth in seats have helped carriers pass higher fuel costs on to passengers. US airline fares rose an average of about 25% from a year earlier in the five months through August, according to the Bureau of Labor Statistics' consumer price index.
With fuel prices remaining elevated and planned industry capacity growth set to accelerate in the fourth quarter from the third, analysts are watching whether carriers, including Delta, can raise fares further without discouraging travel.
Deutsche Bank analysts expect the industry to recover a smaller share of higher fuel costs through revenue measures in the fourth quarter, with full recovery not expected until early 2027.
Delta said demand remains strong. With almost 60% of the fourth quarter already booked, it expects revenue growth of about 20% from a year ago, Snell said.
It forecast fourth-quarter adjusted earnings of $1.15 to $1.65 a share, with the $1.40 midpoint roughly in line with analysts' average estimate of $1.39, according to LSEG.
REFINERY ADVANTAGEDelta has an advantage over other major US airlines: its ownership of a refinery outside Philadelphia that Snell expects to generate $700 million in profit this year.
"We have a refinery that gives us an offset, a partial offset to fuel prices that no one else does," he said.
Bought in 2012, the Monroe refinery processes crude oil into jet fuel and other products. Delta still pays market prices for fuel transferred to its airline operations, but retains the refining profit within the company.
That helps when the gap between crude and refined fuel prices widens, increasing costs for airlines buying from outside suppliers. The protection varies with refining margins, however, and the refinery can lose money when those margins weaken.
But the refinery can only partly cushion the impact of higher fuel prices. Even with a projected refinery benefit of 40 cents a gallon, Delta expects its fuel cost to rise to $4.25 a gallon in the fourth quarter from $3.61 in the third.
Snell said fuel costs were expected to stay elevated for some time.
"Ultimately, fuel will come down. When that is, we're not exactly sure," he said.
Adds details and background in paragraphs 2, 4 and 5
Reporting by Rajesh Kumar Singh and Shivansh Tiwary; Editing by Jamie Freed, Christian Plumb and Pooja Desai
Our Standards: The Thomson Reuters Trust Principles., opens new tab
Delta Air Lines zvažuje spuštění linky Atlanta–Rijád 23. října po útocích Húsiů; generální ředitel Ed Bastian uvedl, že rozhodujícím faktorem bude bezpečnost.
Delta Air Lines CEO Ed Bastian said his carrier is weighing whether to go ahead with debuting a flight between Atlanta and Riyadh, Saudi Arabia, after attacks claimed by Iran-backed Houthi rebels have escalated there.
The flights between Riyadh and Delta's biggest hub are scheduled to begin on Oct. 23.
Three people were killed in attacks at Riyadh's King Khalid International Airport as Houthis stepped up strikes in the country, Saudi Arabia's civil aviation authority said.
"Obviously, we were disappointed to see the news this week," Bastian told CNBC in an interview. "Safety is is going to make the call."
He said that the airline will let customers know of its decision soon. German airlines Lufthansa said it was pausing flights into Saudi Arabia through at least Oct. 16, a spokesman told CNBC.
Delta is planning to operate the Atlanta-Riyadh flight daily from Oct. 23 to Oct. 30 before moving to three-times-a-week service. When it announced the route earlier this year, Delta said it would be the first nonstop service between the U.S. and Riyadh operated by a U.S. airline.
Read more CNBC airline newsWhy airfare could rise even more, but airline profits won’tBudget airline king Bill Franke warms to premium upgradesCompanies spurn airlines’ cheapest business class ticketsUnited’s next decision: What to do with all those Boeing 737 Max 10 seats it ordered years agoRecord heat, crowds drive offseason boom in international travel
FDA schválila přípravek WELTRUZA společnosti Teva, první a jedinou měsíčně podávanou podkožní injekci olanzapinu s prodlouženým uvolňováním pro dospělé se schizofrenií.
WELTRUZA™ (olanzapine) for extended-release injectable suspension is the first and only once-monthly subcutaneous long-acting injectable (LAI) formulation of olanzapine for the treatment of schizophrenia in adults with no loading doses, no oral supplementation and no post-injection monitoring requiredThe approval is based on results from the pivotal Phase 3 SOLARIS trial, which demonstrated overall symptom improvement, significant reduction in illness severity and improvement in personal and social functioning, with a systemic safety profile consistent with oral olanzapine1As Teva drives forward its Pivot to Growth strategy, the company continues to deliver on its commitment to patient-centered innovation in neuroscience, including a differentiated long-acting injectable franchiseTeva will hold an investor call and live webcast on Friday, October 9, 2026, 8:00 a.m. ET
PARSIPPANY, N.J. and TEL AVIV, Israel, Oct. 09, 2026 (GLOBE NEWSWIRE) -- Teva Pharmaceuticals, a U.S. affiliate of Teva Pharmaceutical Industries Ltd. (NYSE and TASE: TEVA) today announced that the U.S. Food and Drug Administration (FDA) has approved WELTRUZA™ (olanzapine) for extended-release injectable suspension, a new, once-monthly, subcutaneous long-acting injectable (LAI) for the treatment of schizophrenia in adults. WELTRUZA clinical trial results demonstrated improvement in symptoms (PANSS), significant reduction in illness severity (CGI-S), as well as improvement in personal and social functioning (PSP).1 In the coming weeks, WELTRUZA will be available in three different strengths (318 mg, 425 mg, 531 mg) with no loading doses, no oral supplementation and no post-injection monitoring required.1
A suite of downloadable multimedia assets is available here.
“WELTRUZA offers the proven efficacy of olanzapine in an innovative long-acting subcutaneous injectable, helping to fill a major, long-standing gap in the schizophrenia treatment landscape,” said Chris Fox, Executive Vice President, U.S. Commercial and Head of Innovative Franchise at Teva. “WELTRUZA was developed with the patient in mind from day one and it is a powerful demonstration of what is possible when the needs of the patient guide the development of a truly innovative medicine. This important milestone also helps further Teva’s Pivot to Growth strategy.”
Olanzapine is the most widely prescribed atypical antipsychotic for schizophrenia as a daily oral treatment.2 However, it is well documented that daily options may make it difficult to sustain long-term symptom improvement due to challenges with adherence, increasing the risk for instability and relapse.1 WELTRUZA was developed to address this significant unmet need by offering the established efficacy of olanzapine in a once-monthly subcutaneous injectable formulation.1
“This approval reflects the strength of patient-centric innovation at Teva and what our R&D organization can deliver,” said Eric Hughes, MD, PhD, Executive Vice President, Global R&D and Chief Medical Officer at Teva. “WELTRUZA combines proven science and novel formulation innovation to eliminate the need for monitoring after each injection, addressing a significant barrier to treatment and advancing care for people living with schizophrenia.”
WELTRUZA will be available in once-monthly subcutaneous injectable doses of 318 mg, 425 mg and 531 mg that correspond to the approved daily dose range of oral olanzapine of 10 mg, 15 mg and 20 mg, respectively.1
“Olanzapine has been a trusted and foundational treatment option for people living with schizophrenia for more than 30 years, but adherence continues to be a major barrier to stability, particularly for those who rely on daily oral medications,” said Christoph Correll, MD, Clinical Professor of Psychiatry at the Zucker School of Medicine at Hofstra/Northwell, Hempstead, NY. “By offering a subcutaneous long-acting injectable formulation with achievement of therapeutic blood levels without oral cotreatment, loading doses or booster injections, this new treatment option can help empower patients, support their care partners and provide clinicians with an important new tool to assist in managing this complex condition more effectively.”
In the Phase 3 SOLARIS trial, all three doses of WELTRUZA were similarly tolerated, with the most common reported adverse events (AEs) inclusive of increased weight, somnolence, headache, constipation and injection site reactions.1 Weight gain and metabolic changes were observed and were consistent with the systemic safety profile of oral olanzapine, including clinically significant weight gain.1 Discontinuations of WELTRUZA due to common AEs were consistent with placebo at 5% and 4% of trial participants, respectively.1 Please refer to the Important Safety Information below for additional safety information.
An estimated 2.1 million people are currently diagnosed with schizophrenia in the U.S. It is a chronic, progressive and severely debilitating mental disorder that affects how one thinks, feels and behaves.3 Schizophrenia is a complex medical condition that may require switching from oral options or between long-acting injectable options during the treatment journey.
WELTRUZA utilizes SteadyTeq™, a copolymer technology proprietary to Medincell that provides a controlled steady, sustained release of olanzapine.
WELTRUZA will be available in the U.S. in the coming weeks.
The European Medicines Agency (EMA) accepted the Marketing Authorization Application (MAA) for olanzapine long-acting injectable (TEV-‘749) for the treatment of schizophrenia in adults in May 2026. The EMA submission is supported by an extensive clinical development program, including the Phase 3 SOLARIS study. TEV-‘749 is not approved by the EMA at this time.
Teva Investor Call
Teva will hold an investor call and live webcast today, Friday, October 9, 2026, at 8:00 a.m. ET/ 2:00 p.m. CET. To participate, please register in advance here. To access a live webcast of the presentation, visit Teva’s Investor Relations website. An archived version of the webcast will be available 24 hours after the end of the live discussion.
APPROVED USE
WELTRUZA™ (olanzapine) for extended-release injectable suspension is a prescription medicine used in adults for the treatment of schizophrenia.
IMPORTANT SAFETY INFORMATION
What is the most important information I should know about WELTRUZA?
WELTRUZA can cause serious side effects, including an increased risk of death in elderly people who have lost touch with reality (psychosis) due to confusion and memory loss (dementia). WELTRUZA is not for the treatment of people with dementia-related psychosis.
WELTRUZA may cause serious side effects, including:
Post-injection delirium/sedation syndrome (PDSS) is a serious problem that can happen when too much olanzapine enters the bloodstream too quickly. PDSS has happened in people who received another extended-release olanzapine medicine by injection into their muscles (intramuscularly). WELTRUZA is injected under the skin (subcutaneously). It is not known whether PDSS can happen with WELTRUZA. PDSS with an extended-release intramuscular injection has led to hospitalization, has happened within the first 3 hours of injection, but also happened after 3 hours of injection, and has the risk each time an injection is received. Tell your healthcare provider right away or go to the nearest emergency room if you get signs or symptoms of PDSS, including more sleepiness than usual, dizziness, confusion or disorientation, trouble walking or talking, stiff muscles or shakiness, weakness, feeling grouchy or angry, feeling anxious or nervous, increased blood pressure, seizures (convulsions), or passing out.Strokes in elderly people (cerebral problems) that can lead to death.Neuroleptic Malignant Syndrome (NMS). NMS is a serious condition that can lead to death. Seek medical attention right away if you have any of these symptoms: high fever, stiff muscles, confusion, changes in pulse, heart rate, or blood pressure, increased sweating.Drug Reaction with Eosinophilia and Systemic Symptoms (DRESS). DRESS is an allergic reaction that can cause death that may affect your skin or other parts of your body including your liver, kidney, lungs, or heart. Contact your healthcare provider right away if you experience any signs or symptoms of DRESS, including fever, skin rash or blistering or peeling skin, swelling of face, glands, or other body parts, cough or trouble breathing, chest pain, yellowing of the skin or eyes, dark urine or changes in urination.Problems with your metabolism that may include high blood sugar (hyperglycemia), diabetes mellitus, changes in the fat levels in your blood (dyslipidemia), and weight gain. Extremely high blood sugar can lead to coma or death. If you have diabetes or are at risk of diabetes (e.g., obesity, family history of diabetes), your healthcare provider should check your blood sugar before you start and during treatment with WELTRUZA. Call your healthcare provider if you have symptoms of high blood sugar, including feeling very thirsty, hungry, sick to your stomach, weak or tired, or confused; needing to urinate more than usual; or your breath smells fruity.Uncontrolled facial or body movements (tardive dyskinesia) that may not go away, even if you stop receiving WELTRUZA. Tell your healthcare provider if you get any body movements that you cannot control.Decreased blood pressure (orthostatic hypotension). You may feel dizzy or lightheaded, get a fast or slow heartbeat, or faint, when you rise too quickly from a sitting or lying position. Drinking alcohol and using other medicines that make you dizzy can increase your risk for orthostatic hypotension. Avoid drinking alcohol during treatment with WELTRUZA.Falls. WELTRUZA may make you sleepy or dizzy, may cause a decrease in your blood pressure when changing position (orthostatic hypotension), and can slow your thinking and motor skills which may lead to falls that can cause fractures or other injuries.Low white blood cell counts. Your healthcare provider may do white blood cell count tests during your first few months of treatment with WELTRUZA.Difficulty swallowing that can cause food or liquid to get into your lungs.Seizures (convulsions). Sleepiness, drowsiness, feeling tired, difficulty thinking and doing normal activities. Do not drive, operate machinery, or do other dangerous activities until you know how WELTRUZA affects you.Problems controlling your body temperature so that you feel too warm. Avoid getting overheated or dehydrated.Certain side effects from the way WELTRUZA works in your body such as constipation, dry mouth, fast heartbeat, urinary retention, or prostate and bowel problems. Your risk is increased if you take other medicines that also cause these side effects.Increased prolactin levels in your blood (hyperprolactinemia). WELTRUZA can cause a rise in the blood levels of a hormone called prolactin that may cause side effects including missed menstrual periods, a reversible reduction in fertility in females who are able to become pregnant, leakage of milk from the breasts, development of breasts in men, or problems with erection.The most common side effects of olanzapine in patients with schizophrenia include weight gain, sleepiness, headache, and constipation. Injection site reactions, including hardness, pain, redness, itching, and swelling, were reported with WELTRUZA.
These are not all the possible side effects with WELTRUZA. Tell your healthcare provider if you have any side effect that does not go away. For more information, ask your healthcare provider or pharmacist.
Before receiving WELTRUZA, tell your healthcare provider about all of your medical conditions, including if you:
have or had diabetes or high blood sugarhave or had high levels of total cholesterol, LDL cholesterol, or triglycerides, or low HDL levels in your bloodhave or had low or high blood pressurehave or had heart problems or strokeare dehydratedhave or had a low white blood cell counthave or had seizures (convulsions)have or had problems with urination or prostate problemshave Alzheimer’s diseasehave or had constipation or bowel obstructionhave or had breast cancerare pregnant or plan to become pregnant. WELTRUZA may harm your unborn baby. Receiving WELTRUZA during your third trimester of pregnancy may cause your baby to have abnormal muscle movements or withdrawal symptoms such as agitation, stiffness or floppiness, tremors, sleepiness, and breathing or feeding problems after birth. Talk to your healthcare provider about the risks to your baby if you receive WELTRUZA during pregnancy.If you become pregnant during treatment with WELTRUZA, talk to your healthcare provider about registering with the National Pregnancy Registry for Atypical Antipsychotics. You can register by calling 1-866-961-2388 or go to http://womensmentalhealth.org/clinical-and-research-programs/pregnancyregistry/.are breastfeeding or plan to breastfeed. WELTRUZA passes into breast milk. If you breastfeed during treatment with WELTRUZA, tell your healthcare provider if your baby is very sleepy, irritable, is feeding poorly, or gets tremors or abnormal muscle movements. Talk to your healthcare provider about the best way to feed your baby during treatment with WELTRUZA.Tell your healthcare provider about all the medicines you take or plan to take, including prescription and over-the-counter medicines, vitamins, and herbal supplements. Especially tell your healthcare provider if you take: blood pressure medicines, levodopa or dopamine, or other olanzapine medicines. Your healthcare provider can tell you if it is safe to receive WELTRUZA with your other medicines.
Do not start or stop any medicines during treatment with WELTRUZA without talking to your healthcare provider first.
You are encouraged to report side effects of prescription drugs to the FDA. Visit www.fda.gov/medwatch, or call 1-800-FDA-1088.
For more information about WELTRUZA, see the full Prescribing Information, including Medication Guide and Boxed WARNING, or talk to your healthcare provider.
About Subcutaneous Olanzapine Extended-Release Injection Study (SOLARIS)
SOLARIS was an 8 week, multinational, multicenter, randomized, double-blind, parallel-group, placebo-controlled study to evaluate the efficacy, safety and tolerability of olanzapine extended-release injectable suspension for subcutaneous use as a treatment in patients (ages 18-64 years) with schizophrenia.1 For period one of the study (first 8 weeks), 675 patients were randomized to receive a subcutaneous injection of once-monthly olanzapine LAI (WELTRUZA) (low, medium or high dose) or placebo in a 1:1:1:1 ratio.1 For period two (next 48 weeks), patients who completed period one on placebo were re-randomized and equally allocated to one of the three olanzapine LAI (WELTRUZA) treatment groups, while patients who completed period one on active olanzapine LAI (WELTRUZA) remained on their established dose strength.1 The end-of-treatment and follow-up visits were 4 and 8 weeks after administration of the last treatment dose, respectively.1 The primary objective of the Phase 3 SOLARIS study was to evaluate the efficacy of olanzapine LAI (WELTRUZA) in adult patients with schizophrenia, as measured by PANSS.1 A key secondary objective was to further evaluate the efficacy of olanzapine LAI (WELTRUZA) based on additional parameters in adult patients with schizophrenia, as measured by CGI-S and PSP.1 A secondary objective of period two of the study was to evaluate the safety and tolerability of olanzapine LAI (WELTRUZA) in adult patients with schizophrenia.1
About Schizophrenia
Schizophrenia is a chronic, progressive and severely debilitating mental disorder that affects how one thinks, feels and acts.4 Patients experience an array of symptoms, which may include delusions, hallucinations, disorganized speech or behavior and impaired cognitive ability.4,5,6 Approximately 1% of the world’s population will develop schizophrenia in their lifetime, and 2.1 million people in the U.S. are currently diagnosed with the condition.3,4,5 Although schizophrenia can occur at any age, the average age of onset tends to be in the late teens to the early 20s for men and the late 20s to early 30s for women.4 The long-term course of schizophrenia is marked by episodes of partial or full remission broken by relapses that often occur in the context of psychiatric emergency and require hospitalization.6 Approximately 80% of patients experience multiple relapses over the first five years of treatment, and each relapse carries a biological risk of loss of function, treatment refractoriness and changes in brain morphology.7,8,9 Patients are often unaware of their illness and its consequences, contributing to treatment nonadherence, high discontinuation rates and, ultimately, significant direct and indirect healthcare costs from subsequent relapses and hospitalizations.4,5,6,7,8,9
About Teva
Teva Pharmaceutical Industries Ltd. (NYSE and TASE: TEVA) is transforming into a leading innovative biopharmaceutical company, enabled by a world-class generics business. For over 120 years, Teva’s commitment to bettering health has never wavered. From innovating in the fields of neuroscience and immunology to providing complex generic medicines, biosimilars and pharmacy brands worldwide, Teva is dedicated to addressing patients’ needs, now and in the future. At Teva, We Are All In For Better Health. To learn more about how, visit www.tevapharm.com.
Cautionary Note Regarding Forward-Looking Statements
This Press Release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995, which are based on management’s current beliefs and expectations and are subject to substantial risks and uncertainties, both known and unknown, that could cause our future results, performance or achievements to differ significantly from that expressed or implied by such forward-looking statements. You can identify these forward-looking statements by the use of words such as “should,” “expect,” “anticipate,” “estimate,” “target,” “may,” “project,” “intend,” “plan,” “believe” and other words and terms of similar meaning and expression in connection with any discussion of future operating or financial performance. Important factors that could cause or contribute to such differences include risks relating to: our ability to successfully develop and commercialize WELTRUZA for the treatment of schizophrenia in adults; our ability to successfully compete in the marketplace, including our ability to develop and commercialize additional pharmaceutical products; our ability to successfully execute on our Pivot to Growth strategy, including to expand our innovative and biosimilar medicines pipeline and to profitably commercialize our innovative medicines and biosimilar portfolio, whether organically or through business development; our significant indebtedness; our business and operations in general; compliance, regulatory and litigation matters; financial, economic and other risks; and other factors discussed in our Quarterly Report on Form 10-Q for the second quarter of 2026 and in our Annual Report on Form 10-K for the year ended December 31, 2025, including in the sections captioned “Risk Factors” and “Other Information.” Forward-looking statements speak only as of the date on which they are made, and we assume no obligation to update or revise any forward-looking statements or other information contained herein, whether as a result of new information, future events or otherwise. You are cautioned not to put undue reliance on these forward-looking statements.
Data on file. [CSR/SOLARIS]. West Chester, PA: Teva Neuroscience, Inc.Data on file. [TRx data sourced from IQVIA NPA Full Year 2025; orals factored for SCZ using Analytics Link 2022.] Parsippany, NJ: Teva Neuroscience, Inc.Data on file. [DRG/Clarivate (Nov 2025 Market Forecast Assumptions-Schizophrenia)]. Parsippany, NJ: Teva Neuroscience, Inc.Substance Abuse and Mental Health Services Administration. Schizophrenia. https://www.samhsa.gov/mental-health/schizophrenia. Accessed February 2026.Velligan DI, Rao S. The Epidemiology and Global Burden of Schizophrenia. J Clin Psychiatry. 2023;84(1):MS21078COM5. https://doi.org/10.4088/JCP.MS21078COM5.Wander C. (2020). Schizophrenia: Opportunities to Improve Outcomes and Reduce Economic Burden Through Managed Care. The Am J Manag Care. 26(3 Suppl), S62–S68. https://doi.org/10.37765/ajmc.2020.43013.Emsley, R., & Kilian, S. (2018). Efficacy and safety profile of paliperidone palmitate injections in the management of patients with schizophrenia: an evidence-based review. Neuropsychiatric Dis. Treat., 14, 205–223.Emsley, R., Chiliza, B., Asmal, L. et al. (2013) The nature of relapse in schizophrenia. BMC Psychiatry 13, 50.Andreasen, N. C., et al. (2013). Relapse duration, treatment intensity, and brain tissue loss in schizophrenia: a prospective longitudinal MRI study. The Am J Psychiatry, 170(6), 609–615.Teva Media Inquiries: [email protected]
Teva Investor Relations Inquiries: [email protected]
Farther Finance Advisors ve třetím čtvrtletí zvýšila svůj podíl v IBM o 5,6 % nákupem 3 576 akcií, čímž svůj podíl navýšila na 67 827 akcií v hodnotě 14,917 milionu USD.
Farther Finance Advisors LLC raised its holdings in International Business Machines Corporation (NYSE:IBM – Free Report) by 5.6% during the 3rd quarter, according to the company in its most recent Form 13F filing with the SEC. The fund owned 67,827 shares of the technology company’s stock after purchasing an additional 3,576 shares during the quarter. Farther Finance Advisors LLC’s holdings in International Business Machines were worth $14,917,000 at the end of the most recent reporting period.
A number of other institutional investors and hedge funds have also modified their holdings of IBM. CoreCap Advisors LLC raised its holdings in shares of International Business Machines by 7.6% during the third quarter. CoreCap Advisors LLC now owns 41,308 shares of the technology company’s stock valued at $9,085,000 after acquiring an additional 2,916 shares during the last quarter. Hamlin Capital Management LLC boosted its stake in shares of International Business Machines by 24.5% in the third quarter. Hamlin Capital Management LLC now owns 241,311 shares of the technology company’s stock worth $53,072,000 after acquiring an additional 47,562 shares during the last quarter. YHB Investment Advisors Inc. increased its position in shares of International Business Machines by 4.3% during the third quarter. YHB Investment Advisors Inc. now owns 4,989 shares of the technology company’s stock worth $1,097,000 after purchasing an additional 207 shares in the last quarter. Gradient Investments LLC raised its stake in International Business Machines by 61.8% in the 3rd quarter. Gradient Investments LLC now owns 82,749 shares of the technology company’s stock valued at $18,199,000 after purchasing an additional 31,592 shares during the last quarter. Finally, Valeo Financial Advisors LLC lifted its holdings in International Business Machines by 3.3% in the 3rd quarter. Valeo Financial Advisors LLC now owns 16,155 shares of the technology company’s stock valued at $3,553,000 after purchasing an additional 512 shares in the last quarter. Hedge funds and other institutional investors own 58.96% of the company’s stock.
Here are the key news stories impacting International Business Machines this week:
Positive Sentiment: Quantum computing milestone: IBM advanced to Stage C, the final phase of DARPA’s Quantum Benchmarking Initiative. Independent experts will test IBM’s hardware, architecture and systems engineering, providing important third-party validation of its roadmap toward a fault-tolerant quantum computer. IBM is targeting 2029 for that milestone. IBM Advances to Stage C of DARPA Quantum Benchmarking Initiative Positive Sentiment: AI and consulting recovery hopes: Coverage argues IBM’s valuation has become more attractive following its recent decline, while a rebound in consulting demand and continued hybrid-cloud and AI adoption could support growth. IBM’s self-hosted “Bob” AI offering also targets customers that require secure, customer-managed infrastructure. IBM’s Valuation is Getting Interesting as AI and Consulting Rebound Positive Sentiment: Enterprise partnerships: IBM launched IBM Ready for SAP Solutions, combining its consulting capabilities with SAP cloud ERP to help midsize companies modernize operations and prepare their data for AI. The offering adds a potential channel for consulting and cloud-related revenue. IBM Teams Up with SAP Neutral Sentiment: Upcoming earnings: IBM will report third-quarter 2026 results on October 21, giving investors a near-term catalyst to assess whether delayed large deals have begun returning and whether AI and consulting growth are improving. IBM Third-Quarter 2026 Results Announcement Negative Sentiment: Execution concerns remain: Analysts highlighted IBM’s recent underperformance and the risk that a slowdown could persist after tens of large deals failed to close on time in the second quarter. Management said customers delayed rather than canceled those deals, but the timing of a recovery remains uncertain. What Happens To IBM Stock If Its Slowdown Lasts? Negative Sentiment: Customer attrition in VMware services: 11:11 Systems acquired select IBM VMware Cloud Service Provider enterprise customers. The transaction may modestly pressure IBM’s managed infrastructure and VMware-related business, although the financial impact was not disclosed. 11:11 Systems Acquires Select IBM VMware Cloud Service Provider Enterprise Customers International Business Machines Stock Up 2.8% NYSE IBM opened at $226.70 on Friday. The business’s fifty day simple moving average is $232.24 and its 200-day simple moving average is $244.09. The company has a quick ratio of 0.74, a current ratio of 0.79 and a debt-to-equity ratio of 1.63. The firm has a market cap of $213.58 billion, a PE ratio of 20.12, a P/E/G ratio of 2.10 and a beta of 0.73. International Business Machines Corporation has a 52 week low of $199.19 and a 52 week high of $332.46. International Business Machines (NYSE:IBM – Get Free Report) last announced its quarterly earnings data on Wednesday, July 22nd. The technology company reported $2.93 earnings per share (EPS) for the quarter, meeting analysts’ consensus estimates of $2.93. International Business Machines had a net margin of 15.52% and a return on equity of 35.65%. The firm had revenue of $17.16 billion during the quarter, compared to analyst estimates of $17.46 billion. During the same quarter in the prior year, the firm posted $2.80 earnings per share. International Business Machines’s quarterly revenue was up 1.1% on a year-over-year basis. As a group, equities analysts anticipate that International Business Machines Corporation will post 12.33 earnings per share for the current year.
International Business Machines Dividend Announcement The company also recently declared a quarterly dividend, which was paid on Thursday, September 10th. Stockholders of record on Monday, August 10th were paid a $1.69 dividend. The ex-dividend date of this dividend was Monday, August 10th. This represents a $6.76 annualized dividend and a dividend yield of 3.0%. International Business Machines’s dividend payout ratio is 59.98%.
Analyst Ratings Changes Several brokerages have issued reports on IBM. Citic Securities lifted their target price on shares of International Business Machines from $294.00 to $297.00 and gave the stock a “buy” rating in a research note on Wednesday, July 29th. Stifel Nicolaus decreased their price target on shares of International Business Machines from $290.00 to $235.00 and set a “buy” rating on the stock in a research note on Monday, July 20th. Oppenheimer lowered shares of International Business Machines from an “outperform” rating to a “market perform” rating in a research report on Wednesday, July 15th. Barclays cut their price objective on shares of International Business Machines from $288.00 to $262.00 and set an “overweight” rating for the company in a report on Thursday, July 23rd. Finally, Royal Bank Of Canada reissued an “outperform” rating and issued a $270.00 target price (down from $300.00) on shares of International Business Machines in a research note on Tuesday, July 21st. Eighteen equities research analysts have rated the stock with a Buy rating, twelve have issued a Hold rating and two have issued a Sell rating to the company. According to MarketBeat, the stock currently has a consensus rating of “Moderate Buy” and a consensus target price of $253.52.
Get Our Latest Stock Report on IBM
Insider Activity In other news, SVP Robert Thomas sold 25,000 shares of the firm’s stock in a transaction that occurred on Wednesday, August 26th. The shares were sold at an average price of $230.32, for a total transaction of $5,758,000.00. Following the completion of the sale, the senior vice president owned 47,800 shares in the company, valued at $11,009,296. This trade represents a 34.34% decrease in their position. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available at this hyperlink. 0.27% of the stock is owned by corporate insiders.
International Business Machines Profile (Free Report)
International Business Machines Corporation (NYSE:IBM), commonly known as IBM, is a global technology company that provides hybrid cloud, artificial intelligence, software, consulting and infrastructure solutions. Its offerings help businesses and government organizations manage data, modernize applications, automate processes and improve cybersecurity.
IBM’s portfolio includes the Red Hat hybrid cloud platform, the watsonx suite of artificial intelligence and data tools, consulting services, and enterprise software for areas such as automation, application management, security and asset management.
See Also Five stocks we like better than International Business Machines Want Private-Market Access to Kalshi and Polymarket? Try This ETF Levi’s Stock Dip Reveals Value Opportunity Despite Q3 Headwinds PepsiCo Stock Looks Poised to Bottom With High Yield, Deep Value Alphabet’s $1.8 Billion Black Hills Deal Powers AI Data Center Push Want to see what other hedge funds are holding IBM? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for International Business Machines Corporation (NYSE:IBM – Free Report).
Receive News & Ratings for International Business Machines Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for International Business Machines and related companies with MarketBeat.com's FREE daily email newsletter.
Apella Capital LLC grew its position in shares of Merck & Co., Inc. (NYSE:MRK – Free Report) by 16.6% in the 3rd quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission. The fund owned 43,902 shares of the company’s stock after acquiring an additional 6,239 shares during the period. Apella Capital LLC’s holdings in Merck & Co., Inc. were worth $6,269,000 as of its most recent SEC filing.
A number of other institutional investors also recently modified their holdings of the company. BlackRock Inc. lifted its holdings in Merck & Co., Inc. by 0.5% in the 2nd quarter. BlackRock Inc. now owns 226,999,837 shares of the company’s stock worth $29,169,479,000 after buying an additional 1,073,507 shares during the period. State Street Corp increased its stake in shares of Merck & Co., Inc. by 0.9% during the second quarter. State Street Corp now owns 120,413,256 shares of the company’s stock valued at $15,573,754,000 after buying an additional 1,087,583 shares during the period. Wellington Management Group LLP increased its stake in shares of Merck & Co., Inc. by 2.3% during the second quarter. Wellington Management Group LLP now owns 86,249,283 shares of the company’s stock valued at $11,083,033,000 after buying an additional 1,934,312 shares during the period. Bank of America Corp DE raised its holdings in shares of Merck & Co., Inc. by 10.5% during the first quarter. Bank of America Corp DE now owns 30,774,221 shares of the company’s stock valued at $3,701,831,000 after acquiring an additional 2,919,780 shares in the last quarter. Finally, Invesco Ltd. raised its holdings in shares of Merck & Co., Inc. by 3.5% during the fourth quarter. Invesco Ltd. now owns 20,546,185 shares of the company’s stock valued at $2,162,691,000 after acquiring an additional 701,249 shares in the last quarter. 76.07% of the stock is currently owned by hedge funds and other institutional investors.
Analysts Set New Price Targets Several research firms recently weighed in on MRK. Argus lifted their price target on shares of Merck & Co., Inc. from $145.00 to $170.00 and gave the company a “buy” rating in a report on Tuesday, August 25th. Barclays upped their price objective on shares of Merck & Co., Inc. from $140.00 to $150.00 and gave the stock an “overweight” rating in a report on Wednesday, July 29th. Cantor Fitzgerald lifted their target price on shares of Merck & Co., Inc. from $120.00 to $145.00 and gave the company a “neutral” rating in a research note on Thursday. Wolfe Research boosted their price target on shares of Merck & Co., Inc. from $155.00 to $180.00 and gave the company an “outperform” rating in a research report on Tuesday, August 25th. Finally, Wall Street Zen downgraded shares of Merck & Co., Inc. from a “buy” rating to a “hold” rating in a research note on Saturday, October 3rd. Seventeen research analysts have rated the stock with a Buy rating and ten have issued a Hold rating to the stock. Based on data from MarketBeat, Merck & Co., Inc. presently has a consensus rating of “Moderate Buy” and an average target price of $151.32.
View Our Latest Stock Analysis on Merck & Co., Inc. Merck & Co., Inc. Trading Down 0.2% Merck & Co., Inc. stock opened at $142.45 on Friday. Merck & Co., Inc. has a 12 month low of $82.01 and a 12 month high of $156.92. The company has a market capitalization of $351.45 billion, a price-to-earnings ratio of 113.96, a price-to-earnings-growth ratio of 6.42 and a beta of 0.21. The business’s fifty day simple moving average is $143.59 and its two-hundred day simple moving average is $128.16. The company has a current ratio of 1.32, a quick ratio of 1.10 and a debt-to-equity ratio of 1.22.
Merck & Co., Inc. (NYSE:MRK – Get Free Report) last posted its quarterly earnings results on Tuesday, August 4th. The company reported ($0.13) earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.26) by $0.13. The firm had revenue of $16.61 billion during the quarter, compared to analyst estimates of $16.37 billion. Merck & Co., Inc. had a return on equity of 16.73% and a net margin of 4.77%.Merck & Co., Inc.’s quarterly revenue was up 5.1% compared to the same quarter last year. During the same quarter in the previous year, the firm earned $2.13 EPS. Merck & Co., Inc. has set its FY 2026 guidance at 2.660-2.760 EPS. As a group, equities analysts predict that Merck & Co., Inc. will post 2.67 earnings per share for the current fiscal year.
Merck & Co., Inc. Dividend Announcement The firm also recently announced a quarterly dividend, which was paid on Wednesday, October 7th. Shareholders of record on Tuesday, September 15th were given a $0.85 dividend. The ex-dividend date of this dividend was Tuesday, September 15th. This represents a $3.40 dividend on an annualized basis and a yield of 2.4%. Merck & Co., Inc.’s payout ratio is 272.00%.
Key Merck & Co., Inc. News Here are the key news stories impacting Merck & Co., Inc. this week:
Positive Sentiment: The FDA approved WELIREG plus LENVIMA for adults with advanced renal cell carcinoma previously treated with a PD-1/PD-L1 inhibitor. The decision expands Merck’s oncology portfolio and could create another commercial opportunity beyond Keytruda. Merck also started a first-in-human trial using Cyprumed’s oral peptide-delivery platform, although that program remains at a very early stage. Merck Wins FDA Approval for WELIREG Plus LENVIMA in Kidney Cancer Positive Sentiment: Morgan Stanley maintained an “overweight” rating while trimming its price target modestly to $177, implying substantial upside based on the referenced price. The call indicates continued confidence in Merck’s long-term earnings and pipeline prospects. Morgan Stanley Raises Merck Analyst View Positive Sentiment: Merck’s shareholder dividend was highlighted as part of its income appeal, which may support investor interest while the company navigates product-cycle and patent risks. Merck Dividend Payment Neutral Sentiment: Cantor Fitzgerald raised its price target to $145 but retained a “neutral” rating, suggesting limited near-term upside and a cautious view of Merck’s growth outlook. Cantor Fitzgerald Merck Price Target Neutral Sentiment: Articles comparing Innoviva and Merck frame MRK as a large-cap pharmaceutical value candidate, but provide no new company-specific catalyst likely to materially change the stock’s valuation today. INVA vs. MRK: Which Stock Is the Better Value Option? Negative Sentiment: A Dutch court granted Halozyme an injunction blocking Merck’s subcutaneous Keytruda in eight European markets. The ruling could delay or restrict commercialization of a potentially more convenient Keytruda formulation and heightens litigation risk. Halozyme Wins Court Order Blocking Merck’s Keytruda SC in Europe Negative Sentiment: Industry analysis identifies Merck as particularly exposed to near-term generic competition as major products approach patent losses. That raises concerns about revenue durability and increases the importance of successful launches such as WELIREG. Pharma’s $500 Billion Patent Problem Insider Activity In other news, EVP David R. Maraldo sold 18,706 shares of the stock in a transaction on Wednesday, August 5th. The stock was sold at an average price of $128.72, for a total transaction of $2,407,836.32. Following the transaction, the executive vice president directly owned 18,212 shares of the company’s stock, valued at $2,344,248.64. This represents a 50.67% decrease in their position. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available through this link. Also, EVP David Williams sold 52,847 shares of the firm’s stock in a transaction on Wednesday, August 5th. The stock was sold at an average price of $128.77, for a total value of $6,805,108.19. Following the completion of the transaction, the executive vice president owned 31,716 shares in the company, valued at approximately $4,084,069.32. This trade represents a 62.49% decrease in their ownership of the stock. Additional details regarding this sale are available in the official SEC disclosure. Over the last 90 days, insiders have sold 228,238 shares of company stock worth $29,977,783. 0.17% of the stock is owned by corporate insiders.
Merck & Co., Inc. Profile (Free Report)
Merck & Co, Inc is a global healthcare company that develops and markets prescription medicines, vaccines, and animal-health products. The company serves patients, healthcare providers, and customers in markets around the world, with research and commercial operations spanning multiple geographic regions.
Its pharmaceutical portfolio includes oncology, infectious-disease, cardiovascular, immunology, and other therapeutic areas. Key products include Keytruda, an oncology treatment; Gardasil, a human papillomavirus (HPV) vaccine; Januvia and Janumet for type 2 diabetes; Bridion for anesthesia-related use; and Winrevair for pulmonary arterial hypertension.
Recommended Stories Five stocks we like better than Merck & Co., Inc. Want Private-Market Access to Kalshi and Polymarket? Try This ETF Levi’s Stock Dip Reveals Value Opportunity Despite Q3 Headwinds PepsiCo Stock Looks Poised to Bottom With High Yield, Deep Value Alphabet’s $1.8 Billion Black Hills Deal Powers AI Data Center Push
Receive News & Ratings for Merck & Co. Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Merck & Co. Inc. and related companies with MarketBeat.com's FREE daily email newsletter.
Oracle's cloud backlog keeps growing and its quarterly results keep beating estimates, yet the stock sits near a 52-week low. Something in that gap is either a serious warning sign or the biggest mispricing in megacap tech right now.
This post may contain links from our sponsors and affiliates, and Flywheel Publishing may receive compensation for actions taken through them.
Our 24/7 Wall St. price target for Oracle (NYSE:ORCL | ORCL Price Prediction) is $214.93. That target means 48.5% upside from $144.74. Our model rates the stock a buy with high confidence.
24/7 Wall St. Price Target Summary Metric Value Current Price $144.74 24/7 Wall St. Price Target $214.93 Upside/Downside 48.5% Recommendation BUY Confidence Level 90% Oracle now carries $664B in remaining performance obligations (RPO) and guides to fiscal 2027 revenue of at least $90B. Even so, the stock trades as if that backlog is in question. Our model views the gap between those two facts as a mispricing.
A 50% Slide Despite Triple-Digit Cloud Growth Oracle shares are down 26.28% year to date and 50.64% over the past year. They lost 10.38% over the past month and recovered 3.27% over the past week. The stock sits about 55% below its 52-week high of $319.46 and roughly 26% above its $114.50 low.
Fiscal Q1 revenue, by contrast, rose 29.61% to $19.345B, ahead of the $19.129B estimate. Non-GAAP EPS of $1.92 beat expectations of $1.74. Cloud infrastructure revenue jumped 121%, and management raised fiscal 2027 EPS guidance to $8.10. Two days later, Oracle’s chairman canceled a planned stock sale, according to a September 12 release.
Why Bulls See $326 on the Horizon The bull case hits $326.02. Management expects about half of RPO to convert into revenue within 36 months. GPU utilization hits 97.9%, and renewed capacity was resold at a 20% premium.
Multicloud database revenue rose 353%, and the first NVIDIA (NASDAQ:NVDA) Vera Rubin systems ship in fiscal Q2. On Wall Street, 35 analysts rate the stock Buy or Strong Buy, and the consensus target is $237.97.
Cash Burn and Debt Are the Risks to Watch Fiscal Q1 capital spending of $28.5B left free cash flow at -$5.4B. Interest expense rose 55% to $1.4B, and Oracle plans to raise about $40B through debt and equity. Software revenue slipped 3%. The bear case of $181.37 assumes slower RPO conversion. Permitting delays at the New Mexico and Wisconsin data centers could cause that.
On the other hand, operating cash flow climbed 184% to $23.1B. Most new contracts rely on prepayments or customer-supplied hardware, which limits how much Oracle has to fund itself.
Oracle Trades at a Discount to Microsoft and Amazon Microsoft (NASDAQ:MSFT) runs Azure, Oracle’s most direct competitor for enterprise AI workloads.
Amazon (NASDAQ:AMZN) runs AWS, the largest cloud infrastructure platform. Oracle is growing faster than both and trades at a lower multiple.
Company Forward P/E Quarterly Revenue Growth (YoY) Oracle 18x 29.6% Microsoft 25x 17.7% Amazon 24x 19.6% At $214.93, Oracle would trade near 24x forward earnings. That matches Amazon and sits below Microsoft, so our target looks reasonable next to these peers.
Oracle’s Growth Outweighs the Balance Sheet Strain The 24/7 Wall St. price target is $214.93, with a buy rating and 90% confidence. What tips the scale is a backlog that converts at premium pricing while the stock trades at a discount to its peers.
The thesis gets stronger if cloud revenue growth comes in within the 65% to 71% fiscal Q2 guidance range. It weakens if data-center delays push RPO conversion beyond fiscal 2028. On balance, the growth is real and the market is underpricing it.
Oracle Price Prediction 2026-2030 Here is where our model projects Oracle could trade if current growth trends continue.
Year 24/7 Wall St. Price Target 2026 $158.48 2027 $236.29 2028 $304.76 2029 $352.05 2030 $402.39 Oracle would need to keep executing its current strategy for these projections to hold. Faster RPO conversion could push the stock past these levels, and financing pressure or delays in power delivery could brought it below them.
Contact [email protected] for any questions or corrections.
Toth Financial Advisory Corp purchased a new stake in Snowflake Inc. (NYSE:SNOW – Free Report) during the 3rd quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The fund purchased 2,200 shares of the company’s stock, valued at approximately $747,000.
Several other hedge funds have also recently bought and sold shares of SNOW. Congress Asset Management Co. boosted its stake in shares of Snowflake by 13.4% in the 3rd quarter. Congress Asset Management Co. now owns 35,643 shares of the company’s stock valued at $12,103,000 after purchasing an additional 4,223 shares in the last quarter. Polaris Financial Partners bought a new position in Snowflake during the 3rd quarter valued at about $51,000. Versant Capital Management Inc lifted its holdings in Snowflake by 104.4% during the 3rd quarter. Versant Capital Management Inc now owns 511 shares of the company’s stock valued at $174,000 after purchasing an additional 261 shares during the last quarter. Burkett Financial Services LLC acquired a new position in Snowflake in the third quarter valued at about $82,000. Finally, QRG Capital Management Inc. grew its stake in Snowflake by 67.9% during the second quarter. QRG Capital Management Inc. now owns 82,137 shares of the company’s stock worth $20,904,000 after buying an additional 33,218 shares during the last quarter. 65.10% of the stock is currently owned by institutional investors and hedge funds.
Insider Transactions at Snowflake In related news, Director Michael Speiser sold 50,338 shares of the firm’s stock in a transaction dated Friday, August 7th. The stock was sold at an average price of $324.06, for a total value of $16,312,532.28. Following the transaction, the director owned 26,036 shares in the company, valued at $8,437,226.16. This trade represents a 65.91% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available at the SEC website. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, Director Frank Slootman sold 289,685 shares of Snowflake stock in a transaction dated Monday, July 20th. The stock was sold at an average price of $274.39, for a total value of $79,486,667.15. Following the completion of the sale, the director owned 28,535 shares of the company’s stock, valued at approximately $7,829,718.65. The trade was a 91.03% decrease in their ownership of the stock. The disclosure for this sale is available in the SEC filing. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Over the last three months, insiders sold 1,246,429 shares of company stock worth $396,227,952. 4.80% of the stock is owned by insiders.
Snowflake Stock Up 3.3% NYSE:SNOW opened at $343.90 on Friday. The stock’s fifty day moving average price is $329.72 and its two-hundred day moving average price is $247.89. Snowflake Inc. has a 52-week low of $118.30 and a 52-week high of $384.56. The company has a debt-to-equity ratio of 1.06, a quick ratio of 0.94 and a current ratio of 0.94. The company has a market cap of $121.33 billion, a price-to-earnings ratio of -108.14 and a beta of 1.35. Snowflake (NYSE:SNOW – Get Free Report) last announced its quarterly earnings data on Wednesday, September 2nd. The company reported $0.62 EPS for the quarter, beating analysts’ consensus estimates of $0.45 by $0.17. The firm had revenue of $1.55 billion for the quarter, compared to analyst estimates of $1.48 billion. Snowflake had a negative return on equity of 46.32% and a negative net margin of 20.07%.The business’s quarterly revenue was up 35.1% compared to the same quarter last year. During the same period last year, the company earned $0.35 EPS. On average, analysts anticipate that Snowflake Inc. will post -1.46 EPS for the current year.
Wall Street Analysts Forecast Growth A number of research firms recently commented on SNOW. Canaccord Genuity Group increased their price target on Snowflake from $325.00 to $450.00 and gave the stock a “buy” rating in a research report on Thursday, September 3rd. Citizens Jmp lifted their price objective on Snowflake from $408.00 to $488.00 and gave the company a “market outperform” rating in a research report on Thursday, September 3rd. Wells Fargo & Company boosted their price objective on Snowflake from $500.00 to $525.00 and gave the stock an “overweight” rating in a research note on Thursday, September 3rd. Bank of America lifted their price target on Snowflake from $330.00 to $395.00 and gave the company a “buy” rating in a report on Wednesday, August 19th. Finally, Citigroup upped their price target on shares of Snowflake from $395.00 to $490.00 and gave the stock a “buy” rating in a research report on Thursday, September 3rd. One investment analyst has rated the stock with a Strong Buy rating, thirty-four have issued a Buy rating, five have assigned a Hold rating and one has issued a Sell rating to the company’s stock. According to data from MarketBeat, the company has an average rating of “Moderate Buy” and an average target price of $414.24.
Get Our Latest Analysis on Snowflake
Snowflake Profile (Free Report)
Snowflake Inc (NYSE: SNOW) provides a cloud-based data platform that enables organizations to store, process, analyze and share data. Its platform is designed to support data warehousing, data lakes, data engineering, data science, application development and artificial intelligence workloads in a single environment.
Snowflake’s services include cloud data storage and computing, data sharing and collaboration tools, governance and security capabilities, and access to third-party data through the Snowflake Marketplace.
Featured Stories Five stocks we like better than Snowflake Want Private-Market Access to Kalshi and Polymarket? Try This ETF Levi’s Stock Dip Reveals Value Opportunity Despite Q3 Headwinds PepsiCo Stock Looks Poised to Bottom With High Yield, Deep Value Alphabet’s $1.8 Billion Black Hills Deal Powers AI Data Center Push Want to see what other hedge funds are holding SNOW? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Snowflake Inc. (NYSE:SNOW – Free Report).
Receive News & Ratings for Snowflake Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Snowflake and related companies with MarketBeat.com's FREE daily email newsletter.
CoreCap Advisors LLC lifted its holdings in Costco Wholesale Corporation (NASDAQ:COST – Free Report) by 23.1% in the 3rd quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The institutional investor owned 6,297 shares of the retailer’s stock after acquiring an additional 1,180 shares during the period. CoreCap Advisors LLC’s holdings in Costco Wholesale were worth $5,732,000 as of its most recent filing with the Securities and Exchange Commission.
Other hedge funds and other institutional investors also recently made changes to their positions in the company. Sarasin & Partners LLP raised its stake in Costco Wholesale by 6.9% during the 2nd quarter. Sarasin & Partners LLP now owns 214,194 shares of the retailer’s stock worth $200,372,000 after buying an additional 13,795 shares during the period. Perryman Financial Advisory Inc. AD bought a new position in Costco Wholesale in the fourth quarter worth approximately $9,300,000. Nissay Asset Management Corp Japan grew its stake in Costco Wholesale by 4.1% in the second quarter. Nissay Asset Management Corp Japan now owns 158,416 shares of the retailer’s stock valued at $148,193,000 after acquiring an additional 6,200 shares during the period. Hyperion Asset Management Ltd grew its stake in Costco Wholesale by 9.0% in the second quarter. Hyperion Asset Management Ltd now owns 68,762 shares of the retailer’s stock valued at $64,325,000 after acquiring an additional 5,656 shares during the period. Finally, Concurrent Investment Advisors LLC increased its holdings in shares of Costco Wholesale by 15.0% during the second quarter. Concurrent Investment Advisors LLC now owns 22,766 shares of the retailer’s stock valued at $21,297,000 after acquiring an additional 2,974 shares in the last quarter. 68.48% of the stock is owned by institutional investors and hedge funds.
Insider Transactions at Costco Wholesale In other Costco Wholesale news, EVP Claudine Adamo sold 2,200 shares of the stock in a transaction that occurred on Tuesday, September 29th. The shares were sold at an average price of $915.93, for a total transaction of $2,015,046.00. Following the transaction, the executive vice president directly owned 7,134 shares in the company, valued at $6,534,244.62. This trade represents a 23.57% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available at this hyperlink. 0.10% of the stock is currently owned by corporate insiders.
Costco Wholesale Price Performance Shares of NASDAQ:COST opened at $947.92 on Friday. The company’s fifty day moving average price is $930.81 and its 200-day moving average price is $963.49. The company has a debt-to-equity ratio of 0.11, a current ratio of 1.06 and a quick ratio of 0.62. The firm has a market capitalization of $420.38 billion, a price-to-earnings ratio of 45.66, a PEG ratio of 4.03 and a beta of 0.88. Costco Wholesale Corporation has a one year low of $844.06 and a one year high of $1,096.50. Costco Wholesale (NASDAQ:COST – Get Free Report) last announced its earnings results on Thursday, September 24th. The retailer reported $6.75 earnings per share (EPS) for the quarter, topping the consensus estimate of $6.54 by $0.21. The company had revenue of $95.72 billion during the quarter, compared to analyst estimates of $94.97 billion. Costco Wholesale had a net margin of 3.04% and a return on equity of 27.60%. The firm’s quarterly revenue was up 11.1% compared to the same quarter last year. During the same period in the previous year, the business earned $5.87 earnings per share. On average, equities research analysts anticipate that Costco Wholesale Corporation will post 22.86 earnings per share for the current fiscal year.
Costco Wholesale News Summary Here are the key news stories impacting Costco Wholesale this week:
Positive Sentiment: Strong customer traffic and transaction growth supported broad-based comparable-sales gains. U.S. comparable sales increased 12.5%, Canada rose 6.3%, and other international markets gained 10.8%, offering evidence that Costco’s membership model continues to attract shoppers. Costco sales rise in September as strong traffic drives start to fiscal 2027 Positive Sentiment: Digital sales grew approximately 19%, adding another growth channel and strengthening expectations for a solid start to fiscal 2027. The report also supports the view that Costco’s international operations remain an important contributor to future revenue growth. Costco’s September Sales Rise 13% on Strong Comps, Digital Growth Neutral Sentiment: Investors are paying a premium for this consistency: COST trades at roughly 45 times trailing earnings. The valuation reflects expectations for years of continued growth, leaving the stock particularly sensitive to any slowdown in traffic, memberships, or margins. What Are Costco Investors Betting On? Negative Sentiment: Some of the headline sales strength came from higher gasoline prices and other potentially lower-margin or one-time effects. Analysts therefore caution that the underlying 7.6% increase, while healthy, is less dramatic than the 13% reported-sales gain. Costco’s Sales Rebound in September Looks Great on Paper. Why There’s More to the Story. Wall Street Analyst Weigh In COST has been the subject of a number of analyst reports. HSBC upgraded shares of Costco Wholesale to a “buy” rating in a report on Friday, September 25th. Raymond James Financial dropped their target price on shares of Costco Wholesale from $1,100.00 to $1,050.00 and set an “outperform” rating on the stock in a research note on Friday, September 25th. TD Cowen reiterated a “buy” rating on shares of Costco Wholesale in a research report on Friday, September 25th. Mizuho decreased their price target on Costco Wholesale from $1,100.00 to $1,065.00 and set an “outperform” rating on the stock in a research report on Friday, September 25th. Finally, Jefferies Financial Group reduced their price target on shares of Costco Wholesale from $1,130.00 to $1,100.00 in a research report on Friday, September 25th. Twenty-two equities research analysts have rated the stock with a Buy rating, ten have issued a Hold rating and one has issued a Sell rating to the stock. Based on data from MarketBeat, the company presently has an average rating of “Moderate Buy” and a consensus price target of $1,046.27.
Check Out Our Latest Stock Report on COST
Costco Wholesale Company Profile (Free Report)
Costco Wholesale Corporation operates a membership-based warehouse retail business under the Costco name. The company sells a broad selection of merchandise, including groceries, fresh foods, beverages, appliances, electronics, furniture, apparel, jewelry, hardware, and seasonal products. It also offers services such as gasoline, pharmacies, optical departments, hearing-aid centers, food courts, travel services, and business delivery in selected markets.
Costco markets many products under its private-label Kirkland Signature brand and sells merchandise through warehouse locations and e-commerce platforms.
See Also Five stocks we like better than Costco Wholesale Want Private-Market Access to Kalshi and Polymarket? Try This ETF Levi’s Stock Dip Reveals Value Opportunity Despite Q3 Headwinds PepsiCo Stock Looks Poised to Bottom With High Yield, Deep Value Alphabet’s $1.8 Billion Black Hills Deal Powers AI Data Center Push Want to see what other hedge funds are holding COST? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Costco Wholesale Corporation (NASDAQ:COST – Free Report).
Receive News & Ratings for Costco Wholesale Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Costco Wholesale and related companies with MarketBeat.com's FREE daily email newsletter.
GAMMA Investing LLC grew its position in CF Industries Holdings, Inc. (NYSE:CF – Free Report) by 616.6% in the third quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The institutional investor owned 54,379 shares of the basic materials company’s stock after buying an additional 46,790 shares during the quarter. GAMMA Investing LLC’s holdings in CF Industries were worth $6,797,000 at the end of the most recent quarter.
Several other institutional investors and hedge funds have also made changes to their positions in the business. Farther Finance Advisors LLC increased its holdings in CF Industries by 2,298.8% during the 3rd quarter. Farther Finance Advisors LLC now owns 97,462 shares of the basic materials company’s stock valued at $12,297,000 after acquiring an additional 93,399 shares in the last quarter. Sapient Capital LLC lifted its holdings in shares of CF Industries by 176.8% in the third quarter. Sapient Capital LLC now owns 13,939 shares of the basic materials company’s stock valued at $1,708,000 after purchasing an additional 8,904 shares in the last quarter. CoreCap Advisors LLC grew its position in shares of CF Industries by 340.6% in the third quarter. CoreCap Advisors LLC now owns 3,736 shares of the basic materials company’s stock valued at $467,000 after purchasing an additional 2,888 shares during the last quarter. Everhart Financial Group Inc. grew its position in shares of CF Industries by 306.5% in the third quarter. Everhart Financial Group Inc. now owns 13,753 shares of the basic materials company’s stock valued at $1,704,000 after purchasing an additional 10,370 shares during the last quarter. Finally, Vann Equity Management LLC increased its stake in shares of CF Industries by 127.3% during the 3rd quarter. Vann Equity Management LLC now owns 8,797 shares of the basic materials company’s stock worth $1,071,000 after purchasing an additional 4,926 shares in the last quarter. 93.06% of the stock is currently owned by hedge funds and other institutional investors.
More CF Industries News Here are the key news stories impacting CF Industries this week:
Positive Sentiment: Quarterly dividend maintained: CF Industries declared a quarterly dividend of $0.60 per share, equivalent to $2.40 annually and an indicated 2.1% yield. The dividend is payable November 30 to shareholders of record November 16. The continued payout may appeal to income-focused investors. CF Industries Declares Quarterly Dividend Positive Sentiment: Strong cash flow supports capital allocation: Recent analysis highlights CF Industries’ ability to use cash flow for strategic investments, debt reduction and shareholder returns. Continued cash generation could support growth and improve balance-sheet strength. CF Industries Strong Cash Flow Analysis Neutral Sentiment: Next earnings catalyst scheduled: CF Industries will report third-quarter and nine-month 2026 results after the market closes on November 4, followed by a conference call. Investors will be looking for evidence that operating performance and fertilizer-market conditions are improving. CF Industries Dividend and Earnings Schedule Neutral Sentiment: Analyst stance remains cautious: RBC Capital kept a Hold rating, while another recent report placed a $115 price target, suggesting limited near-term upside from current levels. RBC Capital Maintains Hold Rating Negative Sentiment: Prior earnings miss remains an overhang: CF Industries previously reported earnings and revenue below analyst expectations, despite year-over-year revenue growth. That performance may be contributing to investor caution until the November results provide updated guidance. CF Industries Trading Down 0.8% Shares of CF opened at $113.47 on Friday. CF Industries Holdings, Inc. has a fifty-two week low of $75.42 and a fifty-two week high of $141.96. The company has a market capitalization of $17.17 billion, a PE ratio of 8.41, a price-to-earnings-growth ratio of 0.22 and a beta of 0.53. The stock has a fifty day moving average of $123.88 and a two-hundred day moving average of $120.74. The company has a debt-to-equity ratio of 0.36, a quick ratio of 4.32 and a current ratio of 4.86. CF Industries (NYSE:CF – Get Free Report) last posted its quarterly earnings data on Wednesday, August 5th. The basic materials company reported $4.73 earnings per share (EPS) for the quarter, missing the consensus estimate of $5.63 by ($0.90). The business had revenue of $2.22 billion for the quarter, compared to analyst estimates of $2.45 billion. CF Industries had a return on equity of 24.41% and a net margin of 27.12%.CF Industries’s revenue for the quarter was up 17.6% compared to the same quarter last year. During the same quarter last year, the business earned $2.37 EPS. As a group, analysts forecast that CF Industries Holdings, Inc. will post 13.9 EPS for the current year.
CF Industries Announces Dividend The firm also recently declared a quarterly dividend, which will be paid on Monday, November 30th. Shareholders of record on Monday, November 16th will be paid a $0.60 dividend. This represents a $2.40 dividend on an annualized basis and a yield of 2.1%. The ex-dividend date of this dividend is Monday, November 16th. CF Industries’s dividend payout ratio (DPR) is presently 17.79%.
Wall Street Analysts Forecast Growth CF has been the topic of a number of recent research reports. Scotiabank upped their target price on CF Industries from $125.00 to $130.00 and gave the company an “outperform” rating in a research note on Monday, August 10th. BNP Paribas Exane dropped their price target on CF Industries from $140.00 to $120.00 and set a “neutral” rating for the company in a research report on Monday, June 15th. The Goldman Sachs Group cut their price target on CF Industries from $133.00 to $115.00 and set a “neutral” rating for the company in a report on Tuesday, June 23rd. Weiss Ratings upgraded CF Industries from a “buy (b-)” rating to a “buy (b)” rating in a research report on Wednesday, September 16th. Finally, UBS Group increased their price objective on CF Industries from $115.00 to $123.00 and gave the company a “neutral” rating in a research note on Friday, August 7th. Two investment analysts have rated the stock with a Strong Buy rating, six have given a Buy rating, twelve have issued a Hold rating and three have issued a Sell rating to the stock. Based on data from MarketBeat.com, the company has an average rating of “Hold” and an average target price of $121.11.
Get Our Latest Stock Report on CF Industries
CF Industries Company Profile (Free Report)
CF Industries Holdings, Inc (NYSE: CF) is a major global producer of nitrogen fertilizer and other nitrogen-based products. The company manufactures ammonia, granular urea, urea ammonium nitrate (UAN), ammonium nitrate and specialty nitrogen products used in agriculture, industrial applications and emissions-control systems.
CF Industries operates a network of production facilities in the United States, Canada and the United Kingdom, serving agricultural and industrial customers in North America and international markets.
Featured Articles Five stocks we like better than CF Industries Want Private-Market Access to Kalshi and Polymarket? Try This ETF Levi’s Stock Dip Reveals Value Opportunity Despite Q3 Headwinds PepsiCo Stock Looks Poised to Bottom With High Yield, Deep Value Alphabet’s $1.8 Billion Black Hills Deal Powers AI Data Center Push Want to see what other hedge funds are holding CF? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for CF Industries Holdings, Inc. (NYSE:CF – Free Report).
Receive News & Ratings for CF Industries Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for CF Industries and related companies with MarketBeat.com's FREE daily email newsletter.
GAMMA Investing LLC raised its holdings in shares of AbbVie Inc. (NYSE:ABBV – Free Report) by 10.4% during the 3rd quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The institutional investor owned 75,060 shares of the company’s stock after acquiring an additional 7,058 shares during the period. AbbVie makes up 0.6% of GAMMA Investing LLC’s holdings, making the stock its 24th largest position. GAMMA Investing LLC’s holdings in AbbVie were worth $19,635,000 as of its most recent SEC filing.
A number of other large investors also recently modified their holdings of ABBV. Galvin Gaustad & Stein LLC raised its stake in shares of AbbVie by 0.7% during the third quarter. Galvin Gaustad & Stein LLC now owns 6,941 shares of the company’s stock valued at $1,816,000 after purchasing an additional 46 shares in the last quarter. Grove Bank & Trust lifted its holdings in AbbVie by 0.7% in the third quarter. Grove Bank & Trust now owns 15,465 shares of the company’s stock worth $4,045,000 after purchasing an additional 112 shares during the period. Factor Wealth Management LTD grew its position in AbbVie by 1.1% in the 3rd quarter. Factor Wealth Management LTD now owns 19,240 shares of the company’s stock valued at $5,033,000 after buying an additional 207 shares in the last quarter. Conrad Siegel Investment Advisors Inc. bought a new position in AbbVie in the 3rd quarter valued at about $201,000. Finally, Farther Finance Advisors LLC increased its stake in AbbVie by 10.7% during the 3rd quarter. Farther Finance Advisors LLC now owns 132,821 shares of the company’s stock valued at $34,745,000 after buying an additional 12,862 shares during the period. 70.23% of the stock is owned by institutional investors and hedge funds.
Analyst Ratings Changes A number of analysts have recently weighed in on the stock. Barclays upped their price target on shares of AbbVie from $275.00 to $300.00 and gave the stock an “overweight” rating in a research note on Wednesday, July 29th. Weiss Ratings upgraded shares of AbbVie from a “hold (c)” rating to a “buy (b-)” rating in a research note on Tuesday, August 4th. Bank of America reissued a “buy” rating on shares of AbbVie in a report on Tuesday, September 8th. Argus upped their target price on AbbVie from $250.00 to $270.00 in a research report on Tuesday, August 4th. Finally, Royal Bank Of Canada increased their price target on AbbVie from $260.00 to $280.00 and gave the company an “outperform” rating in a research note on Friday, July 10th. One analyst has rated the stock with a Strong Buy rating, twenty-three have given a Buy rating and six have given a Hold rating to the company’s stock. According to data from MarketBeat, the company currently has a consensus rating of “Moderate Buy” and a consensus price target of $276.64.
Check Out Our Latest Research Report on AbbVie Insiders Place Their Bets In related news, EVP Nicholas Donoghoe sold 32,710 shares of the stock in a transaction dated Friday, August 14th. The stock was sold at an average price of $250.00, for a total value of $8,177,500.00. Following the completion of the sale, the executive vice president directly owned 74,430 shares of the company’s stock, valued at approximately $18,607,500. This represents a 30.53% decrease in their position. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through this hyperlink. Insiders own 0.06% of the company’s stock.
AbbVie Stock Performance AbbVie stock opened at $272.20 on Friday. AbbVie Inc. has a 52 week low of $190.75 and a 52 week high of $274.94. The firm has a market capitalization of $480.92 billion, a price-to-earnings ratio of 76.89, a P/E/G ratio of 1.23 and a beta of 0.24. The company has a 50 day moving average price of $258.56 and a 200 day moving average price of $236.35.
AbbVie (NYSE:ABBV – Get Free Report) last announced its earnings results on Friday, July 31st. The company reported $3.65 earnings per share (EPS) for the quarter, beating the consensus estimate of $3.61 by $0.04. The company had revenue of $16.99 billion for the quarter, compared to the consensus estimate of $16.80 billion. AbbVie had a net margin of 9.80% and a negative return on equity of 422.07%. The company’s revenue was up 10.2% on a year-over-year basis. During the same period in the previous year, the business earned $2.97 EPS. AbbVie has set its Q3 2026 guidance at 3.840-3.880 EPS. Equities analysts forecast that AbbVie Inc. will post 14.01 earnings per share for the current fiscal year.
AbbVie Dividend Announcement The firm also recently declared a quarterly dividend, which will be paid on Monday, November 16th. Investors of record on Thursday, October 15th will be given a dividend of $1.73 per share. This represents a $6.92 annualized dividend and a yield of 2.5%. The ex-dividend date of this dividend is Thursday, October 15th. AbbVie’s payout ratio is presently 195.48%.
Key Headlines Impacting AbbVie Here are the key news stories impacting AbbVie this week:
Positive Sentiment: FDA breakthrough designations for Temab-A: The FDA granted two Breakthrough Therapy Designations to investigational telisotuzumab adizutecan (Temab-A/ABBV-400) for colorectal cancer and non-small cell lung cancer. The designations can accelerate development and regulatory review, while highlighting the potential of AbbVie’s antibody-drug conjugate portfolio. They do not, however, represent an approval or guarantee of commercial success. AbbVie Temab-A FDA Breakthrough Therapy Designations Positive Sentiment: Strong Phase 3 lymphoma data: AbbVie and Genmab reported that epcoritamab plus R-CHOP reduced the risk of disease progression or death by 51% versus R-CHOP alone in newly diagnosed diffuse large B-cell lymphoma. The result supports the potential for broader use of Epkinly/Epkinly and adds another meaningful pipeline catalyst. AbbVie and Genmab Epcoritamab Phase 3 Results Positive Sentiment: Higher analyst price targets: JPMorgan raised its AbbVie target to $300 from $285 and maintained an Overweight rating. Cantor Fitzgerald also raised its target, to $290 from $285, and reiterated Overweight. The revisions indicate analysts see additional upside based on AbbVie’s pipeline and growth outlook. Negative Sentiment: Dividend sustainability concerns: A report highlighted AbbVie’s roughly 190% payout ratio, meaning reported earnings are below the dividend distributed. While noncash charges and other accounting factors can distort this measure, the elevated ratio raises questions about long-term dividend coverage and could weigh on income-focused investors. AbbVie Dividend Payout Concerns AbbVie Company Profile (Free Report)
AbbVie Inc is a global biopharmaceutical company that develops, manufactures and markets medicines for a range of serious and chronic health conditions. Its portfolio spans immunology, oncology, neuroscience, eye care, aesthetics, gastroenterology and women’s health.
The company’s products include the immunology medicines Skyrizi and Rinvoq; neuroscience treatments such as Vraylar, Ubrelvy and Qulipta; and oncology medicines including Imbruvica and Venclexta. AbbVie also markets Botox Cosmetic and Botox Therapeutic, as well as other products for aesthetics, eye care and specialty care.
AbbVie was established in 2013 as an independent, publicly traded company following its separation from Abbott Laboratories.
Further Reading Five stocks we like better than AbbVie Want Private-Market Access to Kalshi and Polymarket? Try This ETF Levi’s Stock Dip Reveals Value Opportunity Despite Q3 Headwinds PepsiCo Stock Looks Poised to Bottom With High Yield, Deep Value Alphabet’s $1.8 Billion Black Hills Deal Powers AI Data Center Push Want to see what other hedge funds are holding ABBV? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for AbbVie Inc. (NYSE:ABBV – Free Report).
Receive News & Ratings for AbbVie Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for AbbVie and related companies with MarketBeat.com's FREE daily email newsletter.
Bell Asset Management ve třetím čtvrtletí snížila svůj podíl ve společnosti AbbVie o 48,2 % prodejem 10 062 akcií; na konci čtvrtletí držela 10 833 akcií v hodnotě 2,834 milionu USD.
Bell Asset Management Ltd cut its holdings in shares of AbbVie Inc. (NYSE:ABBV – Free Report) by 48.2% during the 3rd quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The fund owned 10,833 shares of the company’s stock after selling 10,062 shares during the quarter. AbbVie makes up approximately 1.0% of Bell Asset Management Ltd’s portfolio, making the stock its 23rd largest holding. Bell Asset Management Ltd’s holdings in AbbVie were worth $2,834,000 at the end of the most recent quarter.
A number of other institutional investors and hedge funds have also recently added to or reduced their stakes in ABBV. Burk Holdings LLC bought a new position in AbbVie in the 2nd quarter worth approximately $30,000. Abound Financial LLC purchased a new stake in shares of AbbVie during the fourth quarter worth $32,000. Merkkuri Wealth Advisors LLC bought a new position in shares of AbbVie in the first quarter worth $34,000. Marquette Asset Management LLC grew its position in shares of AbbVie by 52.2% in the second quarter. Marquette Asset Management LLC now owns 140 shares of the company’s stock valued at $35,000 after purchasing an additional 48 shares in the last quarter. Finally, Phillip James Consulting Co. bought a new stake in shares of AbbVie during the 4th quarter valued at $36,000. Institutional investors own 70.23% of the company’s stock.
Insider Activity at AbbVie In related news, EVP Nicholas Donoghoe sold 32,710 shares of the business’s stock in a transaction dated Friday, August 14th. The shares were sold at an average price of $250.00, for a total transaction of $8,177,500.00. Following the transaction, the executive vice president owned 74,430 shares in the company, valued at $18,607,500. The trade was a 30.53% decrease in their ownership of the stock. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available through this hyperlink. 0.06% of the stock is currently owned by corporate insiders.
Analyst Ratings Changes ABBV has been the subject of a number of recent analyst reports. Rothschild & Co Redburn lifted their target price on AbbVie from $284.00 to $285.00 and gave the company a “buy” rating in a report on Tuesday, August 4th. HSBC upped their target price on shares of AbbVie from $300.00 to $315.00 and gave the stock a “buy” rating in a report on Thursday, September 10th. Erste Group Bank raised shares of AbbVie from a “hold” rating to a “buy” rating in a report on Wednesday, August 5th. Weiss Ratings upgraded AbbVie from a “hold (c)” rating to a “buy (b-)” rating in a research report on Tuesday, August 4th. Finally, Morgan Stanley lifted their price target on AbbVie from $296.00 to $310.00 and gave the company an “overweight” rating in a research report on Wednesday. One research analyst has rated the stock with a Strong Buy rating, twenty-three have assigned a Buy rating and six have issued a Hold rating to the company. Based on data from MarketBeat.com, AbbVie currently has a consensus rating of “Moderate Buy” and an average target price of $276.64. Read Our Latest Stock Analysis on AbbVie
AbbVie News Summary Here are the key news stories impacting AbbVie this week:
Positive Sentiment: FDA breakthrough designations for Temab-A: The FDA granted two Breakthrough Therapy Designations to investigational telisotuzumab adizutecan (Temab-A/ABBV-400) for colorectal cancer and non-small cell lung cancer. The designations can accelerate development and regulatory review, while highlighting the potential of AbbVie’s antibody-drug conjugate portfolio. They do not, however, represent an approval or guarantee of commercial success. AbbVie Temab-A FDA Breakthrough Therapy Designations Positive Sentiment: Strong Phase 3 lymphoma data: AbbVie and Genmab reported that epcoritamab plus R-CHOP reduced the risk of disease progression or death by 51% versus R-CHOP alone in newly diagnosed diffuse large B-cell lymphoma. The result supports the potential for broader use of Epkinly/Epkinly and adds another meaningful pipeline catalyst. AbbVie and Genmab Epcoritamab Phase 3 Results Positive Sentiment: Higher analyst price targets: JPMorgan raised its AbbVie target to $300 from $285 and maintained an Overweight rating. Cantor Fitzgerald also raised its target, to $290 from $285, and reiterated Overweight. The revisions indicate analysts see additional upside based on AbbVie’s pipeline and growth outlook. Negative Sentiment: Dividend sustainability concerns: A report highlighted AbbVie’s roughly 190% payout ratio, meaning reported earnings are below the dividend distributed. While noncash charges and other accounting factors can distort this measure, the elevated ratio raises questions about long-term dividend coverage and could weigh on income-focused investors. AbbVie Dividend Payout Concerns AbbVie Price Performance NYSE:ABBV opened at $272.20 on Friday. The company has a market capitalization of $480.92 billion, a price-to-earnings ratio of 76.89, a PEG ratio of 1.23 and a beta of 0.24. The business has a 50 day moving average of $258.56 and a 200 day moving average of $236.35. AbbVie Inc. has a 1-year low of $190.75 and a 1-year high of $274.94.
AbbVie (NYSE:ABBV – Get Free Report) last released its quarterly earnings data on Friday, July 31st. The company reported $3.65 EPS for the quarter, topping the consensus estimate of $3.61 by $0.04. The firm had revenue of $16.99 billion for the quarter, compared to the consensus estimate of $16.80 billion. AbbVie had a negative return on equity of 422.07% and a net margin of 9.80%.The company’s quarterly revenue was up 10.2% on a year-over-year basis. During the same quarter in the previous year, the business earned $2.97 earnings per share. AbbVie has set its Q3 2026 guidance at 3.840-3.880 EPS. As a group, sell-side analysts anticipate that AbbVie Inc. will post 14.01 EPS for the current year.
AbbVie Dividend Announcement The firm also recently announced a quarterly dividend, which will be paid on Monday, November 16th. Investors of record on Thursday, October 15th will be issued a dividend of $1.73 per share. This represents a $6.92 dividend on an annualized basis and a dividend yield of 2.5%. The ex-dividend date is Thursday, October 15th. AbbVie’s dividend payout ratio is currently 195.48%.
AbbVie Company Profile (Free Report)
AbbVie Inc is a global biopharmaceutical company that develops, manufactures and markets medicines for a range of serious and chronic health conditions. Its portfolio spans immunology, oncology, neuroscience, eye care, aesthetics, gastroenterology and women’s health.
The company’s products include the immunology medicines Skyrizi and Rinvoq; neuroscience treatments such as Vraylar, Ubrelvy and Qulipta; and oncology medicines including Imbruvica and Venclexta. AbbVie also markets Botox Cosmetic and Botox Therapeutic, as well as other products for aesthetics, eye care and specialty care.
AbbVie was established in 2013 as an independent, publicly traded company following its separation from Abbott Laboratories.
See Also Five stocks we like better than AbbVie Want Private-Market Access to Kalshi and Polymarket? Try This ETF Levi’s Stock Dip Reveals Value Opportunity Despite Q3 Headwinds PepsiCo Stock Looks Poised to Bottom With High Yield, Deep Value Alphabet’s $1.8 Billion Black Hills Deal Powers AI Data Center Push Want to see what other hedge funds are holding ABBV? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for AbbVie Inc. (NYSE:ABBV – Free Report).
Receive News & Ratings for AbbVie Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for AbbVie and related companies with MarketBeat.com's FREE daily email newsletter.
Gradient Investments ve třetím čtvrtletí zvýšila svůj podíl ve společnosti Palantir Technologies (PLTR) o 1 093,9 % na 37 466 akcií v hodnotě 7,008 milionu USD.
Gradient Investments LLC raised its position in Palantir Technologies Inc. (NASDAQ:PLTR – Free Report) by 1,093.9% during the third quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission (SEC). The firm owned 37,466 shares of the company’s stock after purchasing an additional 34,328 shares during the quarter. Gradient Investments LLC’s holdings in Palantir Technologies were worth $7,008,000 at the end of the most recent quarter.
Several other hedge funds and other institutional investors have also modified their holdings of PLTR. Guardian Wealth Advisors LLC NC raised its holdings in Palantir Technologies by 67.5% during the 2nd quarter. Guardian Wealth Advisors LLC NC now owns 10,627 shares of the company’s stock worth $1,240,000 after buying an additional 4,283 shares during the period. Independent Financial Group LLC boosted its holdings in shares of Palantir Technologies by 20.8% in the second quarter. Independent Financial Group LLC now owns 188,200 shares of the company’s stock worth $21,957,000 after buying an additional 32,427 shares during the period. World Equity Group Inc. increased its position in shares of Palantir Technologies by 7.2% in the second quarter. World Equity Group Inc. now owns 43,627 shares of the company’s stock worth $5,090,000 after acquiring an additional 2,948 shares in the last quarter. Sage Capital Advisors llc increased its position in shares of Palantir Technologies by 63.5% in the second quarter. Sage Capital Advisors llc now owns 66,944 shares of the company’s stock worth $7,810,000 after acquiring an additional 25,995 shares in the last quarter. Finally, V. M. Manning & CO. Inc. acquired a new stake in shares of Palantir Technologies during the second quarter valued at approximately $539,000. 45.65% of the stock is owned by institutional investors and hedge funds.
Insider Activity at Palantir Technologies In related news, Director Lauren Friedman Stat sold 1,337 shares of the stock in a transaction on Thursday, October 1st. The stock was sold at an average price of $189.95, for a total transaction of $253,963.15. Following the completion of the sale, the director directly owned 51,428 shares in the company, valued at approximately $9,768,748.60. This trade represents a 2.53% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through the SEC website. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, insider Alexander C. Karp sold 492,348 shares of the business’s stock in a transaction dated Thursday, August 20th. The shares were sold at an average price of $174.79, for a total value of $86,057,506.92. Following the completion of the transaction, the insider owned 6,432,258 shares in the company, valued at $1,124,294,375.82. This trade represents a 7.11% decrease in their position. The SEC filing for this sale provides additional information. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. The sale was made to cover tax withholding obligations related to the vesting of equity awards. Over the last 90 days, insiders sold 536,364 shares of company stock worth $93,083,303. Corporate insiders own 9.53% of the company’s stock.
Palantir Technologies News Summary Here are the key news stories impacting Palantir Technologies this week: Positive Sentiment: Goldman Sachs upgraded Palantir to Buy from Neutral and set a $230 price target, citing a potentially larger addressable market driven by sovereign AI, custom-built applications and specialized industry solutions. Palantir Gets Goldman Sachs Upgrade as Sovereign AI Opens New Market Positive Sentiment: The upgrade suggests Palantir could benefit as governments and businesses seek greater control over data, infrastructure and AI models. The company’s partnership with Armada to deploy its Sovereign AI Operating System reinforces that growth narrative. Palantir Is Betting on Sovereign AI to Help Take Its Stock Higher Positive Sentiment: Additional bullish commentary from analyst Dan Ives, who named Palantir among his top technology picks for the expected multitrillion-dollar AI spending cycle, added to positive momentum ahead of the company’s next earnings report. Dan Ives Thinks AI Buildout Is Still in Early Stages Neutral Sentiment: Palantir’s strong revenue growth, profitability and government-contract activity continue to support the investment case. However, the stock is trading near its 52-week high with a very elevated earnings multiple, leaving investors focused on whether growth can justify the valuation. Negative Sentiment: Zacks Research lowered its rating from Strong Buy to Hold, while some coverage continues to warn that the valuation may already reflect much of the company’s AI success. Palantir Technologies Stock Dropped to Hold by Zacks Research Negative Sentiment: Reported insider activity has been heavily weighted toward sales, and investor Michael Burry has taken longer-dated bearish positions on Palantir and other AI leaders. These signals may intensify concerns about profit-taking and an eventual slowdown in AI spending. Palantir Technologies Price Performance NASDAQ PLTR opened at $198.78 on Friday. The firm has a market capitalization of $477.68 billion, a price-to-earnings ratio of 169.90, a price-to-earnings-growth ratio of 2.73 and a beta of 1.60. The company has a 50 day simple moving average of $176.28 and a 200-day simple moving average of $149.88. Palantir Technologies Inc. has a 52-week low of $106.37 and a 52-week high of $207.52.
Palantir Technologies (NASDAQ:PLTR – Get Free Report) last announced its quarterly earnings data on Monday, August 3rd. The company reported $0.41 EPS for the quarter, beating analysts’ consensus estimates of $0.34 by $0.07. The firm had revenue of $1.94 billion for the quarter, compared to the consensus estimate of $1.81 billion. Palantir Technologies had a net margin of 49.01% and a return on equity of 30.57%. The firm’s revenue was up 92.8% on a year-over-year basis. During the same period in the previous year, the firm posted $0.16 earnings per share. On average, analysts predict that Palantir Technologies Inc. will post 1.28 EPS for the current year.
Analyst Upgrades and Downgrades Several brokerages recently commented on PLTR. The Goldman Sachs Group upgraded shares of Palantir Technologies from a “neutral” rating to a “buy” rating and set a $230.00 price target for the company in a research report on Thursday. Rosenblatt Securities reiterated a “buy” rating and set a $225.00 price objective on shares of Palantir Technologies in a research report on Wednesday, September 23rd. BNP Paribas Exane started coverage on shares of Palantir Technologies in a research note on Tuesday, June 16th. They set an “underperform” rating on the stock. Northland Securities set a $200.00 target price on Palantir Technologies in a report on Tuesday, August 4th. Finally, Cantor Fitzgerald assumed coverage on Palantir Technologies in a research report on Tuesday, August 4th. They issued an “overweight” rating for the company. One equities research analyst has rated the stock with a Strong Buy rating, twenty-four have issued a Buy rating, nine have given a Hold rating and three have issued a Sell rating to the company. Based on data from MarketBeat, the stock has a consensus rating of “Moderate Buy” and a consensus price target of $198.75.
Read Our Latest Stock Analysis on PLTR
Palantir Technologies Company Profile (Free Report)
Palantir Technologies Inc (NASDAQ: PLTR) develops software platforms that help organizations integrate, analyze and act on large and complex datasets. Its principal platforms include Gotham, which is designed primarily for government and defense applications; Foundry, which supports commercial and institutional data operations; Apollo, which helps deploy and manage software across diverse environments; and the Artificial Intelligence Platform (AIP), which connects large language models and other AI tools with an organization’s data and workflows.
The company serves government agencies, defense and intelligence organizations, and commercial businesses in industries such as manufacturing, healthcare, energy and financial services.
Featured Stories Five stocks we like better than Palantir Technologies Want Private-Market Access to Kalshi and Polymarket? Try This ETF Levi’s Stock Dip Reveals Value Opportunity Despite Q3 Headwinds PepsiCo Stock Looks Poised to Bottom With High Yield, Deep Value Alphabet’s $1.8 Billion Black Hills Deal Powers AI Data Center Push
Receive News & Ratings for Palantir Technologies Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Palantir Technologies and related companies with MarketBeat.com's FREE daily email newsletter.
Artemis Investment Management LLP reduced its holdings in shares of Micron Technology, Inc. (NASDAQ:MU – Free Report) by 93.0% in the 3rd quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The fund owned 4,634 shares of the semiconductor manufacturer’s stock after selling 61,439 shares during the quarter. Artemis Investment Management LLP’s holdings in Micron Technology were worth $4,936,000 as of its most recent SEC filing.
A number of other hedge funds have also made changes to their positions in MU. Andar Capital Management HK Ltd boosted its stake in Micron Technology by 856,960.3% during the 2nd quarter. Andar Capital Management HK Ltd now owns 34,282,413 shares of the semiconductor manufacturer’s stock valued at $39,571,847,000 after acquiring an additional 34,278,413 shares during the last quarter. Primecap Management Co. CA bought a new stake in shares of Micron Technology in the 2nd quarter worth about $22,182,263,000. Legal & General Group Plc bought a new stake in shares of Micron Technology in the 2nd quarter worth about $8,402,393,000. Situational Awareness LP raised its stake in shares of Micron Technology by 1,149.0% in the 2nd quarter. Situational Awareness LP now owns 4,828,786 shares of the semiconductor manufacturer’s stock valued at $5,573,819,000 after purchasing an additional 5,289,124 shares in the last quarter. Finally, Canada Pension Plan Investment Board acquired a new stake in shares of Micron Technology in the 2nd quarter valued at about $3,761,237,000. Institutional investors and hedge funds own 80.84% of the company’s stock.
Insider Activity In other news, EVP Sumit Sadana sold 15,000 shares of the company’s stock in a transaction on Tuesday, August 18th. The shares were sold at an average price of $934.29, for a total value of $14,014,350.00. Following the transaction, the executive vice president directly owned 191,021 shares of the company’s stock, valued at approximately $178,469,010.09. This represents a 7.28% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the SEC, which can be accessed through this link. Also, CEO Sanjay Mehrotra sold 40,000 shares of the stock in a transaction on Friday, August 21st. The stock was sold at an average price of $968.90, for a total value of $38,756,000.00. Following the sale, the chief executive officer owned 264,503 shares of the company’s stock, valued at approximately $256,276,956.70. This represents a 13.14% decrease in their ownership of the stock. Additional details regarding this sale are available in the official SEC disclosure. Insiders have sold 95,879 shares of company stock worth $90,939,466 in the last 90 days. Company insiders own 0.24% of the company’s stock.
Micron Technology News Summary Here are the key news stories impacting Micron Technology this week: Positive Sentiment: Strong earnings and forward guidance support the growth outlook. Micron reported fiscal fourth-quarter revenue of $54.23 billion and adjusted earnings of $33.42 per share, both ahead of expectations. Management also projected fiscal first-quarter 2027 adjusted EPS of $37.15-$39.15, implying another sequential increase. Micron’s Latest Earnings Reveal Why the AI Memory Supercycle Could Run for Years Positive Sentiment: AI-related demand remains a major catalyst. More than 75% of Micron’s fiscal 2027 output is reportedly committed, while customers are already discussing 2028 allocations. Record DRAM revenue and surging enterprise SSD demand suggest data-center customers are securing memory supply well in advance. Micron: This Memory Cycle Could End Differently Positive Sentiment: Analyst support remains strong. Zacks upgraded Micron to “Strong Buy,” while D.A. Davidson raised its price target to $3,000 and maintained a Buy rating, citing a potential multiyear shortage driven by AI infrastructure spending. Micron & 2 Profitable Stocks to Buy in October for Big Upside Neutral Sentiment: Valuation and cyclicality remain debated. Bullish analysts view Micron’s roughly six-to-seven-times forward earnings valuation as inexpensive, but skeptics warn that margins may be near a peak and that memory prices could eventually normalize. A $600 million settlement with Netlist also removes a legal overhang but adds a material cost. Micron Technology, Netlist Settle Patent Dispute for $600 Million Negative Sentiment: Investors reacted negatively to weaker-than-expected AI revenue concerns. A report that OpenAI’s annualized revenue was below expectations triggered a broader selloff in AI and semiconductor stocks. Analysts said the figure may reflect reporting differences rather than a deterioration in AI demand, but the news heightened concern about crowded AI valuations. Micron, Nvidia and AI chip stocks fall as report on OpenAI’s revenue causes undue concern Negative Sentiment: A Taiwan labor dispute adds operational risk. Workers at Micron’s major Taiwan manufacturing sites authorized a strike over bonus changes. No walkout has been announced, but a disruption could threaten production and increase costs. Micron’s Taoyuan union in Taiwan secures authorisation to strike Negative Sentiment: Samsung’s record profit did not reassure memory investors. Although Samsung reported sharply higher operating profit, the slower pace of growth and concerns that the memory cycle is nearing a peak reinforced fears that Micron’s exceptional earnings growth may decelerate. The Memory Trade Cools After Samsung’s Preliminary Results Disappoint Micron Technology Stock Performance NASDAQ:MU opened at $1,035.84 on Friday. The firm has a market cap of $1.17 trillion, a price-to-earnings ratio of 13.96, a price-to-earnings-growth ratio of 0.19 and a beta of 2.22. Micron Technology, Inc. has a twelve month low of $179.61 and a twelve month high of $1,255.00. The company has a 50-day moving average of $975.93 and a 200-day moving average of $840.54. The company has a current ratio of 3.31, a quick ratio of 2.94 and a debt-to-equity ratio of 0.03.
Micron Technology (NASDAQ:MU – Get Free Report) last announced its quarterly earnings data on Wednesday, September 30th. The semiconductor manufacturer reported $33.42 EPS for the quarter, beating analysts’ consensus estimates of $31.77 by $1.65. Micron Technology had a return on equity of 92.62% and a net margin of 63.80%.The company had revenue of $54.23 billion during the quarter, compared to the consensus estimate of $51.33 billion. During the same quarter in the prior year, the firm earned $3.03 EPS. The company’s quarterly revenue was up 379.1% compared to the same quarter last year. Micron Technology has set its Q1 2027 guidance at 37.150-39.150 EPS. Analysts forecast that Micron Technology, Inc. will post 175.82 earnings per share for the current fiscal year.
Micron Technology Announces Dividend The firm also recently declared a quarterly dividend, which will be paid on Thursday, October 29th. Investors of record on Wednesday, October 14th will be given a dividend of $0.15 per share. This represents a $0.60 annualized dividend and a yield of 0.1%. The ex-dividend date of this dividend is Wednesday, October 14th. Micron Technology’s payout ratio is presently 0.81%.
Analyst Ratings Changes MU has been the subject of a number of research reports. CLSA reiterated an “outperform” rating and issued a $1,700.00 price target on shares of Micron Technology in a research note on Friday, October 2nd. JPMorgan Chase & Co. increased their target price on Micron Technology from $550.00 to $1,540.00 and gave the stock an “overweight” rating in a report on Thursday, June 25th. Seaport Research Partners reiterated a “buy” rating on shares of Micron Technology in a research report on Friday, August 14th. Needham & Company LLC reiterated a “buy” rating and issued a $1,650.00 price target on shares of Micron Technology in a report on Thursday, October 1st. Finally, Daiwa Securities Group raised their price objective on Micron Technology from $1,600.00 to $1,700.00 and gave the stock a “buy” rating in a research note on Friday, July 17th. One investment analyst has rated the stock with a Strong Buy rating, forty-one have issued a Buy rating and four have assigned a Hold rating to the company’s stock. According to data from MarketBeat, the company currently has an average rating of “Moderate Buy” and an average price target of $1,407.88.
Check Out Our Latest Analysis on MU
Micron Technology Company Profile (Free Report)
Micron Technology, Inc is a semiconductor company that develops and manufactures memory and storage solutions. Its product portfolio includes dynamic random-access memory (DRAM), NAND flash memory, three-dimensional XPoint-related technologies, solid-state drives, and high-bandwidth memory products designed for demanding computing applications.
The company serves customers across the data center, artificial intelligence, networking, automotive, industrial, mobile, consumer electronics, and embedded markets.
Featured Articles Five stocks we like better than Micron Technology Want Private-Market Access to Kalshi and Polymarket? Try This ETF Levi’s Stock Dip Reveals Value Opportunity Despite Q3 Headwinds PepsiCo Stock Looks Poised to Bottom With High Yield, Deep Value Alphabet’s $1.8 Billion Black Hills Deal Powers AI Data Center Push
Receive News & Ratings for Micron Technology Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Micron Technology and related companies with MarketBeat.com's FREE daily email newsletter.
Taiwan Semiconductor Manufacturing Co., Ltd. (TSM) shares up 4,341% since Big Money bought big in 1999.
TSM is the leading contract semiconductor manufacturer in the world, taking other companies’ chip designs and turning them into finished products. The company’s second-quarter fiscal 2026 report showed $40.2 billion in quarterly revenue (a 36% year-over-year gain), a gross margin of 67.7% (an improvement of 150 basis points), and increased revenue full-year guidance to over 40% higher than the prior year.
No wonder TSM shares are up 51% so far this year – and they could rise more. MoneyFlows data shows how Big Money investors are again betting heavily on the stock.
Institutions Love TSMC Institutional volumes reveal plenty. In the last year, TSM has enjoyed strong investor demand, which we believe to be institutional support.
Each green bar signals unusually large volumes in TSM shares. They reflect our proprietary inflow signal, pushing the stock higher:
TSM shares are up 50.4% in a year thanks to flurries of strong institutional buying. Source: www.moneyflows.com Plenty of technology names are under accumulation right now. But there’s a powerful fundamental story happening with TSMC.
TSMC Fundamental Analysis Institutional support and a healthy fundamental backdrop make this company worth investigating. As you can see, TSM has had strong sales and earnings growth:
Also, EPS is estimated to ramp higher this year by +31.8%.
Now it makes sense why the stock has been generating Big Money interest. TSM has a track record of strong financial performance.
Marrying great fundamentals with MoneyFlows software has found some big winning stocks over the long term.
TSMC recently became a top-rated stock at MoneyFlows. That means the stock has unusual buy pressure and growing fundamentals. We have a ranking process that showcases stocks like this on a weekly basis.
The stock has drawn 14 Big Money outlier inflow signals since 1999, rising 4,341% since the first one. The blue bars below show when TSM was an institutional target in the last three years…Big Money keeps buying:
TSM shares have attracted 14 institutional outlier inflow signals since 1999, including recently, rising 4,341% in that time. Source: www.moneyflows.com Tracking unusual volumes reveals the power of money flows.
This is a trait that most outlier stocks exhibit…the best of the best. Big Money demand drives stocks upward.
TSMC Price Prediction The TSM action isn’t new at all. Big Money buying in the shares is signaling to take notice. Given the historical gains in share price and strong fundamentals, this stock could be worth a spot in a diversified portfolio.
Disclosure: the author holds no position in TSM at the time of publication.
If you are a Registered Investment Advisor (RIA) or a serious investor, take your investing to the next level. MoneyFlows created 11 Frontiers indexes to help serious investors capture AI-driven themes and learn the leading stocks in each Frontier. Get started here.
Lucas is a well-versed equity investor and educator. He currently is co-founder of research and analytics firm, MAPsignals.com, which focuses on finding outlier stocks by following the Big Money.
Kombinace přípravků Taltz a Zepbound ve studii TOGETHER-PsO vedla do 36. týdne ke změnám u 482 proteinů a 467 genů, oproti 140 proteinům a 16 genům při léčbě samotným přípravkem Taltz.
Exploratory data presented at Fall Clinical 2026 showed broader biomarker changes with Taltz and Zepbound vs. Taltz alone as early as Week 12 in first-of-its-kind TOGETHER-PsO study
, /PRNewswire/ -- Eli Lilly and Company (NYSE: LLY) today announced new exploratory data from the TOGETHER-PsO Phase 3b clinical trial evaluating the concomitant use of Taltz (ixekizumab) and Zepbound (tirzepatide) compared with Taltz alone in adults with moderate-to-severe plaque psoriasis and obesity or overweight with at least one additional weight-related comorbid condition. The prespecified analysis, presented at the 2026 Fall Clinical Dermatology Conference in Las Vegas, provides new insights suggesting an immunometabolic relationship between psoriasis and obesity. These data showed that when Taltz and Zepbound were used together, changes were observed in more psoriasis disease-associated and metabolic biomarkers compared to Taltz monotherapy. In the U.S., approximately 61% of people with psoriasis also have obesity or overweight with at least one weight-related comorbidity.1
"People living with psoriasis and obesity carry a compounded burden that extends beyond what is visible, yet these conditions are too often viewed through separate treatment lenses," said Mark Genovese, M.D., senior vice president of Lilly Immunology development. "The broader biomarker changes observed with Taltz and Zepbound, including those associated with skin clearance, may point to a meaningful relationship between immune and metabolic biology. Along with previously reported clinical outcomes, these findings support a more comprehensive approach to psoriasis care that also addresses obesity for people managing both conditions."
This analysis examined circulating proteins and gene expression in the blood to better understand the biological change observed when patients were treated concomitantly with Taltz and Zepbound vs. Taltz alone. At Week 36, observed changes in psoriasis-specific, immune and metabolic biomarkers in both the Taltz and Zepbound and Taltz monotherapy treatment arms were consistent with the known biological effects of each medicine when used for their approved indications. Notably, Taltz and Zepbound used together were associated with broader biomarker responses compared to Taltz alone as early as Week 12. This included changes in more proteins (482 vs. 140 differentially expressed proteins) and genes (467 vs. 16 differentially expressed genes) by Week 36.
Further, the analysis showed greater reductions in inflammatory immune activity with Taltz and Zepbound compared with Taltz alone, including changes related to neutrophils, a type of immune cell involved in inflammation. Changes in a subset of neutrophil-associated markers mediated a portion of the additional Psoriasis Area and Severity Index (PASI) response seen with Taltz and Zepbound vs. Taltz alone.
"This analysis provides new insights into the potential connected immune and metabolic biology in people with psoriasis and obesity," said James G. Krueger, M.D., Ph.D., Professor and Laboratory Head, The Rockefeller University. "What is most compelling is these findings identified differences in inflammatory pathways when patients received concomitant treatment with Taltz plus Zepbound for both conditions. These data at the intersection of psoriasis and obesity highlight immunometabolic health as an important area for continued scientific research."
These data follow previously reported results from TOGETHER-PsO, which showed that Taltz and Zepbound used together delivered superior skin clearance and clinically meaningful weight reduction compared with Taltz alone at the Week 36 primary endpoint. Improvements were maintained or further improved through Week 52, with safety consistent with the known profile of each respective medicine.
About the TOGETHER-PsO trial
TOGETHER-PsO (NCT06588283) is a 52-week Phase 3b, randomized, multicenter, assessor-blinded, open-label study assessing the efficacy and safety of concomitant administration of Taltz and Zepbound compared with Taltz alone in adults with moderate-to-severe plaque psoriasis and obesity or overweight (BMI ≥30 kg/m², or ≥27 to <30 kg/m²) with at least one additional weight-related comorbid condition. A total of 274 participants were randomized 1:1 to receive either Taltz alone or concomitantly with Zepbound, both administered subcutaneously. Patients in both arms received counseling on a reduced-calorie diet and increased physical activity. The primary endpoint is to assess the proportion of participants achieving both Psoriasis Area and Severity Index (PASI) 100 and ≥10% weight reduction at Week 36.
About Taltz (ixekizumab)
Taltz is a monoclonal antibody that selectively binds with interleukin 17A (IL-17A) cytokine and inhibits its interaction with the IL-17 receptor. IL-17A is a naturally occurring cytokine that is involved in normal inflammatory and immune responses. Taltz inhibits the release of pro-inflammatory cytokines and chemokines. Taltz is approved to treat adults with active psoriatic arthritis and adults and children 6 years and older with moderate-to-severe plaque psoriasis who are candidates for systemic therapy or phototherapy. Additionally, Taltz is approved for adults with active ankylosing spondylitis, and adults with active non-radiographic axial spondyloarthritis with objective signs of inflammation.
About Zepbound (tirzepatide) injection
Zepbound (tirzepatide) is the first and only dual GIP (glucose-dependent insulinotropic polypeptide) and GLP-1 (glucagon-like peptide-1) receptor agonist obesity medication. Zepbound tackles an underlying cause of excess weight. It reduces appetite and how much you eat. Zepbound is indicated for adults with obesity, or some adults who are overweight and also have at least one weight-related medical problem, to lose weight and keep it off. Additionally, Zepbound is FDA-approved to treat adults with moderate-to-severe obstructive sleep apnea and obesity. Zepbound should be used with a reduced calorie diet and increased physical activity.
TALTZ INDICATIONS AND SAFETY SUMMARY
Taltz® (tȯl-ts) is an injectable medicine used to treat:
People 6 years of age and older with moderate to severe plaque psoriasis who may benefit from taking injections or pills (systemic therapy) or treatment using ultraviolet or UV light (phototherapy). Adults with active psoriatic arthritis. Adults with active ankylosing spondylitis. Adults with active non-radiographic axial spondyloarthritis with objective signs of inflammation. It is not known if Taltz is safe and effective in children for conditions other than plaque psoriasis or in children under 6 years of age.
Warnings - Taltz affects the immune system. It may increase your risk of infections, some people have had serious infections, including tuberculosis (TB), and infections caused by bacteria, fungi, or viruses that can spread throughout the body. Some people have been hospitalized from these infections. Do not use Taltz if you have any symptoms of infection, unless your doctor tells you to. If you have a symptom after starting Taltz, call your doctor right away.
Your doctor should check you for TB before you start Taltz, and watch you closely for signs of TB during and after treatment with Taltz. If you have TB, or had it in the past, your doctor may treat you for it before you start Taltz.
Do not use Taltz if you have had a serious allergic reaction to ixekizumab or any other ingredient in Taltz, such as: swelling of your eyelids, lips, mouth, tongue or throat, trouble breathing, feeling faint, throat or chest tightness, or skin rash. Get emergency help right away if you have any of these reactions. See the Medication Guide that comes with Taltz for a list of ingredients.
Severe skin reactions that look like eczema can happen during treatment with Taltz from days to months after your first dose and can sometimes lead to hospitalization. Your doctor may temporarily stop treatment with Taltz if you develop severe skin reactions. Tell your doctor if you have any of the following: redness or rash, itching, patches, your skin is dry or feels like leather, blisters or abrasions that ooze or become crusty, small bumps or plaques with scale or crusting.
Crohn's disease or ulcerative colitis (inflammatory bowel disease) can start or get worse with Taltz use. Tell your doctor if you have any of these symptoms or if they get worse: stomach pain, diarrhea, and weight loss.
You should not get live vaccines while taking Taltz. You should get the vaccines you need before you start Taltz.
Common side effects
The most common side effects of Taltz include:
Injection site reactions Nausea Upper respiratory infections Fungal skin infections Tell your doctor if you have any side effects. You can report side effects at 1-800-FDA-1088 or www.fda.gov/medwatch.
Before using
Before you use Taltz, review these questions with your doctor:
Are you being treated for an infection? Do you have an infection that does not go away or keeps coming back? Do you have TB or have you been in close contact with someone with TB? Do you have possible symptoms of an infection such as fever, cough, sores, diarrhea, or other symptoms? Ask your doctor about other possible symptoms. Do you have Crohn's disease or ulcerative colitis? Tell your doctor if:
You need any vaccines or have had one recently. You take prescription or over-the-counter medicines, vitamins, or herbal supplements. You are pregnant or planning to become pregnant. It is not known if Taltz can harm an unborn baby. Pregnancy Exposure Registry: There is a pregnancy registry to collect information about women who are exposed to Taltz during pregnancy. The purpose of this registry is to collect information about the health of you and your baby. If you become pregnant while taking Taltz, you are encouraged to enroll in the pregnancy registry by calling 1-800-284-1695 or by visiting online at http://www.pregnancyregistry.lilly.com. You are breastfeeding or planning to breastfeed. It is not known if Taltz passes into breastmilk. How to take
See the instructions for use that come with Taltz. There you will find information about how to store, prepare, and inject Taltz. Adults may self-inject after receiving training from a healthcare provider.
For children 6 to 17 years of age:
If your child's healthcare provider decides that you may give Taltz injections at home, you should receive training on the right way to prepare and inject Taltz. Do not try to give Taltz to your child until you have been shown how to inject Taltz. Children should not inject themselves with Taltz. You or an adult caregiver should prepare and give Taltz injections to your child. Learn more
Taltz is a prescription medicine available as a 80 mg/mL, 40 mg/0.5mL, 20 mg/0.25mL injection. For more information, call 1-800-545-5979 or go to taltz.lilly.com.
This summary provides basic information about Taltz but does not include all information known about this medicine. Read the information that comes with your prescription each time your prescription is filled. This information does not take the place of talking with your doctor. Be sure to talk to your doctor or other healthcare provider about Taltz and how to take it. Your doctor is the best person to help you decide if Taltz is right for you.
IX CON BS 20AUG2024
U.S. ZEPBOUND INDICATIONS AND SAFETY SUMMARY WITH WARNINGS
Zepbound® (ZEHP-bownd) is an injectable prescription medicine used with a reduced-calorie diet and increased physical activity to help adults with:
obesity, or some adults with overweight who also have weight-related medical problems, to lose excess body weight and keep the weight off. moderate-to-severe obstructive sleep apnea (OSA) and obesity to improve their OSA. Zepbound contains tirzepatide and should not be used with other tirzepatide-containing products or any GLP-1 receptor agonist medicines. It is not known if Zepbound is safe and effective for use in children.
Warnings - Zepbound may cause tumors in the thyroid, including thyroid cancer. Watch for possible symptoms, such as a lump or swelling in the neck, hoarseness, trouble swallowing, or shortness of breath. If you have any of these symptoms, tell your healthcare provider.
Do not use Zepbound if you or any of your family have ever had a type of thyroid cancer called medullary thyroid carcinoma (MTC). Do not use Zepbound if you have Multiple Endocrine Neoplasia syndrome type 2 (MEN 2). Do not use Zepbound if you have had a serious allergic reaction to tirzepatide or any of the ingredients in Zepbound. KwikPen®: Do not share your KwikPen with other people, even if the pen needle has been changed. You may give other people a serious infection or get a serious infection from them.
Zepbound may cause serious side effects, including:
Severe stomach problems. Stomach problems, sometimes severe, have been reported in people who use Zepbound. Tell your healthcare provider if you have stomach problems that are severe or will not go away.
Dehydration leading to kidney problems. Diarrhea, nausea, and vomiting may cause a loss of fluids (dehydration), which may cause kidney problems. It is important for you to drink fluids to help reduce your chance of dehydration. Tell your healthcare provider right away if you have nausea, vomiting, or diarrhea that does not go away.
Gallbladder problems. Gallbladder problems have happened in some people who use Zepbound. Tell your healthcare provider right away if you get symptoms of gallbladder problems, which may include pain in your upper stomach (abdomen), fever, yellowing of skin or eyes (jaundice), or clay-colored stools.
Inflammation of the pancreas (pancreatitis). Stop using Zepbound and call your healthcare provider right away if you have severe pain in your stomach area (abdomen) that will not go away, with or without nausea or vomiting. You may feel the pain from your abdomen to your back.
Serious allergic reactions. Stop using Zepbound and get medical help right away if you have any symptoms of a serious allergic reaction, including swelling of your face, lips, tongue or throat, problems breathing or swallowing, severe rash or itching, fainting or feeling dizzy, or very rapid heartbeat.
Low blood sugar (hypoglycemia). Your risk for getting low blood sugar may be higher if you use Zepbound with medicines that can cause low blood sugar, such as a sulfonylurea or insulin.
Signs and symptoms of low blood sugar may include dizziness or light-headedness, sweating, confusion or drowsiness, headache, blurred vision, slurred speech, shakiness, fast heartbeat, anxiety, irritability, mood changes, hunger, weakness or feeling jittery.
Changes in vision in patients with type 2 diabetes. Tell your healthcare provider if you have changes in vision during treatment with Zepbound.
Food or liquid getting into the lungs during surgery or other procedures that use anesthesia or deep sleepiness (deep sedation). Zepbound may increase the chance of food getting into your lungs during surgery or other procedures. Tell all your healthcare providers that you are taking Zepbound before you are scheduled to have surgery or other procedures.
Common side effects
The most common side effects of Zepbound include nausea, diarrhea, vomiting, constipation, stomach (abdominal) pain, indigestion, injection site reactions, feeling tired, allergic reactions, belching, hair loss, and heartburn. These are not all the possible side effects of Zepbound. Talk to your healthcare provider about any side effect that bothers you or doesn't go away.
Tell your doctor if you have any side effects. You can report side effects at 1-800-FDA-1088 or www.fda.gov/medwatch.
Before using Zepbound
Your healthcare provider should show you how to use Zepbound before you use it for the first time. Talk to your healthcare provider about low blood sugar and how to manage it. Tell your healthcare provider if you are taking medicines to treat diabetes including an insulin or sulfonylurea. If you take birth control pills by mouth, talk to your healthcare provider before you use Zepbound. Birth control pills may not work as well while using Zepbound. Your healthcare provider may recommend another type of birth control for 4 weeks after you start Zepbound and for 4 weeks after each increase in your dose of Zepbound. Review these questions with your healthcare provider:
❑ Do you have other medical conditions, including problems with your pancreas, or severe problems with your stomach, such as slowed emptying of your stomach (gastroparesis) or problems digesting food?
❑ Do you take diabetes medicines, such as insulin or sulfonylureas?
❑ Do you have a history of diabetic retinopathy?
❑ Are you scheduled to have surgery or other procedures that use anesthesia or deep sleepiness (deep sedation)?
❑ Do you take any other prescription medicines or over-the-counter drugs, vitamins, or herbal supplements?
❑ Are you pregnant, plan to become pregnant, breastfeeding, or plan to breastfeed? Zepbound may harm your unborn baby. Tell your healthcare provider if you become pregnant while using Zepbound. Zepbound may pass into your breast milk. You should talk with your healthcare provider about the best way to feed your baby while using Zepbound.
Pregnancy Exposure Registry: There is a pregnancy exposure registry for women who have taken Zepbound during pregnancy. The purpose of this registry is to collect information about the health of you and your baby. Talk to your healthcare provider about how you can take part in this registry, or you may call 1-844-524-0039 or email at [email protected] or visit https://pregnancyregistry.lilly.com/zepbound. How to take
Read the Instructions for Use that come with Zepbound. Use Zepbound exactly as your healthcare provider says. Use Zepbound with a reduced-calorie diet and increased physical activity. Inject Zepbound under the skin (subcutaneously) of your stomach (abdomen), thigh, or
have another person inject in the back of the upper arm. Do not inject ZEPBOUND into a muscle (intramuscularly) or vein (intravenously). Use Zepbound 1 time each week, at any time of the day. Change (rotate) your injection site with each weekly injection. Do not use the same site for each injection. If you take too much Zepbound, call your healthcare provider, call the Poison Help line at 1-800-222-1222 or go to the nearest hospital emergency room right away.
Zepbound is approved as a 2.5 mg, 5 mg, 7.5 mg, 10 mg, 12.5 mg, and 15 mg injection.
Learn more
Zepbound is a prescription medicine. For more information, call 1-800-LillyRx (1-800-545-5979) or go to www.zepbound.lilly.com.
This summary provides basic information about Zepbound but does not include all information known about this medicine. Read the information that comes with your prescription each time your prescription is filled. This information does not take the place of talking with your healthcare provider. Be sure to talk to your healthcare provider about Zepbound and how to take it. Your healthcare provider is the best person to help you decide if Zepbound is right for you.
ZP CON BS 01SEP2026
Zepbound®, its delivery device base and KwikPen® are registered trademarks owned or licensed by Eli Lilly and Company, its subsidiaries, or affiliates.
About Lilly
Lilly is a medicine company turning science into healing to make life better for people around the world. We've been pioneering life-changing discoveries for 150 years, and today our medicines help tens of millions of people across the globe. Harnessing the power of biotechnology, chemistry and genetic medicine, our scientists are urgently advancing new discoveries to solve some of the world's most significant health challenges: redefining diabetes care; treating obesity and curtailing its most devastating long-term effects; advancing the fight against Alzheimer's disease; providing solutions to some of the most debilitating immune system disorders; and transforming the most difficult-to-treat cancers into manageable diseases. With each step toward a healthier world, we're motivated by one thing: making life better for millions more people. That includes delivering innovative clinical trials that reflect the diversity of our world and working to ensure our medicines are accessible and affordable. To learn more, visit Lilly.com and Lilly.com/news, or follow us on Facebook, Instagram, and LinkedIn. P-LLY
Trademarks and Trade Names
All trademarks or trade names referred to in this press release are the property of the company, or, to the extent trademarks or trade names belonging to other companies are referenced in this press release, the property of their respective owners. Solely for convenience, the trademarks and trade names in this press release are referred to without the ® and ™ symbols, but such references should not be construed as any indicator that the company or, to the extent applicable, their respective owners will not assert, to the fullest extent under applicable law, the company's or their rights thereto. We do not intend the use or display of other companies' trademarks and trade names to imply a relationship with, or endorsement or sponsorship of us by, any other companies.
Cautionary Statement Regarding Forward-Looking Statements
This press release contains forward-looking statements (as that term is defined in the Private Securities Litigation Reform Act of 1995) about Taltz (ixekizumab) as a treatment for psoriasis and Zepbound (tirzepatide) as a treatment for adults with obesity or overweight, and potential comprehensive treatment strategies for patients with psoriasis and obesity, and reflects Lilly's current beliefs and expectations. However, as with any pharmaceutical product, there are substantial risks and uncertainties in the process of drug research, development and commercialization. Among other things, there is no guarantee that future study results will be consistent with the results to date, or that Lilly will execute its strategies as planned. For further discussion of these and other risks and uncertainties that could cause actual results to differ from Lilly's expectations, see Lilly's Form 10-K and Form 10-Q filings with the United States Securities and Exchange Commission. Except as required by law, Lilly undertakes no duty to update forward-looking statements to reflect events after the date of this release.
References and endnotes
Armstrong et al, Addressing the Obesity-Psoriasis Connection: Prevalence, Incidence, and Comorbidity Insights from a Large US Population of 19.9 Million (2018-2024). Presented at Maui Derm, 2026. SOURCE Eli Lilly and Company
Farther Finance Advisors LLC lifted its position in Dell Technologies Inc. (NYSE:DELL – Free Report) by 32.3% in the 3rd quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The fund owned 32,808 shares of the technology company’s stock after acquiring an additional 8,008 shares during the quarter. Farther Finance Advisors LLC’s holdings in Dell Technologies were worth $17,649,000 at the end of the most recent reporting period.
Several other hedge funds also recently added to or reduced their stakes in DELL. Bank of America Corp DE lifted its stake in Dell Technologies by 7.6% in the first quarter. Bank of America Corp DE now owns 14,394,835 shares of the technology company’s stock worth $2,362,624,000 after purchasing an additional 1,011,101 shares during the last quarter. Wellington Management Group LLP raised its holdings in shares of Dell Technologies by 140.1% in the second quarter. Wellington Management Group LLP now owns 2,526,987 shares of the technology company’s stock worth $1,090,294,000 after buying an additional 1,474,347 shares during the period. NewEdge Advisors LLC boosted its holdings in Dell Technologies by 5.0% during the 2nd quarter. NewEdge Advisors LLC now owns 480,589 shares of the technology company’s stock valued at $207,355,000 after acquiring an additional 22,924 shares during the period. Dimensional Fund Advisors LP grew its position in Dell Technologies by 3.0% in the 1st quarter. Dimensional Fund Advisors LP now owns 961,675 shares of the technology company’s stock valued at $157,869,000 after acquiring an additional 27,668 shares during the last quarter. Finally, Swiss National Bank grew its position in Dell Technologies by 4.7% in the 1st quarter. Swiss National Bank now owns 931,008 shares of the technology company’s stock valued at $152,806,000 after acquiring an additional 41,700 shares during the last quarter. 76.37% of the stock is currently owned by institutional investors.
More Dell Technologies News Here are the key news stories impacting Dell Technologies this week:
Positive Sentiment: Dell received a bullish catalyst from an analyst upgrade: Mizuho raised its price target to $650 from $600 while maintaining an Outperform rating. The revision reflects reported AI-server orders of $60.9 billion, $16.4 billion in AI-server revenue and a $95 billion backlog. Why Dell Stock Is Trading Up Today Positive Sentiment: Dell launched new Windows PCs and workstations designed for “agentic AI” in collaboration with NVIDIA and Microsoft. The products expand Dell’s AI offerings beyond data-center servers and could support demand from developers and creative professionals. Dell Technologies Drives the Agentic AI Era Positive Sentiment: Coverage continues to highlight Dell’s expanding AI customer base, large backlog and recently enhanced AI Data Platform, including NVIDIA-powered acceleration, data orchestration and enterprise knowledge-graph capabilities. These developments reinforce the long-term AI infrastructure growth narrative. Can Dell Turn Its New AI Data Platform Into a Durable Competitive Advantage? Neutral Sentiment: CEO Michael Dell’s involvement in Trump Accounts and a pledge to fund accounts for children has increased the company’s visibility, but the initiative is philanthropic and does not directly change Dell’s operating outlook. Michael Dell Defends Trump Accounts Negative Sentiment: Several Silver Lake-affiliated directors sold a combined roughly 127,000 Dell shares for about $73 million on October 6. Multiple transactions reduced their holdings by approximately 68%–72%, creating a near-term supply and confidence overhang, although one seller retained a substantial position. SEC insider-trading filing Negative Sentiment: After a steep AI-driven rally, profit-taking across server stocks—including Dell and Hewlett Packard Enterprise—has encouraged investors to question whether the sector’s momentum can continue. Dell’s elevated valuation makes it more vulnerable to consolidation despite strong earnings and guidance. Profit Taking Unwinds Server Rally Dell Technologies Stock Performance NYSE DELL opened at $575.17 on Friday. The company has a market cap of $365.70 billion, a PE ratio of 33.38, a P/E/G ratio of 0.60 and a beta of 1.37. The firm’s 50 day moving average price is $504.43 and its 200-day moving average price is $379.92. Dell Technologies Inc. has a 52-week low of $110.22 and a 52-week high of $595.51. Dell Technologies (NYSE:DELL – Get Free Report) last issued its quarterly earnings data on Tuesday, September 1st. The technology company reported $7.04 EPS for the quarter, topping analysts’ consensus estimates of $4.91 by $2.13. The company had revenue of $46.97 billion during the quarter, compared to the consensus estimate of $44.89 billion. Dell Technologies had a net margin of 7.53% and a negative return on equity of 578.85%. Dell Technologies’s revenue for the quarter was up 57.7% compared to the same quarter last year. During the same quarter in the previous year, the firm posted $1.70 earnings per share. Dell Technologies has set its FY 2027 guidance at 25.500-25.500 EPS and its Q3 2027 guidance at 6.500-6.500 EPS. On average, analysts forecast that Dell Technologies Inc. will post 25.13 earnings per share for the current fiscal year.
Dell Technologies Announces Dividend The business also recently disclosed a quarterly dividend, which will be paid on Friday, October 30th. Investors of record on Tuesday, October 20th will be paid a dividend of $0.63 per share. This represents a $2.52 dividend on an annualized basis and a dividend yield of 0.4%. The ex-dividend date is Tuesday, October 20th. Dell Technologies’s dividend payout ratio is 14.63%.
Insider Activity at Dell Technologies In other Dell Technologies news, Director Spv-2 L.P. Sl sold 46,323 shares of the stock in a transaction dated Tuesday, October 6th. The shares were sold at an average price of $575.43, for a total transaction of $26,655,643.89. Following the completion of the sale, the director directly owned 22,254 shares of the company’s stock, valued at approximately $12,805,619.22. This represents a 67.55% decrease in their ownership of the stock. The transaction was disclosed in a filing with the SEC, which can be accessed through this hyperlink. Also, Director Silver Lake Partners V. De (Aiv sold 26,539 shares of Dell Technologies stock in a transaction that occurred on Tuesday, October 6th. The stock was sold at an average price of $575.43, for a total transaction of $15,271,336.77. Following the completion of the transaction, the director directly owned 11,567 shares in the company, valued at approximately $6,655,998.81. The trade was a 69.65% decrease in their position. The SEC filing for this sale provides additional information. Insiders have sold 1,697,272 shares of company stock valued at $920,162,797 over the last 90 days. Company insiders own 41.50% of the company’s stock.
Analyst Upgrades and Downgrades A number of analysts have recently issued reports on the stock. Susquehanna reissued a “positive” rating on shares of Dell Technologies in a research note on Tuesday, September 29th. Barclays lifted their price objective on shares of Dell Technologies from $550.00 to $603.00 and gave the company an “overweight” rating in a report on Wednesday, September 2nd. US Capital Advisors set a $625.00 price objective on shares of Dell Technologies in a research report on Wednesday, September 2nd. Wells Fargo & Company raised their target price on shares of Dell Technologies from $505.00 to $545.00 and gave the stock an “overweight” rating in a research report on Friday, August 14th. Finally, Melius Research boosted their price target on Dell Technologies from $650.00 to $735.00 and gave the company a “buy” rating in a report on Wednesday, September 2nd. One analyst has rated the stock with a Strong Buy rating, twenty-seven have assigned a Buy rating and eight have issued a Hold rating to the stock. According to data from MarketBeat.com, Dell Technologies currently has a consensus rating of “Moderate Buy” and a consensus price target of $571.12.
Check Out Our Latest Research Report on DELL
(Free Report)
Dell Technologies Inc (NYSE: DELL) is a global technology company that develops, sells and supports information technology hardware, software and services. Its offerings include personal computers, workstations, monitors, accessories and other client devices, as well as enterprise infrastructure products such as servers, storage systems, networking equipment and data protection solutions.
The company also provides technology consulting, support, managed services and infrastructure solutions designed to help organizations operate data centers, private and hybrid clouds, artificial intelligence workloads and digital workplaces.
See Also Five stocks we like better than Dell Technologies Want Private-Market Access to Kalshi and Polymarket? Try This ETF Levi’s Stock Dip Reveals Value Opportunity Despite Q3 Headwinds PepsiCo Stock Looks Poised to Bottom With High Yield, Deep Value Alphabet’s $1.8 Billion Black Hills Deal Powers AI Data Center Push Want to see what other hedge funds are holding DELL? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Dell Technologies Inc. (NYSE:DELL – Free Report).
Receive News & Ratings for Dell Technologies Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Dell Technologies and related companies with MarketBeat.com's FREE daily email newsletter.
GAMMA Investing ve třetím čtvrtletí zvýšila svůj podíl v Dell Technologies o 7,8 % nákupem 925 akcií na celkových 12 846 akcií v hodnotě 6,911 milionu USD.
GAMMA Investing LLC grew its holdings in Dell Technologies Inc. (NYSE:DELL – Free Report) by 7.8% in the third quarter, according to its most recent disclosure with the Securities & Exchange Commission. The fund owned 12,846 shares of the technology company’s stock after buying an additional 925 shares during the period. GAMMA Investing LLC’s holdings in Dell Technologies were worth $6,911,000 as of its most recent filing with the Securities & Exchange Commission.
Several other hedge funds and other institutional investors have also recently modified their holdings of the business. Collective Family Office LLC boosted its position in Dell Technologies by 1.5% during the third quarter. Collective Family Office LLC now owns 1,299 shares of the technology company’s stock worth $699,000 after acquiring an additional 19 shares during the last quarter. Cornerstone Financial Management LLC raised its holdings in Dell Technologies by 56.1% in the 2nd quarter. Cornerstone Financial Management LLC now owns 64 shares of the technology company’s stock valued at $28,000 after acquiring an additional 23 shares during the last quarter. Noble Wealth Management PBC raised its holdings in Dell Technologies by 113.6% in the 3rd quarter. Noble Wealth Management PBC now owns 47 shares of the technology company’s stock valued at $25,000 after acquiring an additional 25 shares during the last quarter. Retirement Wealth Solutions LLC lifted its stake in Dell Technologies by 41.3% in the 3rd quarter. Retirement Wealth Solutions LLC now owns 89 shares of the technology company’s stock worth $48,000 after purchasing an additional 26 shares in the last quarter. Finally, Triumph Capital Management boosted its holdings in shares of Dell Technologies by 2.3% during the 2nd quarter. Triumph Capital Management now owns 1,405 shares of the technology company’s stock worth $606,000 after purchasing an additional 32 shares during the last quarter. 76.37% of the stock is owned by hedge funds and other institutional investors.
Dell Technologies Price Performance Shares of NYSE DELL opened at $575.17 on Friday. The company has a market capitalization of $365.70 billion, a P/E ratio of 33.38, a P/E/G ratio of 0.60 and a beta of 1.37. The company has a 50 day simple moving average of $504.43 and a 200-day simple moving average of $379.92. Dell Technologies Inc. has a 1 year low of $110.22 and a 1 year high of $595.51.
Dell Technologies (NYSE:DELL – Get Free Report) last released its quarterly earnings data on Tuesday, September 1st. The technology company reported $7.04 EPS for the quarter, beating analysts’ consensus estimates of $4.91 by $2.13. The firm had revenue of $46.97 billion for the quarter, compared to analysts’ expectations of $44.89 billion. Dell Technologies had a negative return on equity of 578.85% and a net margin of 7.53%.The firm’s quarterly revenue was up 57.7% on a year-over-year basis. During the same period in the prior year, the firm posted $1.70 earnings per share. Dell Technologies has set its FY 2027 guidance at 25.500-25.500 EPS and its Q3 2027 guidance at 6.500-6.500 EPS. As a group, research analysts expect that Dell Technologies Inc. will post 25.13 EPS for the current year. Dell Technologies Dividend Announcement The firm also recently declared a quarterly dividend, which will be paid on Friday, October 30th. Stockholders of record on Tuesday, October 20th will be paid a $0.63 dividend. This represents a $2.52 annualized dividend and a dividend yield of 0.4%. The ex-dividend date of this dividend is Tuesday, October 20th. Dell Technologies’s dividend payout ratio is 14.63%.
Analyst Ratings Changes A number of equities research analysts have recently issued reports on the company. Royal Bank Of Canada began coverage on Dell Technologies in a research report on Thursday, September 10th. They issued an “outperform” rating and a $640.00 price target for the company. Weiss Ratings reissued a “buy (b)” rating on shares of Dell Technologies in a research note on Wednesday, August 12th. Morgan Stanley upped their target price on Dell Technologies from $499.00 to $511.00 and gave the company an “equal weight” rating in a report on Monday, September 21st. Melius Research raised their target price on Dell Technologies from $650.00 to $735.00 and gave the stock a “buy” rating in a research note on Wednesday, September 2nd. Finally, Fox Advisors upgraded Dell Technologies from an “equal weight” rating to an “overweight” rating and set a $625.00 price target on the stock in a report on Wednesday, September 2nd. One investment analyst has rated the stock with a Strong Buy rating, twenty-seven have issued a Buy rating and eight have given a Hold rating to the stock. According to MarketBeat, the stock currently has a consensus rating of “Moderate Buy” and an average price target of $571.12.
Read Our Latest Research Report on DELL
Dell Technologies News Roundup Here are the key news stories impacting Dell Technologies this week:
Positive Sentiment: Dell received a bullish catalyst from an analyst upgrade: Mizuho raised its price target to $650 from $600 while maintaining an Outperform rating. The revision reflects reported AI-server orders of $60.9 billion, $16.4 billion in AI-server revenue and a $95 billion backlog. Why Dell Stock Is Trading Up Today Positive Sentiment: Dell launched new Windows PCs and workstations designed for “agentic AI” in collaboration with NVIDIA and Microsoft. The products expand Dell’s AI offerings beyond data-center servers and could support demand from developers and creative professionals. Dell Technologies Drives the Agentic AI Era Positive Sentiment: Coverage continues to highlight Dell’s expanding AI customer base, large backlog and recently enhanced AI Data Platform, including NVIDIA-powered acceleration, data orchestration and enterprise knowledge-graph capabilities. These developments reinforce the long-term AI infrastructure growth narrative. Can Dell Turn Its New AI Data Platform Into a Durable Competitive Advantage? Neutral Sentiment: CEO Michael Dell’s involvement in Trump Accounts and a pledge to fund accounts for children has increased the company’s visibility, but the initiative is philanthropic and does not directly change Dell’s operating outlook. Michael Dell Defends Trump Accounts Negative Sentiment: Several Silver Lake-affiliated directors sold a combined roughly 127,000 Dell shares for about $73 million on October 6. Multiple transactions reduced their holdings by approximately 68%–72%, creating a near-term supply and confidence overhang, although one seller retained a substantial position. SEC insider-trading filing Negative Sentiment: After a steep AI-driven rally, profit-taking across server stocks—including Dell and Hewlett Packard Enterprise—has encouraged investors to question whether the sector’s momentum can continue. Dell’s elevated valuation makes it more vulnerable to consolidation despite strong earnings and guidance. Profit Taking Unwinds Server Rally Insiders Place Their Bets In other Dell Technologies news, Director Silver Lake Partners Iv, L.P. sold 91,191 shares of the stock in a transaction dated Thursday, September 3rd. The shares were sold at an average price of $517.34, for a total transaction of $47,176,751.94. Following the completion of the transaction, the director owned 64,209 shares of the company’s stock, valued at $33,217,884.06. This trade represents a 58.68% decrease in their ownership of the stock. The sale was disclosed in a filing with the SEC, which is available through the SEC website. Also, Director Spv-2 L.P. Sl sold 83,006 shares of Dell Technologies stock in a transaction dated Thursday, September 3rd. The shares were sold at an average price of $517.34, for a total transaction of $42,942,324.04. Following the sale, the director owned 73,185 shares of the company’s stock, valued at approximately $37,861,527.90. This represents a 53.14% decrease in their ownership of the stock. The disclosure for this sale is available in the SEC filing. Over the last quarter, insiders have sold 1,697,272 shares of company stock valued at $920,162,797. Company insiders own 41.50% of the company’s stock.
(Free Report)
Dell Technologies Inc (NYSE: DELL) is a global technology company that develops, sells and supports information technology hardware, software and services. Its offerings include personal computers, workstations, monitors, accessories and other client devices, as well as enterprise infrastructure products such as servers, storage systems, networking equipment and data protection solutions.
The company also provides technology consulting, support, managed services and infrastructure solutions designed to help organizations operate data centers, private and hybrid clouds, artificial intelligence workloads and digital workplaces.
Featured Articles Five stocks we like better than Dell Technologies Want Private-Market Access to Kalshi and Polymarket? Try This ETF Levi’s Stock Dip Reveals Value Opportunity Despite Q3 Headwinds PepsiCo Stock Looks Poised to Bottom With High Yield, Deep Value Alphabet’s $1.8 Billion Black Hills Deal Powers AI Data Center Push
Receive News & Ratings for Dell Technologies Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Dell Technologies and related companies with MarketBeat.com's FREE daily email newsletter.
By You're currently following this author! Click to unsubscribe from email alerts.
Anna Moneymaker/Getty Images Dell is joining the list of companies paying into the Trump Accounts of its employees' children.
"We plan to provide a one-time $1,000 contribution for eligible children of our team members, in addition to any government seed contribution for which the child qualifies," a Dell company spokesperson told Business Insider.
The company is still working through the logistics and guidance from the US Treasury, the spokesperson added. Employees can apply for and contribute to their children's Trump Accounts and receive the government's one-time contribution in the meantime.
Trump Accounts, launched on July 4, are a new investment program designed to help children grow their wealth. If your baby is born between 2025 and 2028 and is an American citizen, the government will deposit $1,000 into the account.
Companies, including Goldman Sachs, Micron, and Chipotle, have also announced plans to match the government's $1,000 contribution for their employees.
On Wednesday, Michael Dell, the founder of Dell Technologies, told Fox News that he believes donations to Trump Accounts will become "a standard benefit" at many companies.
Dell is closely tied to the Trump Accounts scheme. His family foundation, which he leads with his wife, Susan, has donated $6.25 billion to the program, and he has made regular appearances alongside the president over the last year to promote the investment program.
The Dells' donation is set to land in Trump Accounts this week as a $250 contribution for eligible recipients. To qualify, recipients must be born between 2016 and 2024, and live in a ZIP code with a median family income of $115,000 or less, based on US Census data.
By the end of the week, 25 million accounts will have received the $250 lump sum, Dell told Fox News on Wednesday.
The Dell Foundation has long focused its philanthropic efforts on children, education, and economic opportunity, aligning with the mission of Trump Accounts.
"We did research in our foundation and found that, when a child has even a small amount, they're much more likely to have greater life outcomes," Dell told Fox News.
Being close to the president has also brought Dell's company some free publicity. On several occasions, Trump has told reporters to "go out and buy a Dell computer." In April, following one such endorsement, Dell's shares popped by as much as 9%.
Since the Dell Foundation announced its donation in December, the president has purchased more than $1 million in Dell stock. In April, he sold at least $50,000 worth of Dell shares and possibly as much as $100,000.
Read next
Polly Thompson You're currently following this author! Click to unsubscribe from email alerts.
Nezávisle spravované portfolio Donalda Trumpa v srpnu prodalo akcie Dell v hodnotě až 1,05 mil. USD, přestože Trump dříve veřejně vyzýval Američany k nákupu počítačů Dell.
Donald Trump spent much of 2026 publicly praising Dell, but newly disclosed transactions show investments held in his name were later reduced after the stock’s extraordinary AI-driven rally.
A federal ethics disclosure released Thursday showed one of his independently managed accounts sold between $500,001 and $1 million of Dell Technologies shares on August 21, followed by another $15,001-$50,000 sale on August 28.
The trades came months after Trump repeatedly urged Americans to “go out and buy a Dell computer”.
There is no evidence Trump personally directed either sale. The White House says third-party financial institutions manage his portfolio independently, while the Trump Organization says Trump and his family do not select or approve individual trades.
Trump’s portfolio bought between $1 million and $5 million of Dell shares on February 10. Nine days later, during remarks in Rome, Georgia, he praised Michael and Susan Dell and told the audience to “go out and buy a Dell computer”.
He repeated it at a July 6 White House event linked to Trump Accounts.
However, by August, Dell had become one of 2026’s biggest stock-market winners. The new filing shows the portfolio sold $500,001-$1 million of Dell on August 21 and another $15,001-$50,000 a week later.
That sequence is striking, but it is not evidence of a personally directed trade.
White House spokesperson Davis Ingle told Reuters that “all investment decisions are made entirely by independent managers”.
The relevant contrast is therefore between Trump’s public praise and the activity of outside portfolio managers.
The sales also make more sense against Dell’s share-price move.
Dell closed at $574.55 on Thursday, leaving the stock up about 356% in 2026. That gain reflects a dramatic rerating as AI infrastructure demand transformed expectations for the company’s server business.
Dell’s latest quarter underscored why. The company booked $60.9 billion of AI-server orders, recognised $16.4 billion of AI-server revenue and exited the period with a record $95 billion backlog. Management raised its full-year AI-server revenue forecast to $74 billion.
Yet valuation has become harder to ignore after such a rapid move.
Morgan Stanley analyst Erik Woodring described enterprise hardware spending as “undeniably strong” and said Dell was “clearly out-executing” competitors. Even so, Morgan Stanley kept an Equal Weight rating and a $511 price target.
Also read: Trump bought up to $5M SpaceX debt days before signing new space policy
Mizuho analyst Vijay Rakesh this week raised his Dell target to $650 from $600 and maintained an Outperform rating, arguing that “agentic AI adoption is accelerating”.
The view is that new AI workloads should keep supporting demand for servers and related infrastructure.
TD Cowen is more cautious. Analyst Krish Sankar raised his target to $550 from $500 but kept a Hold rating, highlighting Dell’s $95 billion AI-server backlog while warning that memory constraints could become a risk in 2027.
The broader consensus remains positive, but targets are increasingly clustering around the current share price after this year’s surge.
Sapient Capital LLC acquired a new stake in shares of McKesson Corporation (NYSE:MCK – Free Report) during the third quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission (SEC). The institutional investor acquired 1,076 shares of the company’s stock, valued at approximately $919,000.
Other institutional investors and hedge funds also recently added to or reduced their stakes in the company. CoreCap Advisors LLC grew its position in McKesson by 15.3% in the 3rd quarter. CoreCap Advisors LLC now owns 423 shares of the company’s stock worth $361,000 after purchasing an additional 56 shares during the period. Apella Capital LLC raised its stake in McKesson by 11.1% during the 3rd quarter. Apella Capital LLC now owns 680 shares of the company’s stock valued at $619,000 after buying an additional 68 shares during the last quarter. Everhart Financial Group Inc. lifted its holdings in shares of McKesson by 2.6% during the 3rd quarter. Everhart Financial Group Inc. now owns 2,028 shares of the company’s stock valued at $1,732,000 after buying an additional 52 shares during the period. Avidian Wealth Enterprises LLC lifted its holdings in shares of McKesson by 70.5% during the 3rd quarter. Avidian Wealth Enterprises LLC now owns 747 shares of the company’s stock valued at $638,000 after buying an additional 309 shares during the period. Finally, Valeo Financial Advisors LLC boosted its stake in shares of McKesson by 4.8% in the 3rd quarter. Valeo Financial Advisors LLC now owns 1,216 shares of the company’s stock worth $1,039,000 after buying an additional 56 shares during the last quarter. Hedge funds and other institutional investors own 85.07% of the company’s stock.
Insiders Place Their Bets In other news, Director Bradley E. Lerman sold 301 shares of the company’s stock in a transaction dated Monday, August 10th. The stock was sold at an average price of $892.33, for a total value of $268,591.33. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through the SEC website. Also, CAO Napoleon B. Rutledge, Jr. sold 111 shares of the stock in a transaction dated Tuesday, September 8th. The stock was sold at an average price of $891.45, for a total value of $98,950.95. Following the sale, the chief accounting officer owned 521 shares of the company’s stock, valued at $464,445.45. This represents a 17.56% decrease in their position. The SEC filing for this sale provides additional information. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Corporate insiders own 0.06% of the company’s stock.
McKesson Trading Up 2.2% NYSE MCK opened at $930.64 on Friday. McKesson Corporation has a 12 month low of $723.68 and a 12 month high of $999.00. The stock has a market cap of $108.50 billion, a price-to-earnings ratio of 24.90, a PEG ratio of 1.91 and a beta of 0.30. The company’s 50 day moving average is $883.59 and its two-hundred day moving average is $833.03. McKesson (NYSE:MCK – Get Free Report) last posted its quarterly earnings results on Wednesday, August 5th. The company reported $9.93 earnings per share for the quarter, topping analysts’ consensus estimates of $9.56 by $0.37. The business had revenue of $105.38 billion during the quarter, compared to analyst estimates of $103.88 billion. McKesson had a net margin of 1.12% and a negative return on equity of 253.21%. The company’s revenue was up 7.7% on a year-over-year basis. During the same period in the prior year, the business posted $8.26 earnings per share. McKesson has set its FY 2027 guidance at 44.200-45.000 EPS. Sell-side analysts forecast that McKesson Corporation will post 44.73 EPS for the current year.
McKesson Increases Dividend The company also recently announced a quarterly dividend, which was paid on Thursday, October 1st. Investors of record on Tuesday, September 1st were issued a $0.94 dividend. The ex-dividend date of this dividend was Tuesday, September 1st. This represents a $3.76 annualized dividend and a yield of 0.4%. This is an increase from McKesson’s previous quarterly dividend of $0.82. McKesson’s payout ratio is currently 10.06%.
Analyst Upgrades and Downgrades Several analysts recently commented on MCK shares. Wall Street Zen lowered McKesson from a “buy” rating to a “hold” rating in a report on Saturday, June 27th. Weiss Ratings upgraded McKesson from a “buy (b-)” rating to a “buy (b)” rating in a research note on Friday, September 4th. Citigroup boosted their price target on McKesson from $945.00 to $1,000.00 and gave the company a “buy” rating in a research note on Friday, July 24th. Robert W. Baird set a $1,015.00 price objective on shares of McKesson in a research note on Thursday, August 6th. Finally, Royal Bank Of Canada reissued a “sector perform” rating and issued a $845.00 price objective on shares of McKesson in a report on Monday, September 14th. Fourteen research analysts have rated the stock with a Buy rating and four have given a Hold rating to the company. According to MarketBeat.com, the stock currently has an average rating of “Moderate Buy” and a consensus price target of $973.19.
View Our Latest Report on McKesson
McKesson News Roundup Here are the key news stories impacting McKesson this week:
Positive Sentiment: Option Care acquisition expands McKesson’s healthcare platform. McKesson and Clayton, Dubilier & Rice agreed to acquire Option Care Health in a transaction valued at approximately $5.8 billion. McKesson plans to invest about $1.4 billion for a 49% stake, giving it exposure to the growing home- and outpatient-infusion market. The deal is expected to benefit from the shift of complex treatments away from hospitals, although integration and execution will be important. CD&R and McKesson ink $5.8bn take-private deal for Option Care Health Positive Sentiment: Leerink Partners raised its price target and maintained an outperform rating. The firm increased its target to $1,070 from $1,030, implying roughly 15% upside from the referenced price. The revision adds to the broader analyst support for McKesson, which carries a consensus “Moderate Buy” recommendation. Leerink Partners Adjusts Price Target on McKesson to $1,070 Positive Sentiment: Growth and earnings trends remain favorable. Zacks highlighted McKesson’s above-average financial growth and positive growth-stock characteristics. In its latest reported quarter, revenue rose 7.7% year over year and adjusted earnings exceeded analysts’ expectations, reinforcing confidence in the company’s outlook. Here’s Why McKesson Is a Strong Growth Stock Neutral Sentiment: Analyst recommendations are supportive but may already be reflected in the valuation. Multiple reports point to bullish brokerage views, while comparisons with other medical stocks show McKesson’s strong year-to-date performance. Investors may therefore focus more heavily on whether future earnings and the Option Care transaction justify the stock’s elevated valuation. Is It Worth Investing in McKesson Based on Wall Street’s Bullish Views? Negative Sentiment: The Option Care deal creates capital and execution risks. McKesson’s planned $1.4 billion investment represents a substantial commitment, and the transaction could pressure near-term returns if expected synergies or growth in home infusion take longer to materialize. The stock also remains near its 12-month high, leaving less room for disappointment. McKesson Profile (Free Report)
McKesson Corporation (NYSE:MCK) is a healthcare services and information technology company that distributes pharmaceuticals, specialty drugs, medical supplies and other healthcare products. The company serves pharmacies, hospitals, health systems, physician practices, biopharma manufacturers and other healthcare providers, helping move products from manufacturers to patients and care settings.
McKesson’s principal operations include pharmaceutical distribution, medical-surgical supply distribution and technology-enabled services for pharmacies and providers.
See Also Five stocks we like better than McKesson Want Private-Market Access to Kalshi and Polymarket? Try This ETF Levi’s Stock Dip Reveals Value Opportunity Despite Q3 Headwinds PepsiCo Stock Looks Poised to Bottom With High Yield, Deep Value Alphabet’s $1.8 Billion Black Hills Deal Powers AI Data Center Push Want to see what other hedge funds are holding MCK? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for McKesson Corporation (NYSE:MCK – Free Report).
Receive News & Ratings for McKesson Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for McKesson and related companies with MarketBeat.com's FREE daily email newsletter.
Carlyle Group již aktivně neusiluje o koupi mezinárodních aktiv ruského producenta ropy Lukoil, jejichž hodnota byla původně odhadována na zhruba 22 miliard USD.
Cars queue to refuel at a Lukoil fuel station in Moscow, Russia, August 17, 2026. REUTERS/Anastasia Barashkova/File Photo Purchase Licensing Rights, opens new tab
CompaniesLONDON, Oct 9 (Reuters) - US private equity firm Carlyle Group (CG.O), opens new tab said on Friday it was no longer actively pursuing a deal to acquire international assets of Russia's second-largest oil producer Lukoil (LKOH.MM), opens new tab, a spokesman for the firm said.
The group did not comment further.
Sign up here.
The assets were put up for sale last year following sanctions imposed by the United States over Russia's war in Ukraine. Another Russian oil major, Rosneft (ROSN.MM), opens new tab, was also sanctioned, but it has not announced any divestments.
Carlyle had initially agreed on January 29 to buy Lukoil's assets, excluding those in Kazakhstan. The fund was in talks to partner with Abu Dhabi-based funds Mubadala, XRG and IHC, as well as the US Development Finance Corporation for the deal, according to people familiar with the matter.
The Lukoil portfolio, initially valued at around $22 billion, had attracted interest from at least a dozen companies including Exxon Mobil (XOM.N), opens new tab and the former owner of Pornhub, Bernd Bergmair.
The Financial Times reported last month that US billionaire businessman Todd Boehly secured the backing of the US government and Gulf power brokers with ties to Donald Trump's family to bid for Lukoil's international assets.
Reporting by Shadia Nasralla; writing by Vladimir Soldatkin;Editing by Elaine Hardcastle
Our Standards: The Thomson Reuters Trust Principles., opens new tab
Apple kvůli vyšším nákladům na paměťové čipy a slabší poptávce snížil říjnové objednávky komponentů pro iPhone 18 oproti původnímu plánu minimálně o 15 %.
Apple (NASDAQ: AAPL) stock fell nearly 2% in pre-market trading on Friday, October 9, following a report that the company reduced production of components for its newly launched iPhone 18 models.
Namely, rising memory chip costs and higher retail prices appear to have weighed on consumer demand, which has led to Apple adopting a more cautious approach to shipments last month, as reported by Nikkei Asia.
As a result, the company cut October component orders by at least 15% compared with its original requests. However, as of press time, Apple is yet to make an official statement.
At the time of writing, AAPL shares were sitting at $333.8 in pre-market.
Apple stock price one-day chart. Source: Google Finance Is low consumer demand putting pressure on Apple stock? According to the reports, the production adjustments come as Apple competes for advanced semiconductors and memory chips to power artificial intelligence (AI) data centers. The highly competitive market has, however, contributed to supply shortages and higher prices, putting pressure on the personal computer and smartphone markets.
Indeed, Apple has already raised prices for some iPad and MacBook models in June, acknowledging that it could no longer fully absorb the rising costs of memory and storage components driven by investment in AI infrastructure.
In addition, consumer demand for devices has reportedly weakened from late August through October. However, Nikkei noted that Apple’s changes to the iPhone launch schedule could also be contributing to the issue, which makes it difficult to attribute the slowdown to pricing alone.
Be that as it may, rising memory costs are becoming an increasingly important factor for Apple as it incorporates more AI-powered features into its devices. After all, such features require greater computing and memory resources, which increases reliance on high-performance chips.
Ultimately, the iPhone order cut reports further highlight a growing challenge for the technology industry, as the major players attempt to balance rising component costs and increasingly expensive devices against consumer demand.
Featured image via Shutterstock
Best Crypto Exchange for Intermediate Traders and Investors
Invest in cryptocurrencies and 3,000+ other assets including stocks and precious metals.
0% commission on stocks - buy in bulk or just a fraction from as little as $10. Other fees apply. For more information, visit etoro.com/trading/fees.
Copy top-performing traders in real time, automatically.
eToro USA is registered with FINRA for securities trading.
30+ million Users worldwide
Securities trading offered by eToro USA Securities, Inc. (“the BD”), member of FINRA and SIPC. Cryptocurrency offered by eToro USA LLC (“the MSB”) (NMLS: 1769299) and is not FDIC or SIPC insured. Investing involves risk, and content is provided for educational purposes only, does not imply a recommendation, and is not a guarantee of future performance. Finbold.com is not an affiliate and may be compensated if you access certain products or services offered by the MSB and/or the BD
Join Finbold's newsroom, become a Sales Executive today! Apply now to join Finbold as a crypto/finance news writer!
As I write, Coca-Cola (KO +2.27%) stock would need to climb about 14% from roughly $88 to hit $100 a share. The shares have already risen about 26% this year, and they closed at a record of almost $92 in late August.
With the end of 2027 about 15 months away, the climb works out to about 11% a year in price alone. A dividend yielding about 2.4% at the stock's current price comes on top of that.
For a company whose organic revenue (sales growth excluding currency moves, acquisitions, and divestitures) rose 5% last year, 11% a year is arguably a fast pace. But I think the stock can get there, if earnings keep growing at their recent rate.
Image source: The Motley Fool.
Where did this year's rise come from?Mainly from a higher valuation. Coca-Cola stock closed 2025 around $70. Against its 2025 non-GAAP (adjusted) earnings per share of $3.00, that was about 23 times earnings. Now, the stock trades at about 27 times adjusted earnings, using the $3.23 per share over its past four quarters.
In other words, adjusted earnings per share grew around 8% while the stock gained 26%. Most of the run-up comes from a higher price on every dollar of Coca-Cola's earnings, and I wouldn't count on another year like that.
So earnings have to carry most of the climb to $100. Management expects 2026 adjusted earnings per share of around $3.27 to $3.30, up 9% to 10%. But currency accounts for around 3 points of it. Leaving out currency and the effect of acquisitions and divestitures, the company expects growth of 7% to 8%.
If adjusted earnings per share rises around 7.5% again in 2027, it'd be near $3.53. If shares still fetch 27 times adjusted earnings then, that points to a stock price of around $96 by the end of 2027. Hitting $100 would take about 28 times adjusted earnings -- or a year of faster growth.
Coca-Cola is selling more drinksShowing how the mix of its growth has changed, Coca-Cola's unit case volume (the amount of its drinks sold in its system) dropped 1% from the year before in the second quarter of 2025. Since then, volume growth has sped up, to 1% in both the third and fourth quarters of 2025, then 3% to start 2026 and 5% in the latest quarter.
Price/mix (the combined impact of price moves and shifts in what drinks and packages sell, and where) went the other way. It slowed from 6% growth in mid-2025 to 2% in this year's second quarter. And organic revenue still rose 6% in the quarter.
I think volume-led growth is the healthier kind, since it doesn't rely on consumers absorbing ever-higher prices.
"[W]e said that this would be a year that if we did everything right, we would see volume and price/mix more in tandem," CEO Henrique Braun said on Coca-Cola's second-quarter earnings call. "And that's exactly what we're seeing."
Granted, management also credited the FIFA World Cup, favorable weather in some markets, and an easy comparison, leaving two-year average volume growth at 2%. But profitability rose, too. Coca-Cola's adjusted operating margin widened to 35.6% from 34.7% a year before.
Premium Feature
Moneyball Superscore
76/100
Today's Change
(
2.27
%) $
1.95
Current Price
$
87.77
What does Oct. 27 have to show?Coca-Cola releases third-quarter results before the opening bell on Tuesday, Oct. 27. Its full-year outlook points to adjusted earnings per share of about $1.44 to $1.47 for the second half, up only about 3% to 5%, partly because the fourth quarter has six fewer days than last year.
Volume is the figure I'd track most closely. Against 1% growth in the year-ago quarter, volume growth of roughly 3% would hold the two-year pace near 2%.
Price/mix counts, too. PepsiCo cut its 2026 outlook for adjusted, currency-neutral earnings-per-share growth to 1% to 2% on Thursday, and said it's lining up more cost cuts partly to offset rising input cost inflation. Coca-Cola noted higher input costs in its second quarter as well, so price/mix staying around 2% could show it can still price through them.
Will Coca-Cola stock clear $100 before 2028? I think so. If volume keeps rising near its two-year pace and pricing holds, earnings growth around 8% a year could carry the stock to the mid-$90s. And a stock that already reached $92 in August needs just a slightly higher valuation on top of that.
But this is a prediction about earnings growth more than a bargain price. At around 25 times projected 2027 earnings, shares already assume steady growth, and one or two quarters of slower volume could easily push $100 to 2028.
SummaryPayPal’s branded checkout grew just 2%, but broader branded experiences reached 6% and debit spending increased over 60%.Venmo TPV rose 14%, while customers combining Debit and Pay with Venmo generate over 9x more revenue per account.PayPal holds $39.7 billion in customer balances, creating opportunities to deepen monetization through spending, credit, and financial services.At 10.1x FY1 earnings, my $67 fair value implies roughly 22% upside without requiring a return to historical growth. mihailomilovanovic/E+ via Getty Images
My outlook towards PayPal (PYPL) has been bullish but not simply because of the stock's low valuation. The stock has low P/E multiples and $6 billion in expected free cash flow from operations this year
2.42K Followers
Analyst’s Disclosure: I/we have no stock, option or similar derivative position in any of the companies mentioned, and no plans to initiate any such positions within the next 72 hours. I wrote this article myself, and it expresses my own opinions. I am not receiving compensation for it (other than from Seeking Alpha). I have no business relationship with any company whose stock is mentioned in this article.
Seeking Alpha's Disclosure: Past performance is no guarantee of future results. No recommendation or advice is being given as to whether any investment is suitable for a particular investor. Any views or opinions expressed above may not reflect those of Seeking Alpha as a whole. Seeking Alpha is not a licensed securities dealer, broker or US investment adviser or investment bank. Our analysts are third party authors that include both professional investors and individual investors who may not be licensed or certified by any institute or regulatory body.
Innovative Industrial Properties nacenila emisi 2 milionů akcií kumulativních prioritních akcií řady B s dividendou 9,25 % za cenu 25 USD za akcii, čímž získá hrubý výnos 50 milionů USD.
Innovative Industrial Properties Prices Public Offering of 9.25% Series B Cumulative Redeemable Preferred Stock Innovative Industrial Properties, Inc. (the “Company”) (NYSE: IIPR) announced today the pricing of an underwritten public offering of 2,000,000 shares of its 9.25% Series B Cumulative Redeemable Preferred Stock, par value $0.001 per share (the “Series B Preferred Stock”), at a price of $25.00 per share, for gross proceeds of $50,000,000. The Company granted the underwriters of the offering a 30-day option to purchase up to an additional 300,000 shares of the Company’s Series B Preferred Stock at the public offering price to cover overallotments, if any. The Company plans to file an application to list the Series B Preferred Stock on the New York Stock Exchange under the symbol “IIPR Pr B.” Shares of the Company’s common stock also trade on the New York Stock Exchange under the symbol “IIPR.” The offering is expected to close on October 19, 2026, subject to customary closing conditions.
Stifel is acting as active bookrunner for the offering. A.G.P./Alliance Global Partners, Huntington Capital Markets and Oppenheimer & Co. are acting as passive bookrunners for the offering, and Academy Securities, Clear Street, Compass Point, Roberts & Ryan, Roth Capital Partners and Wolfe Capital Markets and Advisory are acting as co-managers for the offering.
The Company intends to use the net proceeds from the offering to fund all or a portion of its remaining unfunded commitment under its previously announced mezzanine loan investment in the life science industry and to use any remaining net proceeds to fund investments consistent with its investment strategy and for general corporate purposes.
This offering is being made only by means of a written prospectus. A copy of the final prospectus related to the offering may be obtained from Stifel, Nicolaus & Company, Incorporated, Attention: Syndicate Department, 1201 Wills Street, Suite 600, Baltimore, MD 21231, or by email at [email protected].
The offering is being made pursuant to an effective automatic shelf registration statement on Form S-3 previously filed with the SEC on February 21, 2025. This press release shall not constitute an offer to sell or the solicitation of an offer to buy these securities, nor shall there be any sale of these securities in any state or jurisdiction in which such offer, solicitation or sale would be unlawful prior to registration or qualification under the securities laws of such state or jurisdiction.
About Innovative Industrial Properties
Innovative Industrial Properties, Inc. is an internally managed real estate investment trust (REIT) focused on the acquisition, ownership and management of specialized properties leased to experienced, state-licensed operators for their regulated cannabis facilities and financial investments in the life science industry.
This press release contains statements that are “forward-looking statements” within the meaning of the safe harbor provisions of the Private Securities Litigation Reform Act of 1995 and Section 21E of the Securities Exchange Act of 1934. All statements other than historical facts, including, without limitation, statements regarding the closing of the offering, the terms of the Series B Preferred Stock, and the use of proceeds from the offering, are forward-looking statements. When used in this press release, words such as the Company “believes,” “expects,” “may,” “will,” “should,” “seeks,” “approximately,” “intends,” “plans,” “estimates” or “anticipates” or the negative thereof or similar terminology are generally intended to identify forward-looking statements. Such forward-looking statements are subject to risks and uncertainties that could cause actual results to differ materially from those expressed in, or implied by, such statements. Investors should not place undue reliance upon forward-looking statements. The Company disclaims any obligation to update or revise any forward-looking statements, whether as a result of new information, future events or otherwise.
View source version on businesswire.com: https://www.businesswire.com/news/home/20261008729556/en/
Disclosures I/we have no positions in any stocks mentioned, and have no plans to buy any new positions in the stocks mentioned within the next 72 hours.
Tom Watson z Palantir varoval, že zadávání veřejných zakázek nemá podléhat „davovému rozhodování“, zatímco firma čelí tlaku kvůli smlouvě s NHS v hodnotě £330 mil.
Tom Watson, the former Labour deputy leader who recently joined Palantir, has warned against “mob rule” when it comes to awarding public contracts.
Lord Watson, now a senior vice-president at the US tech corporation, said UK ministers could get themselves “in a lot of trouble” as he was questioned about concerns raised about the government working with his new employer.
Palantir was co-founded by the Trump-supporting billionaire Peter Thiel and has provided AI-powered software to the Israeli military and the White House’s ICE immigration crackdown, leading to a public and political backlash against its deepening involvement in British public services.
The prime minister, Andy Burnham, is under significant pressure from Labour MPs and unions to ditch Palantir from government contracts, including a £330m software deal with the NHS.
The company is also fighting Sadiq Khan in court over the London mayor’s block on a £50m contract to use its AI in Metropolitan police investigations. It is seeking to win more public sector work in the UK, where it already has an annual turnover of £427m.
Watson told the BBC podcast Political Thinking with Nick Robinson: “One of the things I’d say to my former colleagues is: do you want to let the rule of law to lead procurement practice, or do you want to let mob rule to lead procurement practices? Because you get yourself in a lot of trouble if you go down on the latter one.”
He added: “I think we are very targeted by the people that are targeting Israeli companies. We’re not an Israeli company, but because of our work in Israel, we found ourselves in the middle of the row of the Gaza protests.”
Watson told the podcast he would work with a Reform UK government on immigration crackdowns if the situation arose, saying: “We don’t actually work in that sector, but yes, of course we would.”
He called Palantir “the most interesting company on the planet” as he announced his new role last month. The company said his job would be, in part, to “deepen the social and economic value its work creates through better British public services, jobs and skills”.
Watson was a defence minister and a minister for digital engagement in Gordon Brown’s government. Since stepping down from parliament in 2019, he has been an adviser to the gambling and music industries and, since 2024, he has been a part-time adviser to Palantir.
Palantir said Watson had taken a leave of absence from the House of Lords and had relinquished his parliamentary pass while he worked for the company in London.
The Labour MP Chi Onwurah, who chairs the science, innovation and technology committee, which has raised concerns about Palantir, told BBC Radio 4’s Today programme: “Tom is not the first politician to be blinded by tech hype. The key issue is we can’t be so dependent on one company. It’s a US company, subject to US legislation regarding access to our data.”
Paramount Pictures vyvíjí ve spolupráci s producentem Lorenzem di Bonaventurou hraný film podle hry Cyberpunk 2077; akcie společnosti CD Projekt RED v pátečním ranním obchodování vzrostly o 3 %.
Attendees wait in line at the Cyberpunk 2077 booth during the opening day of E3, the annual video games expo revealing the latest in gaming software and hardware in Los Angeles, California,... Purchase Licensing Rights, opens new tab Read more
Oct 9 (Reuters) - Paramount Pictures is developing a live-action film set in the universe of CD Projekt RED's (CDR.WA), opens new tab video game "Cyberpunk 2077" alongside producer Lorenzo di Bonaventura, entertainment outlet Deadline reported on Thursday, which sent the Polish game developer's shares 3% higher in early Friday trading.
"We're excited about Paramount as a future partner who shares our creative ambitions for the Cyberpunk franchise," Michal Nowakowski, joint-CEO of CD Projekt RED, said in a post on social media platform X late on Thursday. "We look forward to sharing more details at the appropriate time."
Sign up here.
CD Projekt RED told Reuters it had nothing to add beyond Nowakowski's post
Paramount did not immediately respond to a Reuters request for comment
Cyberpunk 2077 had sold 40 million copies as of July 3, with its "Phantom Liberty" expansion selling 15 million
As of July 31, CD Projekt RED had 184 developers working on a sequel to the 2020 title, with no launch date announced yet
Paramount's involvement should help sustain interest ahead of the next Cyberpunk instalment, Erste analyst Krzysztof Tkocz said
Reporting by Rafal Nowak and Marta Maciag in Gdansk, editing by Milla Nissi-Prussak
Our Standards: The Thomson Reuters Trust Principles., opens new tab
Investoři společnosti Duolingo, kteří nakoupili akcie třídy A v období od 2. května 2025 do 26. února 2026, podali hromadnou žalobu kvůli údajným zavádějícím informacím.
Duolingo, Inc. Notice of December 7, 2026 Application Deadline for Class Action Lawsuit - Contact Lewis Kahn, Esq. at Kahn Swick & Foti, LLC, Before Application Deadline Kahn Swick & Foti, LLC (“KSF”) and KSF partner, former Attorney General of Louisiana, Charles C. Foti, Jr., notifies investors in Duolingo, Inc. (NasdaqGS: DUOL) of a class action securities lawsuit.
CLASS DEFINITION: The lawsuit seeks to recover losses on behalf of investors who purchased Duolingo, Inc. Class A common stock between May 2, 2025 and February 26, 2026, inclusive (the “Class Period”). This action is pending in the United States District Court for the Western District of Pennsylvania.
Follow the link below to get more information and be contacted by a member of our team:
https://www.ksfcounsel.com/cases/nasdaqgs-duol/
Duolingo investors should contact KSF Managing Partner Lewis Kahn toll-free at 1-833-538-3615 or via email ([email protected]), or visit https://www.ksfcounsel.com/cases/nasdaqgs-duol/ to learn more.
>>>CLICK HERE for more information
CASE DETAILS: According to the Complaint, throughout the Class Period, Defendants made materially false and/or misleading statements, as well as failed to disclose material adverse facts about the Company’s business, operations, and prospects.
Specifically, the lawsuit alleges that Defendants failed to disclose to investors that: (i) Duolingo was deliberately adding friction to the user experience, through sharply increased ad volume, upselling of subscription tiers, and declining product quality, which Defendants knew would drive users away from the app and ultimately slow Daily Active User (“DAU”) growth; (ii) Duolingo’s extensive A/B testing showed Defendants that added friction in the free user experience was hurting DAU growth; (iii) Duolingo’s rapidly produced AI content was degrading its product offerings, harming the user experience and user trends, and putting the sustainability of Duolingo’s financial performance at risk; and (iv) rather than fueling sustained growth and strong user momentum through content and “product improvements” that “get improved retention,” Duolingo’s monetization push and lower-quality AI content were, as its ongoing A/B testing revealed, eroding both the product experience and the value of its subscription tiers.
The case is City of Dearborn Heights Act 345 Police & Fire Retirement System v. Duolingo, Inc., No. 26-cv-02199.
WHAT TO DO? If you invested in Duolingo and suffered a loss during the relevant time frame, you have until December 7, 2026 to request that the Court appoint you as lead plaintiff; however, your ability to share in any recovery does not require that you serve as a lead plaintiff.
>>>To Learn More, Click HERE
About Kahn Swick & Foti, LLC
KSF, whose partners include former Louisiana Attorney General Charles C. Foti, Jr., is one of the nation's premier boutique securities litigation law firms. This past year, KSF was ranked by SCAS among the top 10 firms nationally based upon total settlement value. KSF serves a variety of clients, including public and private institutional investors, and retail investors - in seeking recoveries for investment losses emanating from corporate fraud or malfeasance by publicly traded companies. KSF has offices in New York, Delaware, California, Louisiana, Chicago, and a representative office in Luxembourg.
TOP 10 Plaintiff Law Firms - According to ISS Securities Class Action Services
To learn more about KSF, you may visit www.ksfcounsel.com.
>>>For More Information about the case, Click HERE
View source version on businesswire.com: https://www.businesswire.com/news/home/20261008679615/en/
Disclosures I/we have no positions in any stocks mentioned, and have no plans to buy any new positions in the stocks mentioned within the next 72 hours.
Společnost nCino uzavřela partnerství s Parlay, aby zjednodušila úvěry SBA pro 1 400 amerických věřitelů; integrace již v roce 2026 zpracovala žádosti v hodnotě více než 500 mil. USD.
The partnership joins Parlay's intelligent front-end experience for SBA loans with the nCino’s Commercial and Small Business Solutions, giving every SBA lender in the country one connected, AI-native path from inquiry to originated loan.
ALEXANDRIA, Va. & WILMINGTON, N.C.--(BUSINESS WIRE)--Parlay, the AI-native Loan Intelligence System (LIS) and nCino (NASDAQ: NCNO), the platform for agentic AI banking, today announced a partnership to streamline intake for America's 1,400 Small Business Administration (SBA) lenders. Parlay now connects directly into nCino's Commercial and Small Business Solutions, replacing the manual paperwork that has slowed SBA lending for decades.
Parlay's AI-native intake now connects to nCino, giving America's 1,400 SBA lenders one path from inquiry to originated loan.
Share Parlay’s integration with nCino is live and has already processed more than $500 million in SBA loan inquiries in 2026 for customers including First Internet Bank (NASDAQ:INBK), a nationwide SBA lender known for helping entrepreneurs access capital to grow their businesses. Parlay's agentic technology connects to nCino through a one-click handoff that handles intake, eligibility, and deal structuring before a banker ever opens the file. Lenders using Parlay can screen deals faster and close loans in less time. Existing customers of Parlay have noted the manual work needed to reach a credit-ready file dropped by up to 80%.
With the partnership, nCino and Parlay are closing a long-standing capital access gap for lenders on every Main Street in America. Small businesses generate 43% of U.S. GDP, and too many still don't fit a bank's standard credit box. Community banks and credit unions can now launch and scale SBA programs without building a back office first. High-volume SBA lenders now free up specialist hours for credit judgment instead of paperwork, putting capital in the hands of businesses that earn it but don't fit the mold.
"Hundreds of financial institutions nationwide have told us they want to scale their SBA lending programs. Partnering with nCino enables Parlay to provide a powerful, complementary, and integrated offering: no rip and replace required, so more small businesses across the country gain faster access to capital." — Alex McLeod, Parlay Co-Founder and CEO
"Lenders already trust nCino's intelligent experience to run SBA lending with confidence. Now, paired with Parlay, they get even more: agentic capabilities that help them move eligible borrowers to approval faster and fund more small businesses." — Chris Gufford, nCino Chief Product Officer
Under the agreement, nCino will resell and support Parlay's LIS as an offering for customers prioritizing SBA, and Parlay will continue to serve the broader SBA lending market directly. nCino is offering the integration along with in-branch SBA lending capabilities to its new and existing customer base.
About Parlay Parlay built the AI-native Loan Intelligence System (LIS) category to transform SBA and small business lending. Its agentic workflows streamline intake, eligibility, and structuring before underwriting, helping banks, credit unions, and CDFIs close more deals with less manual work. Learn more at www.parlay.finance.
About nCino nCino (NASDAQ: NCNO) is the platform for agentic AI banking. With over 2,700 customers worldwide - including community banks, credit unions, independent mortgage banks, and the largest financial entities globally - nCino offers a trusted, agentic platform purpose-built for financial services and regulated industries. By deploying AI agents alongside human teams, nCino’s dual workforce enables institutions to eliminate inefficiencies, sharpen decision-making and deliver better outcomes for the customers they serve. For more information, visit www.ncino.com.
Proti společnosti Doximity (DOCS) byla podána hromadná žaloba kvůli tvrzením, že nadhodnocovala přínos služby Newsfeed k růstu tržeb a ztrácela podíl na trhu.
Bragar Eagel & Squire, P.C. Litigation Partner Brandon Walker Encourages Investors Who Suffered Losses In Doximity (DOCS) To Contact Him Directly To Discuss Their Options
If you purchased or acquired Doximity common stock between August 8, 2024, and May 13, 2026 and would like to discuss your legal rights, contact Bragar Eagel & Squire partners Brandon Walker or Melissa Fortunato by email at [email protected] or by telephone at (212) 355-4648.
Click here to participate in the action.
NEW YORK, Oct. 08, 2026 (GLOBE NEWSWIRE) --
What’s Happening:
Bragar Eagel & Squire, P.C., a nationally recognized stockholder rights law firm, announces that a class action lawsuit has been filed against Doximity, Inc. (“Doximity” or the “Company”) (NYSE:DOCS) in the United States District Court for the Northern District of California on behalf of all persons and entities who purchased or otherwise acquired Doximity common stock between August 8, 2024, and May 13, 2026, both dates inclusive (the “Class Period”). Investors have until November 16, 2026 to apply to the Court to be appointed as lead plaintiff in the lawsuit. Allegation Details:
The complaint alleges that during the Class Period defendants claimed the Company's Newsfeed was its "biggest revenue driver." Specifically, defendants claimed that the Company’s growth was “led by our Newsfeed, which is both our most used and most monetized product” and told investors that the Newsfeed was consistently “reach[ing] new highs,” with “an all-time record of quarterly active prescribers and double-digit growth in the number of articles read or tapped.” In addition, Doximity touted its “deep engagement,” assuring investors that Doximity does not “bombard physicians with ads and messages in hopes of getting lucky” and assured investors that “[Doximity does not] have an e-newsletter product.” In truth, Doximity overstated the impact that its Newsfeed had on its revenue growth, and the Company was losing market share to its competitors with more favorable pricing and engagement models. Additionally, notwithstanding its frequent statements to the contrary, Doximity relied heavily on both banner ads and email newsletters as advertising methods. Next Steps:
If you purchased or otherwise acquired Doximity shares and suffered a loss, are a long-term stockholder, have information, would like to learn more about these claims, or have any questions concerning this announcement or your rights or interests with respect to these matters, please contact Brandon Walker or Melissa Fortunato by email at [email protected], telephone at (212) 355-4648, or by filling out this contact form. There is no cost or obligation to you. About Bragar Eagel & Squire, P.C.:
Bragar Eagel & Squire, P.C. is a nationally recognized law firm with offices in New York, South Carolina, and California. The firm represents individual and institutional investors in securities, derivative, and commercial litigation as well as individuals in consumer protection and data privacy litigation. The firm has a nationwide practice and routinely handles cases in both federal and state courts. For more information about the firm, please visit www.bespc.com. Attorney advertising. Prior results do not guarantee similar outcomes.
Follow us for updates on LinkedIn and Facebook, and keep up with other news by following Brandon Walker, Esq. on LinkedIn.
Federální obchodní komise (FTC) zažalovala Hims & Hers kvůli údajnému sdílení citlivých zdravotních údajů a klamavým praktikám; akcie 29. července 2026 klesly o 14,73 % na 25,00 USD.
, /PRNewswire/ -- Pomerantz LLP announces that a class action lawsuit has been filed against Hims & Hers Health, Inc. ("Hims & Hers" or the "Company") (NYSE: HIMS). Such investors are advised to contact Danielle Peyton at [email protected] or 646-581-9980, (or 888.4-POMLAW), toll-free, Ext. 7980. Those who inquire by e-mail are encouraged to include their mailing address, telephone number, and the number of shares purchased.
The class action concerns whether Hims & Hers and certain of its officers and/or directors have engaged in securities fraud or other unlawful business practices.
You have until November 2, 2026, to ask the Court to appoint you as Lead Plaintiff for the class if you purchased or otherwise acquired Hims & Hers securities during the Class Period. A copy of the Complaint can be obtained at www.pomerantzlaw.com.
[Click here for information about joining the class action]
On July 29, 2026, the Federal Trade Commission ("FTC") announced the filing of a lawsuit against Hims & Hers "alleging that the telehealth provider shared consumers' sensitive health information about medical conditions with third-party advertising platforms despite claiming its services maintain consumers' privacy and deceives users about its billing and cancellation practices." According to the FTC complaint, Hims & Hers engages in other deceptive advertising practices, including failing to "clearly disclose that it charges consumers for prescriptions almost immediately after they submit an intake form, despite telling consumers that they will be able to consult with a medical provider to find a treatment that is 'right for them.'" The FTC complaint also includes allegations that Hims & Hers "shared consumers' sensitive health information with third-party advertising companies and platforms . . . such as Meta Platforms, Inc. ('Meta') and Snap Inc. ('Snap')."
On this news, Hims & Hers' stock price fell $4.32 per share, or 14.73%, to close at $25.00 per share on July 29, 2026.
Pomerantz LLP, with offices in New York, Chicago, Los Angeles, London, Paris, and Tel Aviv, is acknowledged as one of the premier firms in the areas of corporate, securities, and antitrust class litigation. Founded by the late Abraham L. Pomerantz, known as the dean of the class action bar, Pomerantz pioneered the field of securities class actions. Today, more than 85 years later, Pomerantz continues in the tradition he established, fighting for the rights of the victims of securities fraud, breaches of fiduciary duty, and corporate misconduct. The Firm has recovered numerous multimillion-dollar damages awards on behalf of class members. See www.pomlaw.com.
Attorney advertising. Prior results do not guarantee similar outcomes.
CSG se prostřednictvím společnosti Federal Ammunition zapojila do vývoje autonomního protidronového systému SwarmShot, který má za pomoci koordinovaného roje vyhledávat a ničit nepřátelské drony.
Zbrojně-průmyslová skupina Czechoslovak Group (CSG) se přes společnost Federal Ammunition z americké muniční divize The Kinetic Group zapojila do vývoje autonomního protidronového systému SwarmShot. Partnery projektu jsou O.F. Mossberg & Sons a Palladyne AI. Cílem jsou opakovaně použitelné bezpilotní prostředky, které dokážou ve vzduchu vyhledávat a ničit nepřátelské drony, a to i v koordinovaném roji.
Projekt rozšiřuje aktivity CSG v oblasti pokročilých protidronových technologií. Kombinuje zkušenosti amerických společností skupiny s vývojem munice a autonomní systémy určené k obraně proti rychle se vyvíjejícím hrozbám spojeným s bezpilotními prostředky. Federal Ammunition do programu SwarmShot přináší zejména své know-how v oblasti speciální munice a zvyšování její účinnosti proti bezpilotním cílům.
„Federal dodává munici, která funguje jako efektor. Mossberg poskytuje zbraň. Palladyne AI zajišťuje dosah, inteligenci a koordinaci jednotlivých strojů,“ uvedl Ben Wolff, prezident a generální ředitel Palladyne AI. „Zásadní je, že všechny tři prvky vyvíjíme společně jako jeden celek.“
Včerejší zpráva vydaná v 17:06h doplněná o komentář analytika:
„Je to další zapojení CSG do odvětví nejmodernějších vojenských obranných technologií se zajímavým potenciálem do budoucna. V rámci nově utvářené sub-divize Advanced Systems CSG postupně vyvíjí aktivity související s bezpilotními prostředky, jako jsou například rozvoj vlastní výroby pohonných motorů do těchto prostředků nebo třeba kapitálový vstup do kanadské společnosti North Vector Dynamics vyvíjející pokročilé technologie protivzdušné obrany. CSG je tak již v tomto segmentu nejmodernějších bezpečnostních technologií zainteresována, je jeho součástí a postupně ho rozvíjí. Vytváří si tak další pilíř v rámci své skupiny, jenž může přinášet zajímavé synergie i pro své jádrové aktivity v segmentech konvenční pozemní vojenské techniky a munice,“ doplnil analytik Fio banky Jan Raška.
Společnost Nvidia ve 2. čtvrtletí fiskálního roku 2027 zvýšila tržby meziročně o 106 % na 96,2 miliardy USD, přičemž segment datových center přinesl 89 miliard USD.
Nvidia (NVDA -2.94%) is highly unlikely to conduct a stock split in 2026, even after recently reaching a new all-time high. The leading chipmaker hasn't announced one, and its previous splits came when its share price was much higher.
It's usually not a good idea to wait for a company to split its stock before you invest. In Nvidia's case, you'd probably be waiting a very long time, and you'd be missing out on a quality company.
Image source: The Motley Fool.
Why an Nvidia stock split probably isn't happening in 2026 A few numbers make it clear why a stock split isn't on the horizon for Nvidia. The first is its share price. Companies usually split their stock to make it more affordable for retail investors. When Nvidia conducted its last stock split, a 10-for-1 split in 2024, it was trading at about $1,200. Before that, it conducted a 4-for-1 split in 2021 when it was trading at about $750.
Nvidia closed at $239 on Oct. 6. Its share price would need to be roughly three to five times larger to be in the same range as during its previous stock splits.
That brings us to the second important number: Nvidia's market cap of $5.8 trillion. If the company were to grow three times larger, it would have a market cap of more than $17 trillion. In all likelihood, Nvidia won't need to split its stock again for the rest of the decade.
Nvidia is set up well for continued growth One of the main reasons some investors are reluctant to buy Nvidia is its size. It already tops the list of the world's largest public companies, so there's the question of how much it can continue to grow from here.
But companies continue to spend heavily on artificial intelligence (AI), and Nvidia is reaping the benefits. It reported $96.2 billion in revenue in Q2 FY 2027, up 106% year over year, on an excellent gross margin of 75%. Most of that ($89 billion) is data center revenue, as Nvidia makes the most popular AI chips, including its Blackwell and Vera Rubin lines.
Premium Feature
Moneyball Superscore
95/100
Today's Change
(
-2.94
%) $
-6.99
Current Price
$
230.48
Even after Nvidia's recent growth, it's reasonably valued for one of the top AI stocks. It trades at about 26 times forward earnings and has a forward price/earnings-to-growth (PEG) ratio of less than 0.3. A PEG ratio below 1 indicates a company may be undervalued, and Nvidia is well below that mark.
Nvidia is doing the opposite of a split, and that's good news for investors A stock split increases a company's number of shares without changing the value of your position or your ownership stake. If a company trades at $500 and carries out a 5-for-1 split, each $500 share becomes five new $100 shares.
Nvidia, on the other hand, is buying back shares. On Sept. 28, the company announced that its board of directors authorized a $150 billion increase to its share repurchase program, increasing the program total to $235 billion. It expects to execute the total remaining through its fiscal 2028, essentially the next five quarters and change.
Buybacks are generally better for investors than stock splits because they reduce the number of outstanding shares. Each share has a larger ownership stake, and earnings per share (EPS) rise. The fact that Nvidia's board authorized a $150 billion increase suggests management considers the stock undervalued, and it's a large commitment to return capital to shareholders.
Nvidia's value isn't about the share price The real value of Nvidia is its crucial role in the AI build-out. Tech companies are investing in AI infrastructure, with the four largest hyperscalers (Alphabet, Amazon, Meta Platforms, and Microsoft) reporting over $300 billion of capital expenditures in the first half of 2026, according to research by The Motley Fool. Even with increased competition from Advanced Micro Devices and custom chipmakers, Nvidia still has an estimated 75% share of the AI accelerator market.
There are valid concerns about Nvidia. My primary worry is that it's heavily dependent on AI spending, and if companies slow down that spending, Nvidia's performance would suffer.
However, given how AI is progressing and its role as a potentially transformative technology, I expect the AI build-out to continue. If you're bullish on AI, then Nvidia is still worth considering as an investment, especially considering its growth and affordable valuation.
JACKSONVILLE, Fla., Oct. 08, 2026 (GLOBE NEWSWIRE) -- CSX Corp. (NASDAQ: CSX) announced that the Company’s Board of Directors approved a $0.14 per share quarterly dividend on the Company’s common stock. The dividend is payable Dec. 15, 2026, to shareholders of record at the close of business Nov. 30, 2026.
About CSX and its Disclosures
CSX, based in Jacksonville, Florida, is a premier transportation company. It provides rail, intermodal and rail-to-truck transload services and solutions to customers across a broad array of markets, including energy, industrial, construction, agricultural, and consumer products. For nearly 200 years, CSX has played a critical role in the nation's economic expansion and industrial development. Its network connects every major metropolitan area in the eastern United States, where nearly two-thirds of the nation's population resides. It also connects approximately 250 short-line railroads and more than 70 ocean, river and lake ports with major population centers and farming towns alike.
This announcement, as well as additional financial information, is available on the Company's website at investors.csx.com. CSX also uses social media channels to communicate information about the company. Although social media channels are not intended to be the primary method of disclosure for material information, it is possible that certain information CSX posts on social media could be deemed to be material. Therefore, we encourage investors, the media, and others interested in the company to review the information we post on Facebook and on X, formerly known as Twitter. The social media channels used by CSX may be updated from time to time. More information about CSX Corporation and its subsidiaries is available at www.csx.com.
Contact:
Matthew Korn, CFA, Investor Relations
904-366-4515
Applied Materials navázala partnerství s UCLA ve svém centru EPIC, aby urychlila komercializaci výzkumu čipů, včetně 3D škálování, pokročilého pouzdření a materiálů pro AI.
R&D programs to focus on speeding up the commercialization pipeline so chip technology moves from breakthrough research to full-scale manufacturing fasterCollaborative work at the state-of-the-art facility in Silicon Valley pairs UCLA’s semiconductor research strength with Applied’s cutting-edge chipmaking equipment and process integration expertise SANTA CLARA, Calif., Oct. 08, 2026 (GLOBE NEWSWIRE) -- Applied Materials, Inc. today announced that the UCLA Samueli School of Engineering will join the company’s EPIC Center in Silicon Valley as a research partner. Together with Applied’s scientists and engineers, UCLA researchers will work to solve semiconductor materials and integration challenges with a focus on shortening the time it takes to bring breakthrough research to commercialization.
“As the industry races to bring new AI chip technologies to market, the EPIC Center will play a pivotal role by convening the industry’s top innovators in a collaborative environment designed to accelerate the path from breakthrough research to full-scale manufacturing,” said Dr. Prabu Raja, President of the Semiconductor Products Group at Applied Materials. “UCLA has a long history of semiconductor technology innovation and Applied looks forward to welcoming their researchers to the EPIC Center where together we will work to solve the industry’s toughest challenges.”
The EPIC Center aims to accelerate chip R&D by bridging the gap between traditional academic innovation and industrial-scale development. UCLA researchers will have access to advanced chipmaking tools so that new ideas can be validated and tested in a commercial fab environment, thereby shortening the path from concept to production.
UCLA Samueli brings extensive expertise across semiconductor devices, materials, electronics and computing. In 1991, Henry Samueli co-founded Broadcom Corporation while teaching at UCLA. The school is also home to the Center for Heterogeneous Integration and Performance Scaling (CHIPS) Lab, which brings together researchers across disciplines to advance semiconductor technologies and address challenges in chip design, manufacturing and integration.
By collaborating at the EPIC Center, Applied Materials and UCLA will focus R&D programs on the semiconductor industry’s most critical challenges in areas including 3D chip scaling, advanced packaging and the discovery of new materials for improving energy-efficient AI compute performance. The work will complement and extend the efforts of UCLA’s Semiconductor Hub, which Applied joined as a co-founding member earlier this year. Applied’s ongoing commitment to strengthen the ties between industry and academia is aimed at empowering the next generation of engineers and researchers to bring semiconductor breakthroughs to market faster.
“Accelerating semiconductor innovation in the new era of AI requires transformative collaboration between universities and industry partners more than ever before,” said Ah-Hyung “Alissa” Park, Ronald and Valerie Sugar Dean of UCLA Samueli. “UCLA has a long history of pioneering semiconductor research and innovation, and this collaboration builds on that legacy by bringing together university research and industry expertise to advance the chip technologies that will define the future of computing while preparing the next generation of engineers.”
Applied’s new EPIC (Equipment and Process Innovation and Commercialization) Center in Silicon Valley represents the largest-ever U.S. investment in advanced semiconductor equipment R&D. The center is designed from the ground up to dramatically reduce the time it takes to commercialize breakthrough technologies from early-stage research to full-scale manufacturing. The facility is on track to become operational in 2026. Visit the EPIC Center website to learn more.
Forward-Looking Statements
This press release contains forward-looking statements, including those regarding Applied’s investment and growth strategies, the development of new materials and technologies, industry outlook and technology requirements, the plans and expectations for the EPIC Center, and other statements that are not historical facts. These statements and their underlying assumptions are subject to risks and uncertainties and are not guarantees of future performance. Factors that could cause actual results to differ materially from those expressed or implied by such statements include, without limitation: the demand for semiconductors and customers’ technology requirements; the ability to develop new and innovative technologies; the ability to obtain and protect intellectual property rights in key technologies; the ability to achieve the objectives of the EPIC Center; and other risks and uncertainties described in Applied’s filings with the Securities and Exchange Commission, including Applied’s most recent Forms 10-K, 10-Q and 8-K. All forward-looking statements are based on management’s current estimates, projections and assumptions, and Applied assumes no obligation to update them.
About Applied Materials
Applied Materials, Inc. (Nasdaq: AMAT) is the leader in materials engineering solutions that are at the foundation of virtually every new semiconductor and advanced display in the world. The technology we create is essential to advancing AI and accelerating the commercialization of next-generation chips. At Applied, we push the boundaries of science and engineering to deliver material innovation that changes the world. Learn more at www.appliedmaterials.com.
Contact:
Ricky Gradwohl (editorial/media) 408.235.4676
Mike Sullivan (financial community) 408.986.7977
Fossil Group zvolila Sebastiana DiGrandeho a Chandhu Naira do představenstva a Wendy Schoppertovou jeho předsedkyní. Představenstvo má nyní sedm členů, z nichž šest je nezávislých.
New Directors Bring Deep Expertise Across Global Retail, Enterprise Technology, Digital & Omnichannel Commerce | Source: Fossil Group, Inc.
RICHARDSON, Texas, Oct. 08, 2026 (GLOBE NEWSWIRE) -- Fossil Group, Inc. (NASDAQ: FOSL) today announced that Sebastian DiGrande and Chandhu Nair were elected to the Board of Directors at the Company’s Annual Meeting of Stockholders held on October 2, 2026. Mr. DiGrande was appointed as a member of the Compensation and Talent Management Committee and Mr. Nair was appointed as a member of the Audit Committee. Wendy Schoppert, who joined the Company’s Board of Directors in May 2025, was elected Chair of the Board of Directors, effective October 2, 2026. The Company’s Board of Directors now consists of seven members, of which six are independent directors.
The two new Directors are seasoned executives with deep expertise in global retail, enterprise technology, digital & omnichannel commerce. The new Directors reflect Fossil Group’s commitment to further advancing its turnaround plan and delivering long-term value to shareholders, customers, associates and partners.
“We are pleased to welcome Sebastian and Chandhu to Fossil Group’s Board. Their expertise across global brands, technology and customer experience at scale will be instrumental as we further advance our turnaround plan,” said Franco Fogliato, CEO. “We look forward to partnering with them as we continue to engage consumers through innovation, technology and impactful storytelling to deliver long-term, profitable growth.”
Wendy Schoppert, Chair of the Board, added, “Sebastian and Chandhu have decades of expertise that is highly relevant to the Company’s business strategy. We are confident they will bring valuable perspectives to the Board as we build the Fossil Group of the future and drive durable value creation for all of our stakeholders.”
Sebastian DiGrande brings more than 30 years of experience spanning the technology, retail and environmental sectors, with notable expertise in digital transformation and omnichannel commerce, technology strategy, data analytics, compensation governance and ESG. He co-founded and currently serves as Chief Executive Officer of PCX Markets, a climate technology and plastic responsibility platform operating in 16 countries. Previously, Mr. DiGrande served as Executive Vice President of Strategy and Chief Customer Officer at Gap, Inc. Earlier in his career, Mr. DiGrande spent 21 years with The Boston Consulting Group, most recently serving as Senior Partner and Managing Director. During his tenure, Mr. DiGrande also spent eight years as Americas Leader of the Technology, Media and Telecommunications Practice and led the global Technology Sector for Marketing, Sales and Pricing for a decade, advising Fortune 500 companies and their boards on strategy, transformation, M&A and organizational change. Mr. DiGrande previously served on the Board of Directors of Big Lots, Inc. from 2018 to 2025.
“I am pleased to join the Board of an industry leader with such a rich heritage in watchmaking,” said Sebastian DiGrande. “I am impressed with the Company’s iconic brands, strengthened operating model and talented teams, all underpinned by a commitment to delivering the best in design and innovation to customers around the world. I’m excited and honored to contribute to this bright future for the Fossil business.”
Chandhu Nair is a senior technology executive with more than 20 years of experience leading enterprise digital, data and artificial intelligence transformation across global consumer businesses. He currently serves as Senior Vice President and Chief AI Officer at Target Corporation. Mr. Nair previously spent six years with Lowe’s Companies, Inc., where he launched and led the Company’s enterprise AI Transformation Office, advancing the use of AI to drive growth, improve inventory productivity and increase operational efficiency. During his tenure, he served as Senior Vice President, Technology – Stores, Artificial Intelligence and Innovation, and Vice President, Technology – Omnichannel Marketing and Customer Engagement. Previously, Mr. Nair co-founded and served as Chief Executive Officer of Cognitive Retail Inc. Earlier in his career, he held e-commerce and technology leadership roles at Staples Inc. and Infosys.
Mr. Nair stated, “I am honored to join the Fossil Group Board at an important point in the Company’s transformation. Fossil has an iconic portfolio of brands and a strong heritage of design and innovation. I look forward to working with the Board and management team as the Company builds on that foundation and advances the next phase of its strategic journey.”
About Fossil Group, Inc.
Fossil Group, Inc. is a global design, marketing, distribution and innovation company specializing in lifestyle accessories. Under a diverse portfolio of owned and licensed brands, our offerings include watches, jewelry, handbags, small leather goods, belts and sunglasses. We are committed to delivering the best in design and innovation across our owned brands, Fossil, Michele, Relic, Skagen and Zodiac, and licensed brands, Armani Exchange, Diesel, Emporio Armani, Michael Kors, Skechers and Tory Burch. We bring each brand story to life through an extensive distribution network across numerous geographies, categories and channels. Certain press release and SEC filing information concerning the Company is also available at www.fossilgroup.com.
Investor Relations:Christine DiSanto (Greany) The Blueshirt Group [email protected]
Media Relations:Michael McMullan Berns & Co. [email protected]
CME Group ve 3. čtvrtletí 2026 meziročně zvýšila mezinárodní průměrný denní objem obchodů o 22 % na 9 milionů kontraktů, zejména díky energetickým produktům.
, /PRNewswire/ -- CME Group, the world's leading derivatives marketplace, today announced it achieved international average daily volume (ADV) of 9 million contracts in Q3 2026, up 22% from a year earlier.
Reflecting all trading reported outside the United States, this volume was driven largely by growth in Energy products, up 40%, Agricultural products, up 28%, and Equity Index products, up 24%.
"Markets remained volatile in the third quarter, with geopolitical issues fueling uncertainty and stoking inflation globally," said Julie Winkler, Chief Commercial Officer at CME Group. "Against this backdrop, customers around the world turned to CME Group to manage their risk, and the growth of our international volumes was testament to that."
International trading volume expanded by at least 20% in the period in all regions including Europe, Middle East and Africa (EMEA), Asia Pacific (APAC), and Latin America.
EMEA ADV increased 20% to 6.5 million contracts driven by:-
Energy products ADV up 33% Agricultural products ADV up 28% Equity Index products ADV up 20% APAC ADV increased by 28% to 2.1 million contracts driven by:-
Energy products ADV up 68% Equity Index products ADV up 32% Agricultural products ADV up 26% Interest Rate products ADV up 24% Canada ADV increased by 21% to 194,000 contracts driven by:-
Energy products ADV up 34% Interest Rate products ADV up 23% Equity Index products ADV up 22% Latin America ADV increased 24% to 188,000 contracts driven by:-
Agricultural products ADV up 49% Equity Index products ADV up 44% Energy products ADV up 23% Globally, CME Group reported an ADV of 29.4 million contracts in Q3 2026, up 16% over the same period in 2025. Q3 volumes in 2026 exceeded the prior Q3 record set in 2024. The increase in Q3 2026 ADV was largely driven by growth in Equity Index products, up 23%, and Foreign Exchange products, up 19%.
As the world's leading derivatives marketplace, CME Group (www.cmegroup.com) enables clients to trade futures, options, cash and OTC markets, optimize portfolios, and analyze data – empowering market participants worldwide to efficiently manage risk and capture opportunities. CME Group exchanges offer the widest range of global benchmark products across all major asset classes based on interest rates, equity indexes, foreign exchange, cryptocurrencies, energy, agricultural products and metals. The company offers futures and options on futures trading through the CME Globex platform, fixed income trading via BrokerTec and foreign exchange trading on the EBS platform. In addition, it operates one of the world's leading central counterparty clearing providers, CME Clearing.
CME Group, the Globe logo, CME, Chicago Mercantile Exchange, Globex, and E-mini are trademarks of Chicago Mercantile Exchange Inc. CBOT and Chicago Board of Trade are trademarks of Board of Trade of the City of Chicago, Inc. NYMEX, New York Mercantile Exchange and ClearPort are trademarks of New York Mercantile Exchange, Inc. COMEX is a trademark of Commodity Exchange, Inc. BrokerTec is a trademark of BrokerTec Americas LLC and EBS is a trademark of EBS Group LTD. The S&P 500 Index is a product of S&P Dow Jones Indices LLC ("S&P DJI"). "S&P®", "S&P 500®", "SPY®", "SPX®", US 500 and The 500 are trademarks of Standard & Poor's Financial Services LLC; Dow Jones®, DJIA® and Dow Jones Industrial Average are service and/or trademarks of Dow Jones Trademark Holdings LLC. These trademarks have been licensed for use by Chicago Mercantile Exchange Inc. Futures contracts based on the S&P 500 Index are not sponsored, endorsed, marketed, or promoted by S&P DJI, and S&P DJI makes no representation regarding the advisability of investing in such products. All other trademarks are the property of their respective owners.
New contracts will be based on CME FutureSports Performance Indexes tracking Official League Data , /PRNewswire/ -- CME Group, the world's leading derivatives marketplace, today announced it will launch the world's first Baseball futures on October 12, pending regulatory review. The new contracts will track CME FutureSports Performance Indexes (CME FSPI) that include statistics on the 30 professional baseball teams, beginning with the 2026 Postseason and the four clubs in the League Championship Series.
"CME Group provides price discovery and risk management across every major investable asset class, and we see an opportunity to bring investing and hedging discipline to the business of professional baseball," said Tim McCourt, Senior Managing Director and Global Head of Equities, FX and Alternative Products at CME Group. "The innovative contracts we're developing with FutureSports will be built on robust indexes using Official League Data, with the transparency and integrity that only regulated exchange-traded products deliver."
CME Group Baseball futures will be available in standard-sized contracts, valued at 10x the underlying CME FSPI MLB indexes, and micro-sized contracts that are 1/10 the value of those indexes. Participants can trade live around the clock, allowing for immediate positions on a regulated exchange with central clearing safeguards, transparent pricing and equal market access.
CME FSPI structure official sports statistics into rules-based, benchmark financial metrics. The performance of the indexes will be calculated using systematic methodologies where point allocations follow transparent statistical frameworks – adding points for positive actions and subtracting for negative plays or setbacks.
The CME FSPI methodologies align with the International Organization of Securities Commissions (IOSCO) Principles for Financial Benchmarks and are supported by published governance and oversight procedures.
CME Group Baseball futures are listed on and subject to the rules of CME. For more information, visit cmegroup.com/fspi.
As the world's leading derivatives marketplace, CME Group (www.cmegroup.com) enables clients to trade futures, options, cash and OTC markets, optimize portfolios, and analyze data – empowering market participants worldwide to efficiently manage risk and capture opportunities. CME Group exchanges offer the widest range of global benchmark products across all major asset classes based on interest rates, equity indexes, foreign exchange, cryptocurrencies, energy, agricultural products and metals. The company offers futures and options on futures trading through the CME Globex platform, fixed income trading via BrokerTec and foreign exchange trading on the EBS platform. In addition, it operates one of the world's leading central counterparty clearing providers, CME Clearing.
CME Group, the Globe logo, CME, Chicago Mercantile Exchange, Globex, and E-mini are trademarks of Chicago Mercantile Exchange Inc. CBOT and Chicago Board of Trade are trademarks of Board of Trade of the City of Chicago, Inc. NYMEX, New York Mercantile Exchange and ClearPort are trademarks of New York Mercantile Exchange, Inc. COMEX is a trademark of Commodity Exchange, Inc. BrokerTec is a trademark of BrokerTec Americas LLC and EBS is a trademark of EBS Group LTD. The S&P 500 Index is a product of S&P Dow Jones Indices LLC ("S&P DJI"). "S&P®", "S&P 500®", "SPY®", "SPX®", US 500 and The 500 are trademarks of Standard & Poor's Financial Services LLC; Dow Jones®, DJIA® and Dow Jones Industrial Average are service and/or trademarks of Dow Jones Trademark Holdings LLC. These trademarks have been licensed for use by Chicago Mercantile Exchange Inc. Futures contracts based on the S&P 500 Index are not sponsored, endorsed, marketed, or promoted by S&P DJI, and S&P DJI makes no representation regarding the advisability of investing in such products. All other trademarks are the property of their respective owners.
